Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:boron group molecular entity
go back to main search page
Accession:CHEBI:33581 term browser browse the term
Synonyms:related_synonym: boron group molecular entities


show annotations for term's descendants           Sort by:
2-[4-[(E)-2-(6,8-dichloro-2-phenyl-2H-chromen-3-yl)ethenyl]phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G NPHS1 NPHS1 adhesion molecule, nephrin increases expression ISO BD4 increases expression of Nphs1 mRNA in podocytes RGD PMID:22125642 RGD:40902998 NCBI chr19:35,862,915...35,869,357
Ensembl chr19:35,825,964...35,869,287 		JBrowse link
G SYNPO synaptopodin increases expression ISO BD4 increases expression of Synpo mRNA in podocytes RGD PMID:22125642 RGD:40902998 NCBI chr 5:150,586,010...150,659,207
Ensembl chr 5:150,601,080...150,659,207 		JBrowse link
2-aminoethoxydiphenylborane term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G BAX BCL2 associated X, apoptosis regulator multiple interactions ISO 2-aminoethoxydiphenylborane inhibits the reaction [cadmium acetate results in increased expression of BAX protein] CTD PMID:29883672 NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798 		JBrowse link
G BCL2 BCL2 apoptosis regulator multiple interactions ISO 2-aminoethoxydiphenylborane inhibits the reaction [cadmium acetate results in decreased expression of BCL2 protein] CTD PMID:29883672 NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128 		JBrowse link
G CASP12 caspase 12 (gene/pseudogene) multiple interactions ISO 2-aminoethoxydiphenylborane inhibits the reaction [cadmium acetate results in increased cleavage of CASP12 protein] CTD PMID:29883672 NCBI chr11:104,883,286...104,898,460
Ensembl chr11:104,885,718...104,898,670 		JBrowse link
G CASP3 caspase 3 multiple interactions ISO 2-aminoethoxydiphenylborane inhibits the reaction [cadmium acetate results in increased cleavage of CASP3 protein] CTD PMID:29883672 NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062 		JBrowse link
G CD28 CD28 molecule multiple interactions EXP 2-aminoethoxydiphenylborane inhibits the reaction [CD28 protein results in increased abundance of Calcium]; 2-aminoethoxydiphenylborane inhibits the reaction [CD28 protein results in increased abundance of Nitric Oxide]; 2-aminoethoxydiphenylborane inhibits the reaction [CD28 protein results in increased abundance of Reactive Oxygen Species] CTD PMID:14607919 NCBI chr 2:203,706,482...203,738,912
Ensembl chr 2:203,706,517...203,739,756 		JBrowse link
G GRM1 glutamate metabotropic receptor 1 multiple interactions ISO 2-aminoethoxydiphenylborane inhibits the reaction [3,5-dihydroxyphenylglycine results in increased activity of GRM1 protein] CTD PMID:14622174 NCBI chr 6:146,027,707...146,437,601
Ensembl chr 6:146,027,646...146,437,601 		JBrowse link
G NFE2L2 NFE2 like bZIP transcription factor 2 multiple interactions EXP 2-aminoethoxydiphenylborane inhibits the reaction [bisphenol A results in increased expression of NFE2L2 protein] CTD PMID:33408296 NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756 		JBrowse link
4,4-difluoro-4-bora-3a,4a-diaza-s-indacene term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCB11 ATP binding cassette subfamily B member 11 affects transport EXP ABCB11 protein affects the transport of 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene CTD PMID:12739759 NCBI chr 2:168,915,390...169,031,324
Ensembl chr 2:168,915,498...169,031,324 		JBrowse link
aluminium hydroxide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCC2 ATP binding cassette subfamily C member 2 decreases expression ISO Aluminum Hydroxide results in decreased expression of ABCC2 protein CTD PMID:14976346 NCBI chr10:99,782,640...99,852,594
Ensembl chr10:99,782,640...99,852,594 		JBrowse link
G ACTA2 actin alpha 2, smooth muscle multiple interactions ISO [Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of ACTA2 protein; dioscin inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of ACTA2 protein] CTD PMID:35481609 NCBI chr10:88,935,074...88,991,337
Ensembl chr10:88,934,822...88,991,339 		JBrowse link
G AKT1 AKT serine/threonine kinase 1 multiple interactions
increases expression		 ISO
EXP		 [Ovalbumin co-treated with Aluminum Hydroxide] results in increased phosphorylation of AKT1 protein; dioscin inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased phosphorylation of AKT1 protein]
[Tretinoin co-treated with BDNF protein co-treated with Aluminum Hydroxide] results in decreased expression of AKT1 protein; dihydrolipoic acid inhibits the reaction [[Tretinoin co-treated with BDNF protein co-treated with Aluminum Hydroxide] results in decreased expression of AKT1 protein]; dihydrolipoic acid inhibits the reaction [Aluminum Hydroxide results in increased expression of AKT1 protein]		 CTD PMID:35481609 PMID:37409350 NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,759 		JBrowse link
G APP amyloid beta precursor protein multiple interactions
increases expression		 EXP Aluminum Hydroxide promotes the reaction [[BDNF protein co-treated with Tretinoin] results in increased expression of APP protein]; Coconut Oil inhibits the reaction [Aluminum Hydroxide promotes the reaction [[BDNF protein co-treated with Tretinoin] results in increased expression of APP protein]]; Coconut Oil inhibits the reaction [Aluminum Hydroxide results in increased expression of APP protein] CTD PMID:37989595 NCBI chr21:25,880,550...26,171,128
Ensembl chr21:25,880,535...26,171,128 		JBrowse link
G BDNF brain derived neurotrophic factor multiple interactions EXP [BDNF protein co-treated with Tretinoin co-treated with Aluminum Hydroxide] results in increased expression of MAPT protein; [BDNF protein co-treated with Tretinoin co-treated with Aluminum Hydroxide] results in increased expression of SNCA protein; [Tretinoin co-treated with Aluminum Hydroxide co-treated with BDNF protein] results in decreased expression of CTNNB1 protein; [Tretinoin co-treated with BDNF protein co-treated with Aluminum Hydroxide] results in decreased expression of AKT1 protein; Aluminum Hydroxide inhibits the reaction [[Tretinoin co-treated with BDNF protein] results in increased expression of MAPT protein]; Aluminum Hydroxide promotes the reaction [[BDNF protein co-treated with Tretinoin] results in decreased expression of SLC6A3 protein]; Aluminum Hydroxide promotes the reaction [[BDNF protein co-treated with Tretinoin] results in increased expression of APP protein]; Aluminum Hydroxide promotes the reaction [[Tretinoin co-treated with BDNF protein] results in decreased expression of PPP1CA protein]; Aluminum Hydroxide promotes the reaction [[Tretinoin co-treated with BDNF protein] results in decreased expression of WNT5A protein]; Aluminum Hydroxide promotes the reaction [[Tretinoin co-treated with BDNF protein] results in increased expression of GSK3B protein]; Coconut Oil inhibits the reaction [[BDNF protein co-treated with Tretinoin co-treated with Aluminum Hydroxide] results in increased expression of MAPT protein]; Coconut Oil inhibits the reaction [[BDNF protein co-treated with Tretinoin co-treated with Aluminum Hydroxide] results in increased expression of SNCA protein]; Coconut Oil inhibits the reaction [Aluminum Hydroxide promotes the reaction [[BDNF protein co-treated with Tretinoin] results in decreased expression of SLC6A3 protein]]; Coconut Oil inhibits the reaction [Aluminum Hydroxide promotes the reaction [[BDNF protein co-treated with Tretinoin] results in increased expression of APP protein]]; dihydrolipoic acid inhibits the reaction [[Tretinoin co-treated with Aluminum Hydroxide co-treated with BDNF protein] results in decreased expression of CTNNB1 protein]; dihydrolipoic acid inhibits the reaction [[Tretinoin co-treated with BDNF protein co-treated with Aluminum Hydroxide] results in decreased expression of AKT1 protein]; dihydrolipoic acid inhibits the reaction [Aluminum Hydroxide promotes the reaction [[Tretinoin co-treated with BDNF protein] results in decreased expression of PPP1CA protein]]; dihydrolipoic acid inhibits the reaction [Aluminum Hydroxide promotes the reaction [[Tretinoin co-treated with BDNF protein] results in decreased expression of WNT5A protein]]; dihydrolipoic acid inhibits the reaction [Aluminum Hydroxide promotes the reaction [[Tretinoin co-treated with BDNF protein] results in increased expression of GSK3B protein]]; dihydrolipoic acid promotes the reaction [Aluminum Hydroxide inhibits the reaction [[Tretinoin co-treated with BDNF protein] results in increased expression of MAPT protein]] CTD PMID:37409350 PMID:37989595 NCBI chr11:27,654,893...27,722,030
Ensembl chr11:27,654,893...27,722,058 		JBrowse link
G CASP1 caspase 1 multiple interactions EXP
ISO		 [Aluminum Hydroxide co-treated with Magnesium Hydroxide] promotes the reaction [N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine results in increased activity of CASP1 protein]; [Aluminum Hydroxide co-treated with Magnesium Hydroxide] promotes the reaction [N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine results in increased expression of and results in increased secretion of CASP1 protein modified form]; CASP1 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]
[Aluminum Hydroxide co-treated with Magnesium Hydroxide] promotes the reaction [N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine results in increased expression of and results in increased secretion of CASP1 protein modified form]; [OVAL protein co-treated with Aluminum Hydroxide] results in increased expression of and results in increased cleavage of CASP1 protein; [OVAL protein co-treated with Aluminum Hydroxide] results in increased expression of CASP1 mRNA; nonylphenol promotes the reaction [[OVAL protein co-treated with Aluminum Hydroxide] results in increased expression of and results in increased cleavage of CASP1 protein]; nonylphenol promotes the reaction [[OVAL protein co-treated with Aluminum Hydroxide] results in increased expression of CASP1 mRNA]		 CTD PMID:18604214 PMID:22075093 PMID:38176579 NCBI chr11:105,025,443...105,036,686
Ensembl chr11:105,025,397...105,035,250 		JBrowse link
G CAT catalase decreases activity
multiple interactions
increases activity		 ISO
EXP		 Aluminum Hydroxide results in decreased activity of CAT protein
[Thimerosal co-treated with Aluminum Hydroxide] results in increased activity of CAT protein
Aluminum Hydroxide results in increased activity of CAT protein		 CTD PMID:14976346 PMID:36411272 NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060 		JBrowse link
G CCL2 C-C motif chemokine ligand 2 increases secretion EXP Aluminum Hydroxide results in increased secretion of CCL2 protein CTD PMID:18390722 NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,274...34,257,208 		JBrowse link
G CCL3 C-C motif chemokine ligand 3 increases secretion EXP Aluminum Hydroxide results in increased secretion of CCL3 protein CTD PMID:18390722 NCBI chr17:36,088,256...36,090,143
Ensembl chr17:36,088,256...36,090,169 		JBrowse link
G CCL4 C-C motif chemokine ligand 4 increases secretion EXP Aluminum Hydroxide results in increased secretion of CCL4 protein CTD PMID:18390722 NCBI chr17:36,103,827...36,105,614
Ensembl chr17:36,103,827...36,105,621 		JBrowse link
G CCL5 C-C motif chemokine ligand 5 increases secretion EXP Aluminum Hydroxide results in increased secretion of CCL5 protein CTD PMID:18390722 NCBI chr17:35,871,491...35,880,360
Ensembl chr17:35,871,491...35,880,793 		JBrowse link
G CCR7 C-C motif chemokine receptor 7 multiple interactions EXP Aluminum Hydroxide promotes the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of CCR7 protein] CTD PMID:18390722 NCBI chr17:40,553,769...40,565,472
Ensembl chr17:40,551,081...40,565,472 		JBrowse link
G CD14 CD14 molecule decreases expression EXP Aluminum Hydroxide results in decreased expression of CD14 protein CTD PMID:18390722 NCBI chr 5:140,631,732...140,633,701
Ensembl chr 5:140,631,728...140,633,700 		JBrowse link
G CD1A CD1a molecule multiple interactions EXP Aluminum Hydroxide inhibits the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of CD1A protein] CTD PMID:18390722 NCBI chr 1:158,248,336...158,258,269
Ensembl chr 1:158,254,424...158,258,269 		JBrowse link
G CD4 CD4 molecule affects response to substance EXP CD4 protein affects the susceptibility to Aluminum Hydroxide CTD PMID:11160013 NCBI chr12:6,789,528...6,820,799
Ensembl chr12:6,786,858...6,820,799 		JBrowse link
G CD40 CD40 molecule increases expression EXP Aluminum Hydroxide results in increased expression of CD40 protein CTD PMID:11160013 NCBI chr20:46,118,314...46,129,858
Ensembl chr20:46,118,271...46,129,863 		JBrowse link
G CD58 CD58 molecule increases expression EXP Aluminum Hydroxide results in increased expression of CD58 protein CTD PMID:11160013 NCBI chr 1:116,514,534...116,571,026
Ensembl chr 1:116,514,534...116,571,039 		JBrowse link
G CD80 CD80 molecule multiple interactions EXP Aluminum Hydroxide inhibits the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of CD80 protein] CTD PMID:18390722 NCBI chr 3:119,524,293...119,559,614
Ensembl chr 3:119,524,293...119,559,614 		JBrowse link
G CD83 CD83 molecule increases expression EXP Aluminum Hydroxide results in increased expression of CD83 protein CTD PMID:11160013 NCBI chr 6:14,117,256...14,136,918
Ensembl chr 6:14,117,256...14,140,682 		JBrowse link
G CD86 CD86 molecule increases expression
multiple interactions		 EXP Aluminum Hydroxide results in increased expression of CD86 protein
Aluminum Hydroxide promotes the reaction [CSF2 protein results in increased expression of CD86 protein]		 CTD PMID:11160013 PMID:18390722 NCBI chr 3:122,055,362...122,121,136
Ensembl chr 3:122,055,362...122,121,139 		JBrowse link
G CHRNA4 cholinergic receptor nicotinic alpha 4 subunit multiple interactions EXP Aluminum Hydroxide inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein co-treated with CHRNB2 protein]] CTD PMID:22750351 NCBI chr20:63,343,223...63,361,349
Ensembl chr20:63,343,223...63,378,401 		JBrowse link
G CHRNB2 cholinergic receptor nicotinic beta 2 subunit multiple interactions EXP Aluminum Hydroxide inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein co-treated with CHRNB2 protein]] CTD PMID:22750351 NCBI chr 1:154,567,778...154,580,013
Ensembl chr 1:154,567,778...154,580,013 		JBrowse link
G CRLF2 cytokine receptor like factor 2 multiple interactions ISO [Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of CRLF2 mRNA; [Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of CRLF2 protein; nonylphenol promotes the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of CRLF2 mRNA]; nonylphenol promotes the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of CRLF2 protein] CTD PMID:36029577 NCBI chr  X:1,190,490...1,212,649
NCBI chr  Y:1,190,490...1,212,649
Ensembl chr  Y:1,190,490...1,212,723
Ensembl chr  X:1,190,490...1,212,723 		JBrowse link
G CSF2 colony stimulating factor 2 multiple interactions EXP Aluminum Hydroxide inhibits the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of CD1A protein]; Aluminum Hydroxide inhibits the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of CD80 protein]; Aluminum Hydroxide promotes the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of CCR7 protein]; Aluminum Hydroxide promotes the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of TFRC protein]; Aluminum Hydroxide promotes the reaction [CSF2 protein results in increased expression of CD86 protein] CTD PMID:18390722 NCBI chr 5:132,073,789...132,076,170
Ensembl chr 5:132,073,789...132,076,170 		JBrowse link
G CTNNB1 catenin beta 1 multiple interactions
decreases expression		 EXP [Tretinoin co-treated with Aluminum Hydroxide co-treated with BDNF protein] results in decreased expression of CTNNB1 protein; dihydrolipoic acid inhibits the reaction [[Tretinoin co-treated with Aluminum Hydroxide co-treated with BDNF protein] results in decreased expression of CTNNB1 protein]; dihydrolipoic acid inhibits the reaction [Aluminum Hydroxide results in decreased expression of CTNNB1 protein] CTD PMID:37409350 NCBI chr 3:41,199,505...41,240,443
Ensembl chr 3:41,194,741...41,260,096 		JBrowse link
G CXCL10 C-X-C motif chemokine ligand 10 multiple interactions EXP [Aluminum Hydroxide co-treated with Magnesium Hydroxide] inhibits the reaction [K-12 lipopolysaccharide results in increased secretion of CXCL10 protein] CTD PMID:17404311 NCBI chr 4:76,021,118...76,023,497
Ensembl chr 4:76,021,118...76,023,497 		JBrowse link
G CXCL8 C-X-C motif chemokine ligand 8 increases secretion EXP Aluminum Hydroxide results in increased secretion of CXCL8 protein CTD PMID:18390722 NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716 		JBrowse link
G DBH dopamine beta-hydroxylase multiple interactions EXP [Thimerosal co-treated with Aluminum Hydroxide] results in increased expression of DBH protein CTD PMID:36411272 NCBI chr 9:133,636,363...133,659,329
Ensembl chr 9:133,636,363...133,659,329 		JBrowse link
G EGFR epidermal growth factor receptor multiple interactions ISO [Aluminum Hydroxide co-treated with Ovalbumin] affects the expression of EGFR mRNA; cang er zi wan affects the reaction [[Aluminum Hydroxide co-treated with Ovalbumin] affects the expression of EGFR mRNA] CTD PMID:36855022 NCBI chr 7:55,019,017...55,211,628
Ensembl chr 7:55,019,017...55,211,628 		JBrowse link
G GATA3 GATA binding protein 3 multiple interactions ISO [Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of GATA3 mRNA; nonylphenol promotes the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of GATA3 mRNA] CTD PMID:36029577 NCBI chr10:8,045,333...8,075,198
Ensembl chr10:8,045,378...8,075,198 		JBrowse link
G GSDMD gasdermin D multiple interactions ISO [OVAL protein co-treated with Aluminum Hydroxide] results in increased expression of and results in increased cleavage of GSDMD protein; [OVAL protein co-treated with Aluminum Hydroxide] results in increased expression of GSDMD mRNA; nonylphenol promotes the reaction [[OVAL protein co-treated with Aluminum Hydroxide] results in increased expression of and results in increased cleavage of GSDMD mRNA]; nonylphenol promotes the reaction [[OVAL protein co-treated with Aluminum Hydroxide] results in increased expression of and results in increased cleavage of GSDMD protein] CTD PMID:38176579 NCBI chr 8:143,553,387...143,563,062
Ensembl chr 8:143,553,207...143,563,062 		JBrowse link
G GSK3B glycogen synthase kinase 3 beta multiple interactions
increases expression		 EXP Aluminum Hydroxide promotes the reaction [[Tretinoin co-treated with BDNF protein] results in increased expression of GSK3B protein]; dihydrolipoic acid inhibits the reaction [Aluminum Hydroxide promotes the reaction [[Tretinoin co-treated with BDNF protein] results in increased expression of GSK3B protein]]; dihydrolipoic acid inhibits the reaction [Aluminum Hydroxide results in increased expression of GSK3B protein] CTD PMID:37409350 NCBI chr 3:119,821,321...120,094,447
Ensembl chr 3:119,821,321...120,094,994 		JBrowse link
G ICAM1 intercellular adhesion molecule 1 increases expression EXP Aluminum Hydroxide results in increased expression of ICAM1 protein CTD PMID:11160013 NCBI chr19:10,271,120...10,286,615
Ensembl chr19:10,271,093...10,286,615 		JBrowse link
G IL13 interleukin 13 increases expression
multiple interactions		 ISO Aluminum Hydroxide results in increased expression of IL13 mRNA
[Aluminum Hydroxide co-treated with Ovalbumin] affects the expression of IL13 protein; [Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL13 protein; cang er zi wan affects the reaction [[Aluminum Hydroxide co-treated with Ovalbumin] affects the expression of IL13 protein]; Dexamethasone inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL13 protein]; dioscin inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL13 protein]		 CTD PMID:9328138 PMID:35481609 PMID:36029577 PMID:36855022 NCBI chr 5:132,656,522...132,661,110
Ensembl chr 5:132,656,263...132,661,110 		JBrowse link
G IL18 interleukin 18 multiple interactions ISO [OVAL protein co-treated with Aluminum Hydroxide] results in increased expression of IL18 mRNA; [OVAL protein co-treated with Aluminum Hydroxide] results in increased secretion of IL18 protein; nonylphenol promotes the reaction [[OVAL protein co-treated with Aluminum Hydroxide] results in increased expression of IL18 mRNA]; nonylphenol promotes the reaction [[OVAL protein co-treated with Aluminum Hydroxide] results in increased secretion of IL18 protein] CTD PMID:38176579 NCBI chr11:112,143,260...112,164,094
Ensembl chr11:112,143,251...112,164,096 		JBrowse link
G IL1B interleukin 1 beta multiple interactions EXP
ISO		 [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] co-treated with K-12 lipopolysaccharide] results in increased secretion of IL1B protein modified form; [Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein; CASP1 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]; N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine promotes the reaction [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL1B protein]
[[Aluminum Hydroxide co-treated with Magnesium Hydroxide] co-treated with N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine] results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein; [OVAL protein co-treated with Aluminum Hydroxide] results in increased expression of IL1B mRNA; [OVAL protein co-treated with Aluminum Hydroxide] results in increased secretion of IL1B protein; IL1R1 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]; NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]; nonylphenol promotes the reaction [[OVAL protein co-treated with Aluminum Hydroxide] results in increased expression of IL1B mRNA]; nonylphenol promotes the reaction [[OVAL protein co-treated with Aluminum Hydroxide] results in increased secretion of IL1B protein]; PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]		 CTD PMID:17404311 PMID:18604214 PMID:22075093 PMID:38176579 NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816 		JBrowse link
G IL1R1 interleukin 1 receptor type 1 multiple interactions ISO IL1R1 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein] CTD PMID:18604214 NCBI chr 2:102,070,390...102,179,874
Ensembl chr 2:102,064,544...102,179,874 		JBrowse link
G IL1RN interleukin 1 receptor antagonist increases secretion EXP Aluminum Hydroxide results in increased secretion of IL1RN protein CTD PMID:18390722 NCBI chr 2:113,099,360...113,134,014
Ensembl chr 2:113,099,315...113,134,016 		JBrowse link
G IL2 interleukin 2 increases expression
multiple interactions		 ISO Aluminum Hydroxide results in increased expression of IL2 mRNA
[Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL2 protein; N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine promotes the reaction [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL2 protein]; TLR4 protein affects the reaction [N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine promotes the reaction [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL2 protein]]		 CTD PMID:9328138 PMID:22075093 NCBI chr 4:122,451,470...122,456,725
Ensembl chr 4:122,451,470...122,456,725 		JBrowse link
G IL4 interleukin 4 increases expression
multiple interactions
affects response to substance		 ISO
EXP		 Aluminum Hydroxide results in increased expression of IL4 mRNA
[Aluminum Hydroxide co-treated with Ovalbumin] affects the expression of IL4 protein; [Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL4 protein; cang er zi wan affects the reaction [[Aluminum Hydroxide co-treated with Ovalbumin] affects the expression of IL4 protein]; Dexamethasone inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL4 protein]; dioscin inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL4 protein]; nonylphenol promotes the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL4 protein]
IL4 protein affects the susceptibility to Aluminum Hydroxide
Aluminum Hydroxide inhibits the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of CD1A protein]; Aluminum Hydroxide inhibits the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of CD80 protein]; Aluminum Hydroxide promotes the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of CCR7 protein]; Aluminum Hydroxide promotes the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of TFRC protein]		 CTD PMID:9328138 PMID:11160013 PMID:18390722 PMID:35481609 PMID:36029577 More... NCBI chr 5:132,673,989...132,682,678
Ensembl chr 5:132,673,986...132,682,678 		JBrowse link
G IL5 interleukin 5 increases expression
multiple interactions		 ISO Aluminum Hydroxide results in increased expression of IL5 mRNA
[Aluminum Hydroxide co-treated with Ovalbumin] affects the expression of IL5 protein; [Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL5 protein; cang er zi wan affects the reaction [[Aluminum Hydroxide co-treated with Ovalbumin] affects the expression of IL5 protein]; Dexamethasone inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL5 protein]; dioscin inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL5 protein]; nonylphenol promotes the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL5 protein]		 CTD PMID:9328138 PMID:35481609 PMID:36029577 PMID:36855022 NCBI chr 5:132,541,445...132,556,815
Ensembl chr 5:132,541,445...132,556,838 		JBrowse link
G IL6 interleukin 6 increases expression
multiple interactions		 ISO Aluminum Hydroxide results in increased expression of IL6 mRNA
[OVAL protein co-treated with Aluminum Hydroxide] results in increased expression of IL6 mRNA; [OVAL protein co-treated with Aluminum Hydroxide] results in increased secretion of IL6 protein; nonylphenol promotes the reaction [[OVAL protein co-treated with Aluminum Hydroxide] results in increased expression of IL6 mRNA]; nonylphenol promotes the reaction [[OVAL protein co-treated with Aluminum Hydroxide] results in increased secretion of IL6 protein]		 CTD PMID:9328138 PMID:38176579 NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002 		JBrowse link
G IL7R interleukin 7 receptor multiple interactions ISO [Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL7R mRNA; [Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL7R protein; nonylphenol promotes the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL7R mRNA]; nonylphenol promotes the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL7R protein] CTD PMID:36029577 NCBI chr 5:35,856,891...35,879,603
Ensembl chr 5:35,852,695...35,879,603 		JBrowse link
G JAK1 Janus kinase 1 multiple interactions ISO [Ovalbumin co-treated with Aluminum Hydroxide] results in increased phosphorylation of JAK1 protein; nonylphenol promotes the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased phosphorylation of JAK1 protein] CTD PMID:36029577 NCBI chr 1:64,833,229...65,067,746
Ensembl chr 1:64,833,223...65,067,754 		JBrowse link
G JAK2 Janus kinase 2 multiple interactions ISO [Ovalbumin co-treated with Aluminum Hydroxide] results in increased phosphorylation of JAK2 protein; nonylphenol promotes the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased phosphorylation of JAK2 protein] CTD PMID:36029577 NCBI chr 9:4,984,390...5,129,948
Ensembl chr 9:4,984,390...5,129,948 		JBrowse link
G MAPK3 mitogen-activated protein kinase 3 multiple interactions ISO [Aluminum Hydroxide co-treated with Ovalbumin] affects the expression of MAPK3 mRNA; cang er zi wan affects the reaction [[Aluminum Hydroxide co-treated with Ovalbumin] affects the expression of MAPK3 mRNA] CTD PMID:36855022 NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506 		JBrowse link
G MAPT microtubule associated protein tau increases expression
multiple interactions		 EXP Aluminum Hydroxide results in increased expression of MAPT protein
[BDNF protein co-treated with Tretinoin co-treated with Aluminum Hydroxide] results in increased expression of MAPT protein; Aluminum Hydroxide inhibits the reaction [[Tretinoin co-treated with BDNF protein] results in increased expression of MAPT protein]; Coconut Oil inhibits the reaction [[BDNF protein co-treated with Tretinoin co-treated with Aluminum Hydroxide] results in increased expression of MAPT protein]; Coconut Oil inhibits the reaction [Aluminum Hydroxide results in increased expression of MAPT protein]; dihydrolipoic acid promotes the reaction [Aluminum Hydroxide inhibits the reaction [[Tretinoin co-treated with BDNF protein] results in increased expression of MAPT protein]]		 CTD PMID:37409350 PMID:37989595 NCBI chr17:45,894,554...46,028,334
Ensembl chr17:45,894,527...46,028,334 		JBrowse link
G MUC5AC mucin 5AC, oligomeric mucus/gel-forming multiple interactions ISO [Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of MUC5AC mRNA; dioscin inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of MUC5AC mRNA] CTD PMID:35481609 NCBI chr11:1,157,953...1,201,138
Ensembl chr11:1,157,953...1,201,138 		JBrowse link
G NFE2L2 NFE2 like bZIP transcription factor 2 multiple interactions
increases expression		 EXP Aluminum Hydroxide promotes the reaction [Thimerosal results in increased expression of NFE2L2 protein]
Aluminum Hydroxide results in increased expression of NFE2L2 protein		 CTD PMID:36411272 NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756 		JBrowse link
G NLRP3 NLR family pyrin domain containing 3 multiple interactions ISO [OVAL protein co-treated with Aluminum Hydroxide] results in increased expression of NLRP3 protein; NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]; nonylphenol promotes the reaction [[OVAL protein co-treated with Aluminum Hydroxide] results in increased expression of NLRP3 protein]; nonylphenol results in increased expression of [[OVAL protein co-treated with Aluminum Hydroxide] results in increased expression of NLRP3 mRNA] CTD PMID:18604214 PMID:38176579 NCBI chr 1:247,416,077...247,448,817
Ensembl chr 1:247,332,331...247,449,108 		JBrowse link
G PPP1CA protein phosphatase 1 catalytic subunit alpha multiple interactions EXP Aluminum Hydroxide promotes the reaction [[Tretinoin co-treated with BDNF protein] results in decreased expression of PPP1CA protein]; dihydrolipoic acid inhibits the reaction [Aluminum Hydroxide promotes the reaction [[Tretinoin co-treated with BDNF protein] results in decreased expression of PPP1CA protein]] CTD PMID:37409350 NCBI chr11:67,398,183...67,401,858
Ensembl chr11:67,398,181...67,421,183 		JBrowse link
G PTGS2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO [Aluminum Hydroxide co-treated with Ovalbumin] affects the expression of PTGS2 mRNA; cang er zi wan affects the reaction [[Aluminum Hydroxide co-treated with Ovalbumin] affects the expression of PTGS2 mRNA] CTD PMID:36855022 NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922 		JBrowse link
G PYCARD PYD and CARD domain containing multiple interactions ISO [OVAL protein co-treated with Aluminum Hydroxide] results in increased expression of PYCARD mRNA; [OVAL protein co-treated with Aluminum Hydroxide] results in increased expression of PYCARD protein; nonylphenol promotes the reaction [[OVAL protein co-treated with Aluminum Hydroxide] results in increased expression of PYCARD mRNA]; PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein] CTD PMID:18604214 PMID:38176579 NCBI chr16:31,201,486...31,202,760
Ensembl chr16:31,201,486...31,203,450 		JBrowse link
G RELA RELA proto-oncogene, NF-kB subunit multiple interactions ISO [OVAL protein co-treated with Aluminum Hydroxide] results in increased phosphorylation of RELA protein; nonylphenol promotes the reaction [[OVAL protein co-treated with Aluminum Hydroxide] results in increased phosphorylation of RELA protein] CTD PMID:38176579 NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090 		JBrowse link
G SLC6A3 solute carrier family 6 member 3 increases expression
decreases expression
multiple interactions		 EXP Aluminum Hydroxide results in increased expression of SLC6A3 protein
Aluminum Hydroxide results in decreased expression of SLC6A3 protein
[Thimerosal co-treated with Aluminum Hydroxide] results in increased expression of SLC6A3 protein; Aluminum Hydroxide promotes the reaction [[BDNF protein co-treated with Tretinoin] results in decreased expression of SLC6A3 protein]; Coconut Oil inhibits the reaction [Aluminum Hydroxide promotes the reaction [[BDNF protein co-treated with Tretinoin] results in decreased expression of SLC6A3 protein]]; Coconut Oil inhibits the reaction [Aluminum Hydroxide results in decreased expression of SLC6A3 protein]		 CTD PMID:36411272 PMID:37989595 NCBI chr 5:1,392,794...1,445,440
Ensembl chr 5:1,392,794...1,445,440 		JBrowse link
G SNCA synuclein alpha multiple interactions
increases expression		 EXP [BDNF protein co-treated with Tretinoin co-treated with Aluminum Hydroxide] results in increased expression of SNCA protein; Coconut Oil inhibits the reaction [[BDNF protein co-treated with Tretinoin co-treated with Aluminum Hydroxide] results in increased expression of SNCA protein]
Aluminum Hydroxide results in increased expression of SNCA protein		 CTD PMID:37989595 NCBI chr 4:89,724,099...89,838,304
Ensembl chr 4:89,700,345...89,838,315 		JBrowse link
G STAT3 signal transducer and activator of transcription 3 multiple interactions ISO [Ovalbumin co-treated with Aluminum Hydroxide] results in increased phosphorylation of STAT3 protein; nonylphenol promotes the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased phosphorylation of STAT3 protein] CTD PMID:36029577 NCBI chr17:42,313,324...42,388,442
Ensembl chr17:42,313,324...42,388,568 		JBrowse link
G TFRC transferrin receptor multiple interactions EXP Aluminum Hydroxide promotes the reaction [[CSF2 protein co-treated with IL4 protein] results in increased expression of TFRC protein] CTD PMID:18390722 NCBI chr 3:196,049,284...196,082,090
Ensembl chr 3:196,012,511...196,082,153 		JBrowse link
G TGFB1 transforming growth factor beta 1 multiple interactions ISO [Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of TGFB1 protein; dioscin inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of TGFB1 protein] CTD PMID:35481609 NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922 		JBrowse link
G TLR4 toll like receptor 4 multiple interactions ISO TLR4 protein affects the reaction [N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine promotes the reaction [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL2 protein]]; TLR4 protein affects the susceptibility to [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] co-treated with N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine]; TLR4 protein affects the susceptibility to [Aluminum Hydroxide co-treated with Magnesium Hydroxide] CTD PMID:22075093 NCBI chr 9:117,704,403...117,724,735
Ensembl chr 9:117,704,175...117,724,735 		JBrowse link
G TNF tumor necrosis factor multiple interactions ISO [OVAL protein co-treated with Aluminum Hydroxide] results in increased expression of TNF mRNA; [OVAL protein co-treated with Aluminum Hydroxide] results in increased secretion of TNF protein; [Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of TNF protein; Dexamethasone inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of TNF protein]; dioscin inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of TNF protein]; nonylphenol promotes the reaction [[OVAL protein co-treated with Aluminum Hydroxide] results in increased expression of TNF mRNA]; nonylphenol promotes the reaction [[OVAL protein co-treated with Aluminum Hydroxide] results in increased secretion of TNF protein] CTD PMID:35481609 PMID:38176579 NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336 		JBrowse link
G TNFRSF4 TNF receptor superfamily member 4 multiple interactions ISO [Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of TNFRSF4 mRNA; nonylphenol promotes the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of TNFRSF4 mRNA] CTD PMID:36029577 NCBI chr 1:1,211,340...1,214,153
Ensembl chr 1:1,211,326...1,214,153 		JBrowse link
G TNFSF4 TNF superfamily member 4 multiple interactions ISO [Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of TNFSF4 mRNA; nonylphenol promotes the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of TNFSF4 mRNA] CTD PMID:36029577 NCBI chr 1:173,172,870...173,450,733
Ensembl chr 1:173,162,645...173,477,583 		JBrowse link
G TSLP thymic stromal lymphopoietin multiple interactions ISO [Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of TSLP mRNA; [Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of TSLP protein; nonylphenol promotes the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of TSLP protein] CTD PMID:36029577 NCBI chr 5:111,070,062...111,078,026
Ensembl chr 5:111,070,062...111,078,026 		JBrowse link
G WNT5A Wnt family member 5A decreases expression
multiple interactions		 EXP Aluminum Hydroxide results in decreased expression of WNT5A protein
Aluminum Hydroxide promotes the reaction [[Tretinoin co-treated with BDNF protein] results in decreased expression of WNT5A protein]; dihydrolipoic acid inhibits the reaction [Aluminum Hydroxide promotes the reaction [[Tretinoin co-treated with BDNF protein] results in decreased expression of WNT5A protein]]; dihydrolipoic acid inhibits the reaction [Aluminum Hydroxide results in decreased expression of WNT5A protein]		 CTD PMID:37409350 NCBI chr 3:55,465,715...55,505,263
Ensembl chr 3:55,465,715...55,490,539 		JBrowse link
aluminium ion term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G HMBS hydroxymethylbilane synthase decreases activity ISO Aluminium ion decreases activity of purified Hmbs protein RGD PMID:6732900 RGD:25394584 NCBI chr11:119,084,881...119,093,549
Ensembl chr11:119,084,866...119,093,834 		JBrowse link
aluminium oxide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ACP5 acid phosphatase 5, tartrate resistant decreases expression EXP Aluminum Oxide results in decreased expression of ACP5 mRNA CTD PMID:15585240 NCBI chr19:11,574,660...11,578,975
Ensembl chr19:11,574,653...11,579,993 		JBrowse link
G ACTR2 actin related protein 2 multiple interactions ISO [Nanotubes, Carbon co-treated with Aluminum Oxide] results in increased secretion of ACTR2 protein CTD PMID:25598225 NCBI chr 2:65,227,831...65,271,253
Ensembl chr 2:65,227,788...65,271,253 		JBrowse link
G ALPL alkaline phosphatase, biomineralization associated increases expression EXP Aluminum Oxide results in increased expression of ALPL mRNA CTD PMID:19464052 NCBI chr 1:21,508,984...21,578,410
Ensembl chr 1:21,509,397...21,578,410 		JBrowse link
G BCL2L1 BCL2 like 1 increases expression EXP Aluminum Oxide analog results in increased expression of BCL2L1 mRNA CTD PMID:23132795 NCBI chr20:31,664,452...31,723,963
Ensembl chr20:31,664,452...31,723,989 		JBrowse link
G BGLAP bone gamma-carboxyglutamate protein increases expression EXP Aluminum Oxide results in increased expression of BGLAP mRNA CTD PMID:19464052 NCBI chr 1:156,242,184...156,243,317
Ensembl chr 1:156,242,184...156,243,317 		JBrowse link
G BGN biglycan increases expression EXP Aluminum Oxide results in increased expression of BGN mRNA CTD PMID:19464052 NCBI chr  X:153,494,980...153,509,546
Ensembl chr  X:153,494,980...153,509,546 		JBrowse link
G BMP1 bone morphogenetic protein 1 increases expression EXP Aluminum Oxide results in increased expression of BMP1 mRNA CTD PMID:19464052 NCBI chr 8:22,165,372...22,212,326
Ensembl chr 8:22,165,140...22,212,326 		JBrowse link
G BMP2 bone morphogenetic protein 2 increases expression EXP Aluminum Oxide results in increased expression of BMP2 mRNA CTD PMID:19464052 NCBI chr20:6,767,686...6,780,246
Ensembl chr20:6,767,686...6,780,246 		JBrowse link
G BMP4 bone morphogenetic protein 4 increases expression EXP Aluminum Oxide results in increased expression of BMP4 mRNA CTD PMID:19464052 NCBI chr14:53,949,736...53,956,891
Ensembl chr14:53,949,736...53,958,761 		JBrowse link
G BMP6 bone morphogenetic protein 6 decreases expression EXP Aluminum Oxide results in decreased expression of BMP6 mRNA CTD PMID:19464052 NCBI chr 6:7,726,099...7,881,728
Ensembl chr 6:7,726,099...7,881,728 		JBrowse link
G C3 complement C3 multiple interactions ISO [Nanotubes, Carbon co-treated with Aluminum Oxide] results in increased secretion of C3 protein CTD PMID:25598225 NCBI chr19:6,677,704...6,720,650
Ensembl chr19:6,677,704...6,730,562 		JBrowse link
G CAMP cathelicidin antimicrobial peptide multiple interactions ISO [Nanotubes, Carbon co-treated with Aluminum Oxide] results in increased secretion of CAMP protein CTD PMID:25598225 NCBI chr 3:48,223,495...48,225,485
Ensembl chr 3:48,223,347...48,225,491 		JBrowse link
G CASP3 caspase 3 increases expression
multiple interactions		 ISO Aluminum Oxide results in increased expression of CASP3
sesamol inhibits the reaction [Aluminum Oxide results in increased expression of CASP3 mRNA]		 CTD PMID:21329562 PMID:35403826 NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062 		JBrowse link
G CAT catalase multiple interactions
decreases activity		 ISO sesamol inhibits the reaction [Aluminum Oxide results in decreased activity of CAT protein] CTD PMID:35403826 NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060 		JBrowse link
G CCL2 C-C motif chemokine ligand 2 increases secretion EXP Aluminum Oxide results in increased secretion of CCL2 protein CTD PMID:17618502 NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,274...34,257,208 		JBrowse link
G CD14 CD14 molecule multiple interactions ISO [Nanotubes, Carbon co-treated with Aluminum Oxide] results in increased secretion of CD14 protein CTD PMID:25598225 NCBI chr 5:140,631,732...140,633,701
Ensembl chr 5:140,631,728...140,633,700 		JBrowse link
G CD36 CD36 molecule (CD36 blood group) increases expression EXP Aluminum Oxide results in increased expression of CD36 mRNA CTD PMID:19464052 NCBI chr 7:80,602,207...80,679,274
Ensembl chr 7:80,369,575...80,679,277 		JBrowse link
G CDH11 cadherin 11 increases expression EXP Aluminum Oxide results in increased expression of CDH11 mRNA CTD PMID:19464052 NCBI chr16:64,943,753...65,123,744
Ensembl chr16:64,943,753...65,126,112 		JBrowse link
G CDKN1A cyclin dependent kinase inhibitor 1A increases expression EXP Aluminum Oxide analog results in increased expression of CDKN1A mRNA CTD PMID:23132795 NCBI chr 6:36,676,463...36,687,332
Ensembl chr 6:36,676,460...36,687,397 		JBrowse link
G CLU clusterin multiple interactions ISO [Nanotubes, Carbon co-treated with Aluminum Oxide] results in increased secretion of CLU protein CTD PMID:25598225 NCBI chr 8:27,596,917...27,614,700
Ensembl chr 8:27,596,917...27,614,700 		JBrowse link
G COL10A1 collagen type X alpha 1 chain increases expression EXP Aluminum Oxide results in increased expression of COL10A1 mRNA CTD PMID:19464052 NCBI chr 6:116,118,909...116,217,144
Ensembl chr 6:116,118,909...116,158,747 		JBrowse link
G COL11A1 collagen type XI alpha 1 chain increases expression EXP Aluminum Oxide results in increased expression of COL11A1 mRNA CTD PMID:19464052 NCBI chr 1:102,876,473...103,108,522
Ensembl chr 1:102,876,467...103,108,872 		JBrowse link
G COL15A1 collagen type XV alpha 1 chain increases expression EXP Aluminum Oxide results in increased expression of COL15A1 mRNA CTD PMID:19464052 NCBI chr 9:98,943,907...99,070,787
Ensembl chr 9:98,943,179...99,070,787 		JBrowse link
G COL1A1 collagen type I alpha 1 chain multiple interactions EXP [Aluminum Oxide co-treated with Magnesium] results in increased expression of COL1A1 protein CTD PMID:12209937 NCBI chr17:50,184,101...50,201,631
Ensembl chr17:50,184,101...50,201,632 		JBrowse link
G COL1A2 collagen type I alpha 2 chain increases expression EXP Aluminum Oxide results in increased expression of COL1A2 mRNA CTD PMID:19464052 NCBI chr 7:94,394,895...94,431,227
Ensembl chr 7:94,394,895...94,431,227 		JBrowse link
G COMP cartilage oligomeric matrix protein increases expression EXP Aluminum Oxide results in increased expression of COMP mRNA CTD PMID:19464052 NCBI chr19:18,782,773...18,791,305
Ensembl chr19:18,782,773...18,791,305 		JBrowse link
G CSF2 colony stimulating factor 2 increases secretion EXP Aluminum Oxide results in increased secretion of CSF2 protein CTD PMID:15046894 NCBI chr 5:132,073,789...132,076,170
Ensembl chr 5:132,073,789...132,076,170 		JBrowse link
G CTSK cathepsin K increases expression EXP Aluminum Oxide results in increased expression of CTSK mRNA CTD PMID:19464052 NCBI chr 1:150,796,208...150,808,260
Ensembl chr 1:150,794,880...150,809,577 		JBrowse link
G CXCL8 C-X-C motif chemokine ligand 8 increases expression EXP Aluminum Oxide results in increased expression of CXCL8 mRNA CTD PMID:15183442 NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716 		JBrowse link
G EGFR epidermal growth factor receptor increases expression EXP Aluminum Oxide results in increased expression of EGFR mRNA CTD PMID:19464052 NCBI chr 7:55,019,017...55,211,628
Ensembl chr 7:55,019,017...55,211,628 		JBrowse link
G FGB fibrinogen beta chain multiple interactions ISO [Nanotubes, Carbon co-treated with Aluminum Oxide] results in increased secretion of FGB protein CTD PMID:25598225 NCBI chr 4:154,562,980...154,572,807
Ensembl chr 4:154,563,011...154,572,807 		JBrowse link
G FLT1 fms related receptor tyrosine kinase 1 increases expression EXP Aluminum Oxide results in increased expression of FLT1 mRNA CTD PMID:19464052 NCBI chr13:28,300,346...28,495,128
Ensembl chr13:28,300,346...28,495,145 		JBrowse link
G FN1 fibronectin 1 increases expression EXP Aluminum Oxide results in increased expression of FN1 mRNA CTD PMID:19464052 NCBI chr 2:215,360,865...215,436,068
Ensembl chr 2:215,360,440...215,436,073 		JBrowse link
G FOS Fos proto-oncogene, AP-1 transcription factor subunit decreases expression EXP Aluminum Oxide results in decreased expression of FOS mRNA CTD PMID:15585240 NCBI chr14:75,278,828...75,282,230
Ensembl chr14:75,278,826...75,283,190 		JBrowse link
G GSTA1 glutathione S-transferase alpha 1 multiple interactions
increases expression		 ISO sesamol inhibits the reaction [Aluminum Oxide results in increased expression of GSTA1 mRNA] CTD PMID:35403826 NCBI chr 6:52,791,371...52,803,816
Ensembl chr 6:52,791,371...52,803,860 		JBrowse link
G IBSP integrin binding sialoprotein increases expression EXP Aluminum Oxide results in increased expression of IBSP mRNA CTD PMID:19464052 NCBI chr 4:87,799,554...87,812,435
Ensembl chr 4:87,799,554...87,812,435 		JBrowse link
G ICAM1 intercellular adhesion molecule 1 increases expression EXP Aluminum Oxide results in increased expression of ICAM1 protein CTD PMID:18456438 NCBI chr19:10,271,120...10,286,615
Ensembl chr19:10,271,093...10,286,615 		JBrowse link
G IGF1 insulin like growth factor 1 affects expression EXP Aluminum Oxide affects the expression of IGF1 mRNA CTD PMID:19464052 NCBI chr12:102,395,874...102,481,839
Ensembl chr12:102,395,874...102,481,744 		JBrowse link
G IL10 interleukin 10 increases expression EXP Aluminum Oxide results in increased expression of IL10 mRNA CTD PMID:15183442 NCBI chr 1:206,767,602...206,772,494
Ensembl chr 1:206,767,602...206,774,541 		JBrowse link
G IL1A interleukin 1 alpha increases expression EXP Aluminum Oxide results in increased expression of IL1A mRNA CTD PMID:15183442 NCBI chr 2:112,773,925...112,784,493
Ensembl chr 2:112,773,925...112,784,493 		JBrowse link
G IL1B interleukin 1 beta increases expression
increases secretion
multiple interactions		 EXP
ISO		 Aluminum Oxide results in increased expression of IL1B mRNA
Aluminum Oxide results in increased secretion of IL1B protein
[Aluminum Oxide co-treated with Nanotubes, Carbon] results in decreased secretion of IL1B protein; Aluminum Oxide inhibits the reaction [Nanotubes, Carbon results in increased secretion of IL1B protein]
[Aluminum Oxide co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein; [Aluminum Oxide co-treated with Nanotubes, Carbon co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein; [Aluminum Oxide co-treated with Nanotubes, Carbon] promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; Aluminum Oxide promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; Aluminum Oxide promotes the reaction [Nanotubes, Carbon results in increased secretion of IL1B protein]		 CTD PMID:15183442 PMID:16488289 PMID:17618502 PMID:25216247 NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816 		JBrowse link
G IL6 interleukin 6 increases expression
multiple interactions
decreases secretion		 EXP
ISO		 Aluminum Oxide results in increased expression of IL6 mRNA; Aluminum Oxide results in increased expression of IL6 protein
[Aluminum Oxide co-treated with Nanotubes, Carbon] results in increased secretion of IL6 protein
Aluminum Oxide results in decreased secretion of IL6 protein
Aluminum Oxide inhibits the reaction [Nanotubes, Carbon results in increased secretion of IL6 protein]		 CTD PMID:11771709 PMID:25216247 NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002 		JBrowse link
G ITGA1 integrin subunit alpha 1 increases expression EXP Aluminum Oxide results in increased expression of ITGA1 mRNA CTD PMID:19464052 NCBI chr 5:52,787,916...52,959,209
Ensembl chr 5:52,787,916...52,959,209 		JBrowse link
G ITGA3 integrin subunit alpha 3 increases expression EXP Aluminum Oxide results in increased expression of ITGA3 mRNA CTD PMID:19464052 NCBI chr17:50,056,110...50,090,481
Ensembl chr17:50,055,968...50,090,481 		JBrowse link
G ITGA5 integrin subunit alpha 5 multiple interactions EXP [Aluminum Oxide co-treated with Magnesium] results in increased expression of ITGA5 protein CTD PMID:12209937 NCBI chr12:54,395,261...54,419,266
Ensembl chr12:54,395,261...54,419,266 		JBrowse link
G ITGB1 integrin subunit beta 1 multiple interactions EXP [Aluminum Oxide co-treated with Magnesium] results in increased expression of ITGB1 protein CTD PMID:12209937 NCBI chr10:32,900,318...32,958,230
Ensembl chr10:32,887,273...33,005,792 		JBrowse link
G ITIH4 inter-alpha-trypsin inhibitor heavy chain 4 multiple interactions ISO [Nanotubes, Carbon co-treated with Aluminum Oxide] results in increased secretion of ITIH4 protein CTD PMID:25598225 NCBI chr 3:52,812,962...52,830,672
Ensembl chr 3:52,812,962...52,830,688 		JBrowse link
G JUN Jun proto-oncogene, AP-1 transcription factor subunit increases expression EXP Aluminum Oxide results in increased expression of JUN mRNA CTD PMID:16488289 NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,776,845...58,784,048 		JBrowse link
G LCN2 lipocalin 2 multiple interactions ISO [Nanotubes, Carbon co-treated with Aluminum Oxide] results in increased secretion of LCN2 protein CTD PMID:25598225 NCBI chr 9:128,149,453...128,153,453
Ensembl chr 9:128,149,071...128,153,453 		JBrowse link
G LTF lactotransferrin multiple interactions ISO [Nanotubes, Carbon co-treated with Aluminum Oxide] results in increased secretion of LTF protein CTD PMID:25598225 NCBI chr 3:46,435,645...46,485,234
Ensembl chr 3:46,435,645...46,485,234 		JBrowse link
G MMP1 matrix metallopeptidase 1 increases expression EXP Aluminum Oxide results in increased expression of MMP1 mRNA CTD PMID:16488289 NCBI chr11:102,789,919...102,798,160
Ensembl chr11:102,789,401...102,798,160 		JBrowse link
G MMP2 matrix metallopeptidase 2 increases expression EXP Aluminum Oxide results in increased expression of MMP2 mRNA CTD PMID:14661256 NCBI chr16:55,478,830...55,506,691
Ensembl chr16:55,389,700...55,506,691 		JBrowse link
G MMP3 matrix metallopeptidase 3 increases expression EXP Aluminum Oxide results in increased expression of MMP3 mRNA CTD PMID:16488289 NCBI chr11:102,835,801...102,843,609
Ensembl chr11:102,835,801...102,843,609 		JBrowse link
G MMP8 matrix metallopeptidase 8 decreases expression EXP Aluminum Oxide results in decreased expression of MMP8 mRNA CTD PMID:19464052 NCBI chr11:102,711,796...102,724,954
Ensembl chr11:102,711,796...102,727,050 		JBrowse link
G MMP9 matrix metallopeptidase 9 increases expression EXP Aluminum Oxide results in increased expression of MMP9 mRNA CTD PMID:16488289 NCBI chr20:46,008,908...46,016,561
Ensembl chr20:46,008,908...46,016,561 		JBrowse link
G MPO myeloperoxidase multiple interactions ISO [Nanotubes, Carbon co-treated with Aluminum Oxide] results in increased secretion of MPO protein CTD PMID:25598225 NCBI chr17:58,269,855...58,280,935
Ensembl chr17:58,269,855...58,280,935 		JBrowse link
G PDGFA platelet derived growth factor subunit A increases expression EXP Aluminum Oxide results in increased expression of PDGFA mRNA CTD PMID:19464052 NCBI chr 7:497,258...520,700
Ensembl chr 7:497,258...520,296 		JBrowse link
G PHEX phosphate regulating endopeptidase X-linked increases expression EXP Aluminum Oxide results in increased expression of PHEX mRNA CTD PMID:19464052 NCBI chr  X:22,032,325...22,251,310
Ensembl chr  X:22,032,325...22,494,713 		JBrowse link
G PTK2 protein tyrosine kinase 2 multiple interactions EXP [Aluminum Oxide co-treated with Magnesium] results in increased expression of PTK2 protein CTD PMID:12209937 NCBI chr 8:140,657,900...141,002,079
Ensembl chr 8:140,657,900...141,002,216 		JBrowse link
G S100A8 S100 calcium binding protein A8 multiple interactions ISO [Nanotubes, Carbon co-treated with Aluminum Oxide] results in increased secretion of S100A8 protein CTD PMID:25598225 NCBI chr 1:153,390,032...153,422,583
Ensembl chr 1:153,390,032...153,391,073 		JBrowse link
G S100A9 S100 calcium binding protein A9 multiple interactions ISO [Nanotubes, Carbon co-treated with Aluminum Oxide] results in increased secretion of S100A9 protein CTD PMID:25598225 NCBI chr 1:153,357,854...153,361,023
Ensembl chr 1:153,357,854...153,361,023 		JBrowse link
G SCARB1 scavenger receptor class B member 1 decreases expression EXP Aluminum Oxide results in decreased expression of SCARB1 mRNA CTD PMID:19464052 NCBI chr12:124,776,856...124,863,864
Ensembl chr12:124,776,856...124,882,668 		JBrowse link
G SELE selectin E increases expression EXP Aluminum Oxide results in increased expression of SELE protein CTD PMID:18456438 NCBI chr 1:169,722,640...169,734,079
Ensembl chr 1:169,722,640...169,764,705 		JBrowse link
G SERPINH1 serpin family H member 1 increases expression EXP Aluminum Oxide results in increased expression of SERPINH1 mRNA CTD PMID:19464052 NCBI chr11:75,562,253...75,572,783
Ensembl chr11:75,562,056...75,572,783 		JBrowse link
G SHC1 SHC adaptor protein 1 multiple interactions EXP [Aluminum Oxide co-treated with Magnesium] results in increased expression of SHC1 protein; [Aluminum Oxide co-treated with Magnesium] results in increased expression of SHC1 protein alternative form CTD PMID:12209937 NCBI chr 1:154,962,298...154,974,376
Ensembl chr 1:154,962,298...154,974,395 		JBrowse link
G SOD1 superoxide dismutase 1 decreases activity
multiple interactions		 ISO Aluminum Oxide results in decreased activity of SOD1 protein
sesamol inhibits the reaction [Aluminum Oxide results in decreased activity of SOD1 protein]		 CTD PMID:35403826 NCBI chr21:31,659,693...31,668,931
Ensembl chr21:31,659,666...31,668,931 		JBrowse link
G SP7 Sp7 transcription factor increases expression EXP Aluminum Oxide results in increased expression of SP7 mRNA CTD PMID:19464052 NCBI chr12:53,326,575...53,344,793
Ensembl chr12:53,326,575...53,345,315 		JBrowse link
G SPP1 secreted phosphoprotein 1 increases expression
multiple interactions
decreases secretion		 EXP
ISO		 Aluminum Oxide results in increased expression of SPP1 mRNA
[Aluminum Oxide co-treated with Nanotubes, Carbon] results in increased secretion of SPP1 protein; Aluminum Oxide inhibits the reaction [Nanotubes, Carbon results in increased expression of SPP1 mRNA]; Aluminum Oxide inhibits the reaction [Nanotubes, Carbon results in increased secretion of SPP1 protein]
Aluminum Oxide results in decreased secretion of SPP1 protein
[Aluminum Oxide co-treated with Nanotubes, Carbon] inhibits the reaction [Lipopolysaccharides results in increased secretion of SPP1 protein]; Aluminum Oxide inhibits the reaction [Lipopolysaccharides results in increased secretion of SPP1 protein]; Aluminum Oxide inhibits the reaction [Nanotubes, Carbon results in increased secretion of SPP1 protein]		 CTD PMID:19464052 PMID:25216247 NCBI chr 4:87,975,714...87,983,411
Ensembl chr 4:87,975,667...87,983,532 		JBrowse link
G STATH statherin increases expression EXP Aluminum Oxide results in increased expression of STATH mRNA CTD PMID:19464052 NCBI chr 4:69,995,966...70,002,570
Ensembl chr 4:69,995,966...70,002,570 		JBrowse link
G TGFB1 transforming growth factor beta 1 increases expression EXP Aluminum Oxide results in increased expression of TGFB1 mRNA CTD PMID:19464052 NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922 		JBrowse link
G TGFBR2 transforming growth factor beta receptor 2 increases expression EXP Aluminum Oxide results in increased expression of TGFBR2 mRNA CTD PMID:19464052 NCBI chr 3:30,606,356...30,694,142
Ensembl chr 3:30,606,478...30,694,249 		JBrowse link
G TNF tumor necrosis factor increases activity
increases expression
multiple interactions
affects secretion		 ISO
EXP		 Aluminum Oxide results in increased activity of TNF protein
Aluminum Oxide results in increased expression of TNF mRNA
sesamol inhibits the reaction [Aluminum Oxide results in increased expression of TNF mRNA]
[Aluminum Oxide co-treated with Nanotubes, Carbon] results in increased expression of TNF mRNA
Aluminum Oxide inhibits the reaction [Nanotubes, Carbon results in increased secretion of TNF protein]
Aluminum Oxide affects the secretion of TNF protein		 CTD PMID:10413987 PMID:11306444 PMID:15183442 PMID:16488289 PMID:25216247 More... NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336 		JBrowse link
G TNFSF10 TNF superfamily member 10 increases expression EXP Aluminum Oxide analog results in increased expression of TNFSF10 mRNA CTD PMID:23132795 NCBI chr 3:172,505,508...172,523,430
Ensembl chr 3:172,505,508...172,523,475 		JBrowse link
G TP53 tumor protein p53 increases expression EXP Aluminum Oxide analog results in increased expression of TP53 mRNA CTD PMID:23132795 NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,546 		JBrowse link
G VCAM1 vascular cell adhesion molecule 1 increases expression EXP Aluminum Oxide results in increased expression of VCAM1 mRNA; Aluminum Oxide results in increased expression of VCAM1 protein CTD PMID:18456438 PMID:19464052 NCBI chr 1:100,719,742...100,739,045
Ensembl chr 1:100,719,742...100,739,045 		JBrowse link
G VEGFA vascular endothelial growth factor A increases expression EXP Aluminum Oxide results in increased expression of VEGFA mRNA CTD PMID:19464052 NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487 		JBrowse link
G VEGFB vascular endothelial growth factor B increases expression EXP Aluminum Oxide results in increased expression of VEGFB mRNA CTD PMID:19464052 NCBI chr11:64,234,584...64,239,264
Ensembl chr11:64,234,584...64,239,264 		JBrowse link
aluminium phosphide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CAT catalase decreases expression
decreases activity		 ISO aluminum phosphide results in decreased expression of CAT protein
aluminum phosphide results in decreased activity of CAT protein		 CTD PMID:11742581 PMID:23041170 NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060 		JBrowse link
G G6PC1 glucose-6-phosphatase catalytic subunit 1 increases activity ISO aluminum phosphide results in increased activity of G6PC1 protein CTD PMID:20929055 NCBI chr17:42,900,799...42,914,438
Ensembl chr17:42,900,797...42,914,438 		JBrowse link
G G6PD glucose-6-phosphate dehydrogenase decreases activity ISO aluminum phosphide results in decreased activity of G6PD protein CTD PMID:20929055 NCBI chr  X:154,531,390...154,547,569
Ensembl chr  X:154,517,825...154,547,572 		JBrowse link
G NPPB natriuretic peptide B increases expression
multiple interactions		 ISO aluminum phosphide results in increased expression of NPPB mRNA
Exenatide inhibits the reaction [aluminum phosphide results in increased expression of NPPB mRNA]		 CTD PMID:34569344 NCBI chr 1:11,857,464...11,858,945
Ensembl chr 1:11,857,464...11,858,945 		JBrowse link
G PFKL phosphofructokinase, liver type decreases activity ISO aluminum phosphide results in decreased activity of PFKL protein CTD PMID:20929055 NCBI chr21:44,300,053...44,327,373
Ensembl chr21:44,300,051...44,327,376 		JBrowse link
G PYGL glycogen phosphorylase L increases activity ISO aluminum phosphide results in increased activity of PYGL protein CTD PMID:20929055 NCBI chr14:50,905,217...50,944,483
Ensembl chr14:50,857,891...50,944,483 		JBrowse link
G REN renin increases activity EXP aluminum phosphide results in increased activity of REN protein CTD PMID:2200784 NCBI chr 1:204,154,819...204,166,337
Ensembl chr 1:204,154,819...204,190,324 		JBrowse link
G TNNI1 troponin I1, slow skeletal type increases expression
multiple interactions		 ISO aluminum phosphide results in increased expression of TNNI1 protein
Exenatide inhibits the reaction [aluminum phosphide results in increased expression of TNNI1 protein]		 CTD PMID:34569344 NCBI chr 1:201,403,784...201,421,730
Ensembl chr 1:201,403,784...201,429,866 		JBrowse link
G TNNI3 troponin I3, cardiac type multiple interactions
increases expression		 ISO Taurine inhibits the reaction [aluminum phosphide results in increased expression of TNNI3 protein] CTD PMID:34139304 NCBI chr19:55,151,767...55,157,732
Ensembl chr19:55,151,767...55,157,773 		JBrowse link
aluminium sulfate (anhydrous) term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ADAM9 ADAM metallopeptidase domain 9 decreases expression EXP aluminum sulfate results in decreased expression of ADAM9 mRNA CTD PMID:15961160 NCBI chr 8:38,996,973...39,105,261
Ensembl chr 8:38,996,754...39,105,445 		JBrowse link
G APP amyloid beta precursor protein affects expression
increases expression		 ISO
EXP		 aluminum sulfate affects the expression of APP protein
aluminum sulfate results in increased expression of APP mRNA		 CTD PMID:10721010 PMID:15961160 NCBI chr21:25,880,550...26,171,128
Ensembl chr21:25,880,535...26,171,128 		JBrowse link
G ATF4 activating transcription factor 4 multiple interactions ISO [Ovalbumin co-treated with aluminum sulfate] results in increased expression of ATF4 mRNA; [Ovalbumin co-treated with aluminum sulfate] results in increased expression of ATF4 protein; Dexamethasone inhibits the reaction [[Ovalbumin co-treated with aluminum sulfate] results in increased expression of ATF4 mRNA]; Gu-Ben-Fang-Xiao decoction inhibits the reaction [[Ovalbumin co-treated with aluminum sulfate] results in increased expression of ATF4 mRNA]; Gu-Ben-Fang-Xiao decoction inhibits the reaction [[Ovalbumin co-treated with aluminum sulfate] results in increased expression of ATF4 protein]; montelukast inhibits the reaction [[Ovalbumin co-treated with aluminum sulfate] results in increased expression of ATF4 mRNA] CTD PMID:27660012 NCBI chr22:39,520,559...39,522,686
Ensembl chr22:39,519,695...39,522,686 		JBrowse link
G CASP1 caspase 1 multiple interactions ISO [Lipopolysaccharides co-treated with aluminum sulfate] results in increased activity of CASP1 protein; CASP1 protein promotes the reaction [[Lipopolysaccharides co-treated with aluminum sulfate] results in increased secretion of IL1B protein]; leptomycin B inhibits the reaction [[Lipopolysaccharides co-treated with aluminum sulfate] results in increased activity of CASP1 protein] CTD PMID:23430110 PMID:24158569 NCBI chr11:105,025,443...105,036,686
Ensembl chr11:105,025,397...105,035,250 		JBrowse link
G CCL11 C-C motif chemokine ligand 11 multiple interactions ISO [Ovalbumin co-treated with aluminum sulfate] results in increased secretion of CCL11 protein CTD PMID:27660012 NCBI chr17:34,285,742...34,288,334
Ensembl chr17:34,285,742...34,288,334 		JBrowse link
G CTSB cathepsin B increases expression EXP aluminum sulfate results in increased expression of CTSB protein CTD PMID:24158569 NCBI chr 8:11,842,524...11,868,087
Ensembl chr 8:11,842,524...11,869,533 		JBrowse link
G CXCL1 C-X-C motif chemokine ligand 1 multiple interactions ISO [Ovalbumin co-treated with aluminum sulfate] results in increased secretion of CXCL1 protein; Dexamethasone inhibits the reaction [[Ovalbumin co-treated with aluminum sulfate] results in increased secretion of CXCL1 protein]; Gu-Ben-Fang-Xiao decoction inhibits the reaction [[Ovalbumin co-treated with aluminum sulfate] results in increased secretion of CXCL1 protein] CTD PMID:27660012 NCBI chr 4:73,869,393...73,871,308
Ensembl chr 4:73,869,393...73,871,308 		JBrowse link
G CXCL2 C-X-C motif chemokine ligand 2 multiple interactions ISO [Ovalbumin co-treated with aluminum sulfate] results in increased secretion of CXCL2 protein CTD PMID:27660012 NCBI chr 4:74,097,040...74,099,195
Ensembl chr 4:74,097,040...74,099,196 		JBrowse link
G DAXX death domain associated protein increases expression EXP aluminum sulfate results in increased expression of DAXX mRNA CTD PMID:15961160 NCBI chr 6:33,318,558...33,322,959
Ensembl chr 6:33,318,558...33,323,016 		JBrowse link
G DDIT3 DNA damage inducible transcript 3 multiple interactions ISO [Ovalbumin co-treated with aluminum sulfate] results in increased expression of DDIT3 mRNA; [Ovalbumin co-treated with aluminum sulfate] results in increased expression of DDIT3 protein; Gu-Ben-Fang-Xiao decoction inhibits the reaction [[Ovalbumin co-treated with aluminum sulfate] results in increased expression of DDIT3 mRNA]; Gu-Ben-Fang-Xiao decoction inhibits the reaction [[Ovalbumin co-treated with aluminum sulfate] results in increased expression of DDIT3 protein]; montelukast inhibits the reaction [[Ovalbumin co-treated with aluminum sulfate] results in increased expression of DDIT3 mRNA]; montelukast inhibits the reaction [[Ovalbumin co-treated with aluminum sulfate] results in increased expression of DDIT3 protein] CTD PMID:27660012 NCBI chr12:57,516,588...57,520,517
Ensembl chr12:57,516,588...57,521,737 		JBrowse link
G EIF2AK3 eukaryotic translation initiation factor 2 alpha kinase 3 multiple interactions ISO [Ovalbumin co-treated with aluminum sulfate] results in increased expression of EIF2AK3 mRNA; [Ovalbumin co-treated with aluminum sulfate] results in increased expression of EIF2AK3 protein; Gu-Ben-Fang-Xiao decoction inhibits the reaction [[Ovalbumin co-treated with aluminum sulfate] results in increased expression of EIF2AK3 mRNA]; Gu-Ben-Fang-Xiao decoction inhibits the reaction [[Ovalbumin co-treated with aluminum sulfate] results in increased expression of EIF2AK3 protein]; montelukast inhibits the reaction [[Ovalbumin co-treated with aluminum sulfate] results in increased expression of EIF2AK3 mRNA] CTD PMID:27660012 NCBI chr 2:88,556,741...88,628,145
Ensembl chr 2:88,556,741...88,691,518 		JBrowse link
G EIF2S1 eukaryotic translation initiation factor 2 subunit alpha multiple interactions ISO [Ovalbumin co-treated with aluminum sulfate] results in increased expression of and results in increased phosphorylation of EIF2S1 protein; [Ovalbumin co-treated with aluminum sulfate] results in increased expression of EIF2S1 mRNA; Dexamethasone inhibits the reaction [[Ovalbumin co-treated with aluminum sulfate] results in increased expression of EIF2S1 mRNA]; Gu-Ben-Fang-Xiao decoction inhibits the reaction [[Ovalbumin co-treated with aluminum sulfate] results in increased expression of EIF2S1 mRNA]; Gu-Ben-Fang-Xiao decoction inhibits the reaction [[Ovalbumin co-treated with aluminum sulfate] results in increased phosphorylation of EIF2S1 protein] CTD PMID:27660012 NCBI chr14:67,360,328...67,386,516
Ensembl chr14:67,360,328...67,386,516 		JBrowse link
G ERN1 endoplasmic reticulum to nucleus signaling 1 multiple interactions ISO [Ovalbumin co-treated with aluminum sulfate] results in increased expression of ERN1 mRNA; [Ovalbumin co-treated with aluminum sulfate] results in increased expression of ERN1 protein; Dexamethasone inhibits the reaction [[Ovalbumin co-treated with aluminum sulfate] results in increased expression of ERN1 mRNA]; Dexamethasone inhibits the reaction [[Ovalbumin co-treated with aluminum sulfate] results in increased expression of ERN1 protein]; Gu-Ben-Fang-Xiao decoction inhibits the reaction [[Ovalbumin co-treated with aluminum sulfate] results in increased expression of ERN1 mRNA]; Gu-Ben-Fang-Xiao decoction inhibits the reaction [[Ovalbumin co-treated with aluminum sulfate] results in increased expression of ERN1 protein]; montelukast inhibits the reaction [[Ovalbumin co-treated with aluminum sulfate] results in increased expression of ERN1 mRNA]; montelukast inhibits the reaction [[Ovalbumin co-treated with aluminum sulfate] results in increased expression of ERN1 protein] CTD PMID:27660012 NCBI chr17:64,039,142...64,130,144
Ensembl chr17:64,039,080...64,130,819 		JBrowse link
G GATA2 GATA binding protein 2 decreases expression EXP aluminum sulfate results in decreased expression of GATA2 mRNA CTD PMID:15961160 NCBI chr 3:128,479,422...128,493,201
Ensembl chr 3:128,479,427...128,493,201 		JBrowse link
G GTF2H1 general transcription factor IIH subunit 1 decreases expression EXP aluminum sulfate results in decreased expression of GTF2H1 mRNA CTD PMID:15961160 NCBI chr11:18,322,567...18,367,045
Ensembl chr11:18,322,295...18,367,045 		JBrowse link
G IFNG interferon gamma multiple interactions ISO [Ovalbumin co-treated with aluminum sulfate] results in increased expression of IFNG protein; Gu-Ben-Fang-Xiao decoction promotes the reaction [[Ovalbumin co-treated with aluminum sulfate] results in increased expression of IFNG protein]; montelukast promotes the reaction [[Ovalbumin co-treated with aluminum sulfate] results in increased expression of IFNG protein] CTD PMID:27660012 NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740 		JBrowse link
G IGF1 insulin like growth factor 1 increases secretion EXP aluminum sulfate results in increased secretion of IGF1 protein CTD PMID:7685579 NCBI chr12:102,395,874...102,481,839
Ensembl chr12:102,395,874...102,481,744 		JBrowse link
G IGF2 insulin like growth factor 2 increases secretion EXP aluminum sulfate results in increased secretion of IGF2 mRNA; aluminum sulfate results in increased secretion of IGF2 protein CTD PMID:7685579 NCBI chr11:2,129,117...2,149,566
Ensembl chr11:2,129,112...2,158,391 		JBrowse link
G IGFBP3 insulin like growth factor binding protein 3 decreases secretion EXP aluminum sulfate results in decreased secretion of IGFBP3 protein CTD PMID:7685579 NCBI chr 7:45,912,245...45,921,272
Ensembl chr 7:45,912,245...45,921,874 		JBrowse link
G IGFBP4 insulin like growth factor binding protein 4 decreases secretion EXP aluminum sulfate results in decreased secretion of IGFBP4 protein CTD PMID:7685579 NCBI chr17:40,443,450...40,457,725
Ensembl chr17:40,443,450...40,457,725 		JBrowse link
G IL18 interleukin 18 increases expression EXP aluminum sulfate results in increased expression of IL18 protein CTD PMID:16100009 NCBI chr11:112,143,260...112,164,094
Ensembl chr11:112,143,251...112,164,096 		JBrowse link
G IL1B interleukin 1 beta increases expression
multiple interactions		 EXP
ISO		 aluminum sulfate results in increased expression of IL1B mRNA
[Tetradecanoylphorbol Acetate co-treated with aluminum sulfate] results in increased secretion of IL1B protein; bafilomycin A1 inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with aluminum sulfate] results in increased secretion of IL1B protein]; Cytochalasin D inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with aluminum sulfate] results in increased secretion of IL1B protein]; Sodium inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with aluminum sulfate] results in increased secretion of IL1B protein]
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [[Lipopolysaccharides co-treated with aluminum sulfate] results in increased secretion of IL1B protein]; [Lipopolysaccharides co-treated with aluminum sulfate] results in increased expression of and results in increased activity of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with aluminum sulfate] results in increased secretion of IL1B protein; CASP1 protein promotes the reaction [[Lipopolysaccharides co-treated with aluminum sulfate] results in increased secretion of IL1B protein]; leptomycin B inhibits the reaction [[Lipopolysaccharides co-treated with aluminum sulfate] results in increased expression of IL1B protein]; NLRP3 protein promotes the reaction [[Lipopolysaccharides co-treated with aluminum sulfate] results in increased secretion of IL1B protein]; PYCARD protein promotes the reaction [[Lipopolysaccharides co-treated with aluminum sulfate] results in increased secretion of IL1B protein]		 CTD PMID:15961160 PMID:23430110 PMID:24158569 NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816 		JBrowse link
G MAP2 microtubule associated protein 2 multiple interactions ISO aluminum sulfate inhibits the reaction [Excitatory Amino Acid Agents results in increased metabolism of MAP2 protein] CTD PMID:10428068 NCBI chr 2:209,424,047...209,734,112
Ensembl chr 2:209,424,047...209,734,147 		JBrowse link
G MAPK8 mitogen-activated protein kinase 8 multiple interactions ISO [Ovalbumin co-treated with aluminum sulfate] results in increased expression of MAPK8 mRNA; [Ovalbumin co-treated with aluminum sulfate] results in increased expression of MAPK8 protein; Dexamethasone inhibits the reaction [[Ovalbumin co-treated with aluminum sulfate] results in increased expression of MAPK8 mRNA]; Gu-Ben-Fang-Xiao decoction inhibits the reaction [[Ovalbumin co-treated with aluminum sulfate] results in increased expression of MAPK8 mRNA]; Gu-Ben-Fang-Xiao decoction inhibits the reaction [[Ovalbumin co-treated with aluminum sulfate] results in increased expression of MAPK8 protein]; montelukast inhibits the reaction [[Ovalbumin co-treated with aluminum sulfate] results in increased expression of MAPK8 protein] CTD PMID:27660012 NCBI chr10:48,306,677...48,439,360
Ensembl chr10:48,306,639...48,439,360 		JBrowse link
G MAPT microtubule associated protein tau increases phosphorylation ISO aluminum sulfate results in increased phosphorylation of MAPT protein CTD PMID:11388372 NCBI chr17:45,894,554...46,028,334
Ensembl chr17:45,894,527...46,028,334 		JBrowse link
G MIR146A microRNA 146a multiple interactions EXP [ferrous sulfate co-treated with aluminum sulfate] results in increased expression of MIR146A mRNA; Curcumin inhibits the reaction [[ferrous sulfate co-treated with aluminum sulfate] results in increased expression of MIR146A mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [[ferrous sulfate co-treated with aluminum sulfate] results in increased expression of MIR146A mRNA]; resveratrol analog inhibits the reaction [[ferrous sulfate co-treated with aluminum sulfate] results in increased expression of MIR146A mRNA] CTD PMID:22099153 NCBI chr 5:160,485,352...160,485,450
Ensembl chr 5:160,485,352...160,485,450 		JBrowse link
G MTF1 metal regulatory transcription factor 1 decreases expression EXP aluminum sulfate results in decreased expression of MTF1 mRNA CTD PMID:15961160 NCBI chr 1:37,809,574...37,859,592
Ensembl chr 1:37,809,574...37,859,592 		JBrowse link
G NEFL neurofilament light chain decreases expression EXP aluminum sulfate results in decreased expression of NEFL mRNA CTD PMID:15961160 NCBI chr 8:24,950,955...24,956,612
Ensembl chr 8:24,950,955...24,956,721 		JBrowse link
G NFKB1 nuclear factor kappa B subunit 1 increases expression
multiple interactions		 EXP aluminum sulfate results in increased expression of NFKB1 mRNA
[ferrous sulfate co-treated with aluminum sulfate] results in increased expression of and results in increased activity of [RELA protein binds to NFKB1 protein]		 CTD PMID:15961160 PMID:22099153 NCBI chr 4:102,501,359...102,617,302
Ensembl chr 4:102,501,330...102,617,302 		JBrowse link
G NLRP3 NLR family pyrin domain containing 3 multiple interactions ISO NLRP3 protein promotes the reaction [[Lipopolysaccharides co-treated with aluminum sulfate] results in increased secretion of IL1B protein] CTD PMID:24158569 NCBI chr 1:247,416,077...247,448,817
Ensembl chr 1:247,332,331...247,449,108 		JBrowse link
G NOS1 nitric oxide synthase 1 decreases expression ISO aluminum sulfate results in decreased expression of NOS1 protein CTD PMID:10428068 NCBI chr12:117,208,142...117,361,626
Ensembl chr12:117,208,142...117,452,170 		JBrowse link
G ORMDL3 ORMDL sphingolipid biosynthesis regulator 3 multiple interactions ISO [Ovalbumin co-treated with aluminum sulfate] results in increased expression of ORMDL3 mRNA; [Ovalbumin co-treated with aluminum sulfate] results in increased expression of ORMDL3 protein; Gu-Ben-Fang-Xiao decoction inhibits the reaction [[Ovalbumin co-treated with aluminum sulfate] results in increased expression of ORMDL3 mRNA]; montelukast inhibits the reaction [[Ovalbumin co-treated with aluminum sulfate] results in increased expression of ORMDL3 mRNA] CTD PMID:27660012 NCBI chr17:39,921,041...39,927,601
Ensembl chr17:39,921,041...39,927,601 		JBrowse link
G P2RX1 purinergic receptor P2X 1 decreases expression EXP aluminum sulfate results in decreased expression of P2RX1 mRNA CTD PMID:15961160 NCBI chr17:3,896,592...3,916,465
Ensembl chr17:3,896,592...3,916,476 		JBrowse link
G PLA2G4A phospholipase A2 group IVA increases expression EXP aluminum sulfate results in increased expression of PLA2G4A mRNA CTD PMID:15961160 NCBI chr 1:186,828,949...186,988,981
Ensembl chr 1:186,828,949...186,988,981 		JBrowse link
G PML PML nuclear body scaffold multiple interactions ISO [Lipopolysaccharides co-treated with aluminum sulfate] results in increased expression of PML protein CTD PMID:23430110 NCBI chr15:73,994,716...74,047,827
Ensembl chr15:73,994,673...74,047,827 		JBrowse link
G PTGS2 prostaglandin-endoperoxide synthase 2 increases expression EXP aluminum sulfate results in increased expression of PTGS2 mRNA CTD PMID:15961160 NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922 		JBrowse link
G PYCARD PYD and CARD domain containing multiple interactions ISO PYCARD protein promotes the reaction [[Lipopolysaccharides co-treated with aluminum sulfate] results in increased secretion of IL1B protein] CTD PMID:24158569 NCBI chr16:31,201,486...31,202,760
Ensembl chr16:31,201,486...31,203,450 		JBrowse link
G RELA RELA proto-oncogene, NF-kB subunit multiple interactions EXP [ferrous sulfate co-treated with aluminum sulfate] results in increased expression of and results in increased activity of [RELA protein binds to NFKB1 protein] CTD PMID:22099153 NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090 		JBrowse link
G ROBO2 roundabout guidance receptor 2 decreases expression EXP aluminum sulfate results in decreased expression of ROBO2 mRNA CTD PMID:15961160 NCBI chr 3:75,906,675...77,649,964
Ensembl chr 3:75,906,695...77,649,964 		JBrowse link
G SYN1 synapsin I decreases expression EXP aluminum sulfate results in decreased expression of SYN1 mRNA CTD PMID:15961160 NCBI chr  X:47,571,901...47,619,857
Ensembl chr  X:47,571,901...47,619,857 		JBrowse link
G SYP synaptophysin decreases expression EXP aluminum sulfate results in decreased expression of SYP mRNA CTD PMID:15961160 NCBI chr  X:49,187,815...49,200,193
Ensembl chr  X:49,187,815...49,200,218 		JBrowse link
G XBP1 X-box binding protein 1 multiple interactions ISO [Ovalbumin co-treated with aluminum sulfate] results in increased expression of XBP1 mRNA; [Ovalbumin co-treated with aluminum sulfate] results in increased expression of XBP1 protein; Dexamethasone inhibits the reaction [[Ovalbumin co-treated with aluminum sulfate] results in increased expression of XBP1 protein]; Gu-Ben-Fang-Xiao decoction inhibits the reaction [[Ovalbumin co-treated with aluminum sulfate] results in increased expression of XBP1 mRNA]; Gu-Ben-Fang-Xiao decoction inhibits the reaction [[Ovalbumin co-treated with aluminum sulfate] results in increased expression of XBP1 protein]; montelukast inhibits the reaction [[Ovalbumin co-treated with aluminum sulfate] results in increased expression of XBP1 mRNA]; montelukast inhibits the reaction [[Ovalbumin co-treated with aluminum sulfate] results in increased expression of XBP1 protein] CTD PMID:27660012 NCBI chr22:28,794,560...28,800,569
Ensembl chr22:28,794,555...28,800,597 		JBrowse link
aluminium trifluoride term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ARF6 ARF GTPase 6 increases activity EXP aluminum fluoride results in increased activity of ARF6 protein CTD PMID:16280360 NCBI chr14:49,893,082...49,897,054
Ensembl chr14:49,893,079...49,897,054 		JBrowse link
G CD3E CD3 epsilon subunit of T-cell receptor complex increases phosphorylation
multiple interactions		 ISO aluminum fluoride results in increased phosphorylation of CD3E protein
Tetradecanoylphorbol Acetate inhibits the reaction [aluminum fluoride results in increased phosphorylation of CD3E protein]		 CTD PMID:2824607 NCBI chr11:118,304,730...118,316,173
Ensembl chr11:118,304,730...118,316,175 		JBrowse link
G CD3G CD3 gamma subunit of T-cell receptor complex multiple interactions
increases phosphorylation		 ISO Tetradecanoylphorbol Acetate inhibits the reaction [aluminum fluoride results in increased phosphorylation of CD3G protein] CTD PMID:2824607 NCBI chr11:118,344,344...118,355,161
Ensembl chr11:118,344,344...118,355,161 		JBrowse link
G CD79A CD79a molecule increases phosphorylation ISO aluminum fluoride results in increased phosphorylation of CD79A protein CTD PMID:8559152 NCBI chr19:41,877,279...41,881,372
Ensembl chr19:41,877,279...41,881,372 		JBrowse link
G CD79B CD79b molecule increases phosphorylation ISO aluminum fluoride results in increased phosphorylation of CD79B protein CTD PMID:8559152 NCBI chr17:63,928,740...63,932,331
Ensembl chr17:63,928,738...63,932,336 		JBrowse link
G HERC1 HECT and RLD domain containing E3 ubiquitin protein ligase family member 1 affects localization EXP aluminum fluoride affects the localization of HERC1 protein CTD PMID:14960311 NCBI chr15:63,608,618...63,833,948
Ensembl chr15:63,608,618...63,833,948 		JBrowse link
G IGF2 insulin like growth factor 2 increases expression EXP aluminum fluoride results in increased expression of IGF2 mRNA; aluminum fluoride results in increased expression of IGF2 protein CTD PMID:11996908 NCBI chr11:2,129,117...2,149,566
Ensembl chr11:2,129,112...2,158,391 		JBrowse link
G IGFBP4 insulin like growth factor binding protein 4 decreases expression EXP aluminum fluoride results in decreased expression of IGFBP4 mRNA; aluminum fluoride results in decreased expression of IGFBP4 protein CTD PMID:11996908 NCBI chr17:40,443,450...40,457,725
Ensembl chr17:40,443,450...40,457,725 		JBrowse link
G IGFBP5 insulin like growth factor binding protein 5 increases expression EXP aluminum fluoride results in increased expression of IGFBP5 mRNA; aluminum fluoride results in increased expression of IGFBP5 protein CTD PMID:11996908 NCBI chr 2:216,672,105...216,695,549
Ensembl chr 2:216,672,105...216,695,549 		JBrowse link
G LYN LYN proto-oncogene, Src family tyrosine kinase increases phosphorylation ISO aluminum fluoride results in increased phosphorylation of LYN protein CTD PMID:8559152 NCBI chr 8:55,879,835...56,014,169
Ensembl chr 8:55,879,835...56,014,169 		JBrowse link
G PLCB1 phospholipase C beta 1 multiple interactions ISO PLCB1 protein promotes the reaction [aluminum fluoride results in increased abundance of Inositol Phosphates] CTD PMID:11377826 NCBI chr20:8,132,266...8,884,900
Ensembl chr20:8,077,251...8,968,360 		JBrowse link
aluminium(0) term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ACE angiotensin I converting enzyme decreases activity ISO Aluminum results in decreased activity of ACE protein CTD PMID:12008977 NCBI chr17:63,477,061...63,498,373
Ensembl chr17:63,477,061...63,498,380 		JBrowse link
G ACHE acetylcholinesterase (Yt blood group) multiple interactions
decreases activity		 ISO [Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese co-treated with Selenium co-treated with Zinc] results in increased activity of ACHE protein; [Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese co-treated with Selenium] results in increased activity of ACHE protein; [Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese] results in increased activity of ACHE protein; [Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased activity of ACHE protein; [Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of ACHE mRNA; Aluminum promotes the reaction [Lead results in decreased activity of ACHE protein]; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased activity of ACHE protein]; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of ACHE mRNA]; Copper inhibits the reaction [Aluminum results in decreased activity of ACHE protein]; Plant Extracts inhibits the reaction [Aluminum results in decreased activity of ACHE protein] CTD PMID:15266904 PMID:23354609 PMID:24486960 PMID:29170048 PMID:37415728 NCBI chr 7:100,889,994...100,896,994
Ensembl chr 7:100,889,994...100,896,974 		JBrowse link
G ACLY ATP citrate lyase multiple interactions EXP Aluminum results in increased expression of and results in increased activity of ACLY protein CTD PMID:17762189 NCBI chr17:41,866,917...41,930,545
Ensembl chr17:41,866,917...41,930,542 		JBrowse link
G ACO1 aconitase 1 decreases activity ISO Aluminum results in decreased activity of ACO1 protein CTD PMID:10806405 NCBI chr 9:32,384,643...32,454,769
Ensembl chr 9:32,384,603...32,454,769 		JBrowse link
G ACO2 aconitase 2 decreases activity
multiple interactions		 ISO
EXP		 Aluminum results in decreased activity of ACO2 protein
Aluminum promotes the reaction [Nitroprusside results in decreased activity of ACO2 protein]
Aluminum results in decreased expression of and results in decreased activity of ACO2 protein		 CTD PMID:12470706 PMID:16906525 PMID:19010380 NCBI chr22:41,469,117...41,528,974
Ensembl chr22:41,447,830...41,529,273 		JBrowse link
G ALB albumin affects binding EXP ALB protein binds to Aluminum CTD PMID:14507469 NCBI chr 4:73,404,287...73,421,482
Ensembl chr 4:73,397,114...73,421,482 		JBrowse link
G ALOX5 arachidonate 5-lipoxygenase multiple interactions
increases expression		 ISO caffeic acid inhibits the reaction [Aluminum results in increased expression of ALOX5 mRNA]; caffeic acid inhibits the reaction [Aluminum results in increased expression of ALOX5 protein]
Aluminum results in increased expression of ALOX5 mRNA; Aluminum results in increased expression of ALOX5 protein		 CTD PMID:27368151 NCBI chr10:45,374,216...45,446,117
Ensembl chr10:45,374,176...45,446,119 		JBrowse link
G ALPL alkaline phosphatase, biomineralization associated multiple interactions ISO [Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of ALPL mRNA; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of ALPL mRNA] CTD PMID:34547296 NCBI chr 1:21,508,984...21,578,410
Ensembl chr 1:21,509,397...21,578,410 		JBrowse link
G APOB apolipoprotein B increases expression EXP Aluminum results in increased expression of APOB protein CTD PMID:17762189 NCBI chr 2:21,001,429...21,044,073
Ensembl chr 2:21,001,429...21,044,073 		JBrowse link
G APP amyloid beta precursor protein affects binding
multiple interactions
increases expression
increases cleavage		 EXP
ISO		 APP protein binds to Aluminum
[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of APP mRNA; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of APP mRNA]
[APP protein modified form binds to Aluminum] which results in increased expression of RCVRN mRNA
Aluminum results in increased expression of APP mRNA
APP protein promotes the reaction [Aluminum results in decreased activity of CHAT protein]; meloxicam inhibits the reaction [Aluminum results in increased expression of APP protein]; Vitamin E inhibits the reaction [Aluminum results in increased cleavage of APP protein]		 CTD PMID:12039845 PMID:16308480 PMID:16724269 PMID:16928369 PMID:16942756 More... NCBI chr21:25,880,550...26,171,128
Ensembl chr21:25,880,535...26,171,128 		JBrowse link
G ATXN3 ataxin 3 affects folding
multiple interactions		 ISO
EXP		 Aluminum affects the folding of ATXN3 protein polymorphism
Aluminum promotes the reaction [ATXN3 protein polymorphism binds to ATXN3 protein polymorphism]		 CTD PMID:17300980 NCBI chr14:92,044,775...92,106,582
Ensembl chr14:92,044,496...92,106,621 		JBrowse link
G BAX BCL2 associated X, apoptosis regulator affects response to substance
multiple interactions		 ISO
EXP		 BAX protein affects the susceptibility to Aluminum
[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of BAX mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of BAX protein; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of BAX mRNA]; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of BAX protein]
[aluminum chlorhydrate results in increased abundance of Aluminum] which affects the expression of BAX protein		 CTD PMID:20385067 PMID:31945389 PMID:34547296 NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798 		JBrowse link
G BBOX1 gamma-butyrobetaine hydroxylase 1 multiple interactions
decreases expression		 EXP Aluminum inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]; Ketoglutaric Acids inhibits the reaction [Aluminum inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]]
Aluminum results in decreased expression of BBOX1 protein		 CTD PMID:21439360 NCBI chr11:27,040,815...27,127,809
Ensembl chr11:27,040,725...27,127,809 		JBrowse link
G BCL2 BCL2 apoptosis regulator multiple interactions EXP
ISO		 [aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of BCL2 protein; Fulvestrant inhibits the reaction [[aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of BCL2 protein]
[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of BCL2 mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of BCL2 protein; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of BCL2 mRNA]; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of BCL2 protein]		 CTD PMID:31945389 PMID:34547296 NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128 		JBrowse link
G BCL2L1 BCL2 like 1 multiple interactions EXP [aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of BCL2L1 protein CTD PMID:31945389 NCBI chr20:31,664,452...31,723,963
Ensembl chr20:31,664,452...31,723,989 		JBrowse link
G BGLAP bone gamma-carboxyglutamate protein multiple interactions
decreases secretion		 ISO Aluminum inhibits the reaction [Calcitriol results in increased secretion of BGLAP protein]; Calcitriol inhibits the reaction [Aluminum results in decreased secretion of BGLAP protein]
[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of BGLAP mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of BGLAP protein; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of BGLAP mRNA]; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of BGLAP protein]		 CTD PMID:9626627 PMID:34547296 NCBI chr 1:156,242,184...156,243,317
Ensembl chr 1:156,242,184...156,243,317 		JBrowse link
G BGN biglycan increases expression ISO Aluminum results in increased expression of BGN mRNA CTD PMID:37544489 NCBI chr  X:153,494,980...153,509,546
Ensembl chr  X:153,494,980...153,509,546 		JBrowse link
G CALD1 caldesmon 1 increases expression ISO Aluminum results in increased expression of CALD1 mRNA CTD PMID:37544489 NCBI chr 7:134,745,467...134,970,729
Ensembl chr 7:134,744,252...134,970,729 		JBrowse link
G CASP12 caspase 12 (gene/pseudogene) multiple interactions ISO [aluminum chloride results in increased abundance of Aluminum] which results in increased expression of CASP12 mRNA CTD PMID:29635646 NCBI chr11:104,883,286...104,898,460
Ensembl chr11:104,885,718...104,898,670 		JBrowse link
G CASP3 caspase 3 increases expression
multiple interactions		 ISO Aluminum results in increased expression of CASP3
[Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese] results in increased expression of CASP3 protein
[Aluminum Chloride results in increased abundance of Aluminum] which results in increased cleavage of CASP3 protein; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of CASP3 mRNA; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased cleavage of CASP3 protein]; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of CASP3 mRNA]		 CTD PMID:21972528 PMID:34547296 PMID:37415728 NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062 		JBrowse link
G CASP9 caspase 9 multiple interactions EXP [aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of CASP9 protein; Fulvestrant inhibits the reaction [[aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of CASP9 protein] CTD PMID:31945389 NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534 		JBrowse link
G CASR calcium sensing receptor multiple interactions ISO [Aluminum binds to and results in increased activity of CASR protein] which results in increased abundance of Calcium; [Aluminum binds to and results in increased activity of CASR protein] which results in increased abundance of Inositol Phosphates; Aluminum binds to and results in increased activity of CASR protein CTD PMID:10231437 NCBI chr 3:122,183,668...122,291,629
Ensembl chr 3:122,183,668...122,291,629 		JBrowse link
G CAT catalase decreases activity
multiple interactions		 EXP
ISO		 Aluminum results in decreased activity of CAT protein
[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased activity of CAT protein; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased activity of CAT protein]
[Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese co-treated with Selenium] results in decreased activity of CAT protein; [Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese co-treated with Zinc] results in decreased activity of CAT protein; [Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese] results in decreased activity of CAT protein; CAT protein results in decreased susceptibility to [Tyramine co-treated with Aluminum]; Plant Extracts inhibits the reaction [Aluminum results in decreased activity of CAT protein]
Vitamin E inhibits the reaction [Aluminum results in decreased activity of CAT protein]		 CTD PMID:15526171 PMID:17709913 PMID:24486960 PMID:34547296 PMID:37415728 NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060 		JBrowse link
G CCL7 C-C motif chemokine ligand 7 decreases expression ISO Aluminum results in decreased expression of CCL7 mRNA CTD PMID:37544489 NCBI chr17:34,270,221...34,272,242
Ensembl chr17:34,270,221...34,272,242 		JBrowse link
G CDH1 cadherin 1 multiple interactions EXP 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of CDH1 protein]; [Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of CDH1 mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of CDH1 protein CTD PMID:32437896 NCBI chr16:68,737,292...68,835,537
Ensembl chr16:68,737,292...68,835,537 		JBrowse link
G CHAT choline O-acetyltransferase decreases expression
decreases activity
multiple interactions		 ISO Aluminum results in decreased expression of CHAT protein
Aluminum results in decreased activity of CHAT protein
APP protein promotes the reaction [Aluminum results in decreased activity of CHAT protein]; meloxicam inhibits the reaction [Aluminum results in decreased expression of CHAT protein]		 CTD PMID:16724269 PMID:16928369 NCBI chr10:49,609,095...49,667,942
Ensembl chr10:49,609,095...49,667,942 		JBrowse link
G COL1A1 collagen type I alpha 1 chain multiple interactions
decreases expression		 ISO [Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of COL1A1 mRNA; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of COL1A1 mRNA]
Aluminum results in decreased expression of COL1A1 mRNA		 CTD PMID:34547296 PMID:37544489 NCBI chr17:50,184,101...50,201,631
Ensembl chr17:50,184,101...50,201,632 		JBrowse link
G CRP C-reactive protein multiple interactions EXP [Zinc co-treated with Aluminum] results in increased expression of CRP protein; [Zinc co-treated with Copper co-treated with Aluminum] results in increased expression of CRP protein CTD PMID:27816692 NCBI chr 1:159,712,289...159,714,589
Ensembl chr 1:159,712,289...159,714,589 		JBrowse link
G CX3CL1 C-X3-C motif chemokine ligand 1 increases expression ISO Aluminum results in increased expression of CX3CL1 mRNA CTD PMID:37544489 NCBI chr16:57,372,490...57,385,044
Ensembl chr16:57,372,477...57,385,044 		JBrowse link
G CXCL8 C-X-C motif chemokine ligand 8 increases expression EXP Aluminum analog results in increased expression of CXCL8 mRNA CTD PMID:23724284 NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716 		JBrowse link
G CYCS cytochrome c, somatic multiple interactions ISO [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of CYCS mRNA; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of CYCS mRNA] CTD PMID:34547296 NCBI chr 7:25,118,656...25,125,260
Ensembl chr 7:25,118,656...25,125,260 		JBrowse link
G DAXX death domain associated protein increases expression EXP Aluminum results in increased expression of DAXX mRNA CTD PMID:16308480 NCBI chr 6:33,318,558...33,322,959
Ensembl chr 6:33,318,558...33,323,016 		JBrowse link
G DRD1 dopamine receptor D1 multiple interactions ISO Aluminum inhibits the reaction [SCH 23390 binds to DRD1 protein] CTD PMID:9109525 NCBI chr 5:175,440,036...175,444,182
Ensembl chr 5:175,440,036...175,444,182 		JBrowse link
G DRD2 dopamine receptor D2 multiple interactions ISO Aluminum inhibits the reaction [3-N-methylspiperone binds to DRD2 protein] CTD PMID:9109525 NCBI chr11:113,409,605...113,475,398
Ensembl chr11:113,409,605...113,475,691 		JBrowse link
G ECM1 extracellular matrix protein 1 increases expression ISO Aluminum results in increased expression of ECM1 mRNA CTD PMID:37544489 NCBI chr 1:150,508,109...150,513,789
Ensembl chr 1:150,508,062...150,513,789 		JBrowse link
G EGLN3 egl-9 family hypoxia inducible factor 3 increases expression ISO Aluminum results in increased expression of EGLN3 mRNA; Aluminum results in increased expression of EGLN3 protein CTD PMID:37544489 NCBI chr14:33,924,227...33,951,074
Ensembl chr14:33,924,227...34,462,774 		JBrowse link
G ENO2 enolase 2 decreases activity EXP Aluminum results in decreased activity of ENO2 protein CTD PMID:11860913 NCBI chr12:6,914,580...6,923,697
Ensembl chr12:6,913,745...6,923,698 		JBrowse link
G EPOR erythropoietin receptor affects expression EXP Aluminum affects the expression of EPOR protein CTD PMID:15777837 NCBI chr19:11,377,207...11,384,314
Ensembl chr19:11,377,207...11,384,342 		JBrowse link
G ESR1 estrogen receptor 1 multiple interactions EXP [aluminum chlorhydrate results in increased abundance of Aluminum] inhibits the reaction [Estradiol results in increased phosphorylation of ESR1 protein]; [aluminum chlorhydrate results in increased abundance of Aluminum] inhibits the reaction [NRG1 protein results in increased phosphorylation of ESR1 protein]; [aluminum chlorhydrate results in increased abundance of Aluminum] which results in increased expression of ESR1 protein; [Estradiol co-treated with [aluminum chlorhydrate results in increased abundance of Aluminum]] results in increased expression of ESR1 protein CTD PMID:31945389 NCBI chr 6:151,656,672...152,129,619
Ensembl chr 6:151,656,691...152,129,619 		JBrowse link
G ESR2 estrogen receptor 2 multiple interactions EXP [[aluminum chlorhydrate results in increased abundance of Aluminum] co-treated with [Tretinoin co-treated with Estradiol]] affects the localization of ESR2 protein; [[aluminum chlorhydrate results in increased abundance of Aluminum] which co-treated with Tretinoin] results in decreased expression of and affects the localization of ESR2 protein; [aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of and affects the localization of ESR2 protein; [Estradiol co-treated with [aluminum chlorhydrate results in increased abundance of Aluminum]] results in decreased expression of ESR2 protein CTD PMID:31945389 NCBI chr14:64,226,707...64,338,613
Ensembl chr14:64,084,232...64,338,112 		JBrowse link
G F8 coagulation factor VIII affects folding
multiple interactions		 EXP Aluminum affects the folding of F8 protein
[Aluminum promotes the reaction [F8 protein binds to F8 protein]] which results in decreased activity of F8 protein		 CTD PMID:15349964 NCBI chr  X:154,835,792...155,022,723
Ensembl chr  X:154,835,788...155,026,940 		JBrowse link
G FDFT1 farnesyl-diphosphate farnesyltransferase 1 increases expression ISO Aluminum results in increased expression of FDFT1 mRNA CTD PMID:37544489 NCBI chr 8:11,795,582...11,839,298
Ensembl chr 8:11,795,573...11,839,395 		JBrowse link
G FH fumarate hydratase multiple interactions EXP Aluminum results in decreased expression of and results in decreased activity of FH protein CTD PMID:16906525 NCBI chr 1:241,497,603...241,519,755
Ensembl chr 1:241,497,511...241,519,799 		JBrowse link
G FOS Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 affects the localization of FOS protein] CTD PMID:23690655 NCBI chr14:75,278,828...75,282,230
Ensembl chr14:75,278,826...75,283,190 		JBrowse link
G FOSL1 FOS like 1, AP-1 transcription factor subunit increases expression ISO Aluminum results in increased expression of FOSL1 mRNA CTD PMID:37544489 NCBI chr11:65,892,049...65,900,545
Ensembl chr11:65,892,049...65,900,573 		JBrowse link
G G6PD glucose-6-phosphate dehydrogenase increases activity EXP
ISO		 Aluminum results in increased activity of G6PD protein CTD PMID:16572710 PMID:16979867 NCBI chr  X:154,531,390...154,547,569
Ensembl chr  X:154,517,825...154,547,572 		JBrowse link
G GBP4 guanylate binding protein 4 decreases expression ISO Aluminum results in decreased expression of GBP3 mRNA CTD PMID:37544489 NCBI chr 1:89,181,144...89,198,942
Ensembl chr 1:89,181,144...89,198,942 		JBrowse link
G GCHFR GTP cyclohydrolase I feedback regulator increases expression ISO Aluminum results in increased expression of GCHFR mRNA CTD PMID:37544489 NCBI chr15:40,764,068...40,767,708
Ensembl chr15:40,764,068...40,767,708 		JBrowse link
G GFAP glial fibrillary acidic protein increases expression
multiple interactions		 ISO Aluminum results in increased expression of GFAP protein
[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of GFAP protein
Vitamin E inhibits the reaction [Aluminum results in increased expression of GFAP protein]		 CTD PMID:16545059 PMID:31363819 NCBI chr17:44,903,159...44,915,500
Ensembl chr17:44,903,159...44,916,937 		JBrowse link
G GNAI1 G protein subunit alpha i1 decreases expression ISO Aluminum results in decreased expression of GNAI1 protein CTD PMID:9626627 NCBI chr 7:80,134,831...80,226,181
Ensembl chr 7:79,768,028...80,226,181 		JBrowse link
G GNAI2 G protein subunit alpha i2 decreases expression ISO Aluminum results in decreased expression of GNAI2 protein CTD PMID:9626627 NCBI chr 3:50,227,068...50,263,358
Ensembl chr 3:50,226,292...50,259,362 		JBrowse link
G GNAQ G protein subunit alpha q increases response to substance ISO GNAQ protein results in increased susceptibility to Aluminum CTD PMID:15068510 NCBI chr 9:77,716,097...78,031,811
Ensembl chr 9:77,716,097...78,031,811 		JBrowse link
G GPD1 glycerol-3-phosphate dehydrogenase 1 multiple interactions EXP Aluminum results in increased expression of and results in increased activity of GPD1 protein CTD PMID:17762189 NCBI chr12:50,104,008...50,111,313
Ensembl chr12:50,103,982...50,111,313 		JBrowse link
G GPX1 glutathione peroxidase 1 decreases activity
multiple interactions		 EXP Aluminum results in decreased activity of GPX1 protein
Vitamin E inhibits the reaction [Aluminum results in decreased activity of GPX1 protein]		 CTD PMID:17709913 NCBI chr 3:49,357,176...49,358,353
Ensembl chr 3:49,357,174...49,358,605 		JBrowse link
G GSR glutathione-disulfide reductase decreases expression
multiple interactions		 ISO Aluminum results in decreased expression of GSR protein
Plant Extracts inhibits the reaction [Aluminum results in decreased expression of GSR protein]		 CTD PMID:24486960 NCBI chr 8:30,678,066...30,727,846
Ensembl chr 8:30,678,066...30,727,846 		JBrowse link
G HIF1A hypoxia inducible factor 1 subunit alpha increases localization EXP Aluminum results in increased localization of HIF1A protein CTD PMID:16979867 NCBI chr14:61,695,513...61,748,258
Ensembl chr14:61,695,513...61,748,259 		JBrowse link
G HK1 hexokinase 1 multiple interactions
decreases activity		 ISO Meclofenoxate inhibits the reaction [Aluminum results in decreased activity of HK1 protein] CTD PMID:16969689 NCBI chr10:69,270,000...69,401,882
Ensembl chr10:69,269,984...69,401,884 		JBrowse link
G HMGA1 high mobility group AT-hook 1 increases expression ISO Aluminum results in increased expression of HMGA1 mRNA CTD PMID:37544489 NCBI chr 6:34,236,873...34,246,231
Ensembl chr 6:34,236,873...34,246,231 		JBrowse link
G IDH1 isocitrate dehydrogenase (NADP(+)) 1 decreases activity ISO Aluminum results in decreased activity of IDH1 protein CTD PMID:15486972 NCBI chr 2:208,236,227...208,255,071
Ensembl chr 2:208,236,229...208,266,074 		JBrowse link
G IDH2 isocitrate dehydrogenase (NADP(+)) 2 decreases activity ISO Aluminum results in decreased activity of IDH2 protein CTD PMID:15486972 NCBI chr15:90,083,045...90,102,468
Ensembl chr15:90,083,045...90,102,477 		JBrowse link
G IFI27L2 interferon alpha inducible protein 27 like 2 decreases expression ISO Aluminum results in decreased expression of IFI27L2A mRNA CTD PMID:37544489 NCBI chr14:94,127,781...94,129,604
Ensembl chr14:94,127,779...94,130,253 		JBrowse link
G IFI35 interferon induced protein 35 decreases expression ISO Aluminum results in decreased expression of IFI35 mRNA CTD PMID:37544489 NCBI chr17:43,006,784...43,014,456
Ensembl chr17:43,006,740...43,014,456 		JBrowse link
G IFIT1B interferon induced protein with tetratricopeptide repeats 1B decreases expression ISO Aluminum results in decreased expression of IFIT1 mRNA CTD PMID:37544489 NCBI chr10:89,378,056...89,385,205
Ensembl chr10:89,378,056...89,385,205 		JBrowse link
G IFIT3 interferon induced protein with tetratricopeptide repeats 3 decreases expression ISO Aluminum results in decreased expression of IFIT3 mRNA CTD PMID:37544489 NCBI chr10:89,327,997...89,340,968
Ensembl chr10:89,327,307...89,377,473 		JBrowse link
G IFNB1 interferon beta 1 multiple interactions ISO [Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IFNB1 mRNA] CTD PMID:23690655 NCBI chr 9:21,077,104...21,077,942
Ensembl chr 9:21,077,104...21,077,942 		JBrowse link
G IGF1 insulin like growth factor 1 multiple interactions EXP Aluminum inhibits the reaction [IGF1 protein results in increased activity of MTR protein] CTD PMID:14745455 NCBI chr12:102,395,874...102,481,839
Ensembl chr12:102,395,874...102,481,744 		JBrowse link
G IL12B interleukin 12B multiple interactions ISO [Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL12B mRNA] CTD PMID:23690655 NCBI chr 5:159,314,780...159,330,487
Ensembl chr 5:159,314,780...159,330,863 		JBrowse link
G IL1B interleukin 1 beta multiple interactions
increases expression		 ISO [Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of IL1B protein; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of IL1B protein]; caffeic acid inhibits the reaction [Aluminum results in increased expression of IL1B protein]; Vitamin E inhibits the reaction [Aluminum results in increased expression of IL1B protein] CTD PMID:16545059 PMID:27368151 PMID:29170048 NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816 		JBrowse link
G IL4 interleukin 4 increases expression ISO Aluminum results in increased expression of IL4 mRNA CTD PMID:16630673 NCBI chr 5:132,673,989...132,682,678
Ensembl chr 5:132,673,986...132,682,678 		JBrowse link
G IL6 interleukin 6 multiple interactions
increases expression		 EXP
ISO		 [Zinc co-treated with Aluminum] results in increased expression of IL6 protein; [Zinc co-treated with Copper co-treated with Aluminum] results in increased expression of IL6 protein
[Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese] results in increased expression of IL6 protein; [Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of IL6 protein; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of IL6 protein]; caffeic acid inhibits the reaction [Aluminum results in increased expression of IL6 protein]		 CTD PMID:27368151 PMID:27816692 PMID:29170048 PMID:37415728 NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002 		JBrowse link
G IRF7 interferon regulatory factor 7 decreases expression ISO Aluminum results in decreased expression of IRF7 mRNA CTD PMID:37544489 NCBI chr11:612,555...615,950
Ensembl chr11:612,553...615,983 		JBrowse link
G ISG15 ISG15 ubiquitin like modifier decreases expression ISO Aluminum results in decreased expression of ISG15 mRNA CTD PMID:37544489 NCBI chr 1:1,013,497...1,014,540
Ensembl chr 1:1,001,138...1,014,540 		JBrowse link
G JUN Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 affects the localization of JUN protein] CTD PMID:23690655 NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,776,845...58,784,048 		JBrowse link
G KLK1 kallikrein 1 multiple interactions EXP Aluminum binds to and results in decreased activity of KLK1 protein CTD PMID:15558947 NCBI chr19:50,819,146...50,823,787
Ensembl chr19:50,819,146...50,823,787 		JBrowse link
G LITAF lipopolysaccharide induced TNF factor multiple interactions EXP [Titanium co-treated with Vanadium co-treated with Aluminum] results in increased expression of LITAF mRNA CTD PMID:17408380 NCBI chr16:11,547,722...11,640,317
Ensembl chr16:11,546,875...11,636,381 		JBrowse link
G LONRF2 LON peptidase N-terminal domain and ring finger 2 decreases expression ISO Aluminum results in decreased expression of LONRF2 mRNA CTD PMID:19010380 NCBI chr 2:100,271,875...100,322,501
Ensembl chr 2:100,271,875...100,322,501 		JBrowse link
G MANF mesencephalic astrocyte derived neurotrophic factor decreases expression ISO Aluminum results in decreased expression of MANF mRNA; Aluminum results in decreased expression of MANF protein CTD PMID:37544489 NCBI chr 3:51,385,291...51,389,397
Ensembl chr 3:51,385,291...51,389,397 		JBrowse link
G MAP1LC3B microtubule associated protein 1 light chain 3 beta multiple interactions ISO [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of MAP1LC3B mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased lipidation of MAP1LC3B protein; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of MAP1LC3B mRNA]; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased lipidation of MAP1LC3B protein] CTD PMID:34547296 NCBI chr16:87,392,336...87,404,774
Ensembl chr16:87,383,953...87,404,779 		JBrowse link
G MAPK3 mitogen-activated protein kinase 3 multiple interactions ISO [Aluminum co-treated with Iron] results in increased phosphorylation of MAPK3 protein CTD PMID:16728372 NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506 		JBrowse link
G MAPT microtubule associated protein tau increases phosphorylation
multiple interactions		 ISO Aluminum results in increased phosphorylation of MAPT protein
[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of MAPT mRNA; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of MAPT mRNA]		 CTD PMID:17662457 PMID:29170048 NCBI chr17:45,894,554...46,028,334
Ensembl chr17:45,894,527...46,028,334 		JBrowse link
G MIR21 microRNA 21 multiple interactions EXP [Air Pollutants, Occupational results in increased abundance of Aluminum] which results in increased expression of MIR21 mRNA CTD PMID:27506416 NCBI chr17:59,841,266...59,841,337
Ensembl chr17:59,841,266...59,841,337 		JBrowse link
G MIR30D microRNA 30d multiple interactions EXP [Air Pollutants, Occupational results in increased abundance of Aluminum] which results in increased expression of MIR30D mRNA CTD PMID:27506416 NCBI chr 8:134,804,876...134,804,945
Ensembl chr 8:134,804,876...134,804,945 		JBrowse link
G MIR424 microRNA 424 multiple interactions EXP [Air Pollutants, Occupational results in increased abundance of Aluminum] which results in increased expression of MIR424 mRNA CTD PMID:27506416 NCBI chr  X:134,546,614...134,546,711
Ensembl chr  X:134,546,614...134,546,711 		JBrowse link
G MIR4516 microRNA 4516 multiple interactions EXP [Air Pollutants results in increased abundance of Aluminum] which results in increased expression of MIR4516 mRNA CTD PMID:27329587 NCBI chr16:2,133,119...2,133,204
Ensembl chr16:2,133,119...2,133,204 		JBrowse link
G MMP2 matrix metallopeptidase 2 increases expression ISO Aluminum results in increased expression of MMP2 protein CTD PMID:16052892 NCBI chr16:55,478,830...55,506,691
Ensembl chr16:55,389,700...55,506,691 		JBrowse link
G MMP7 matrix metallopeptidase 7 multiple interactions EXP [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of MMP7 mRNA CTD PMID:32437896 NCBI chr11:102,520,508...102,530,747
Ensembl chr11:102,520,508...102,530,750 		JBrowse link
G MMP9 matrix metallopeptidase 9 increases expression
multiple interactions		 ISO
EXP		 Aluminum results in increased expression of MMP9 protein
[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of MMP9 mRNA		 CTD PMID:16052892 PMID:32437896 NCBI chr20:46,008,908...46,016,561
Ensembl chr20:46,008,908...46,016,561 		JBrowse link
G MPO myeloperoxidase increases expression EXP Aluminum results in increased expression of MPO protein CTD PMID:17402216 NCBI chr17:58,269,855...58,280,935
Ensembl chr17:58,269,855...58,280,935 		JBrowse link
G MRPL20 mitochondrial ribosomal protein L20 decreases expression ISO Aluminum results in decreased expression of MRPL20 mRNA CTD PMID:37544489 NCBI chr 1:1,401,909...1,407,293
Ensembl chr 1:1,401,909...1,407,293 		JBrowse link
G MSMO1 methylsterol monooxygenase 1 increases expression ISO Aluminum results in increased expression of MSMO1 mRNA CTD PMID:37544489 NCBI chr 4:165,327,669...165,343,164
Ensembl chr 4:165,327,667...165,343,164 		JBrowse link
G MT-RNR2 mitochondrially encoded 16S rRNA increases expression ISO Aluminum results in increased expression of MT-RNR2 mRNA CTD PMID:37544489 NCBI chr MT:1,671...3,229
Ensembl chr MT:1,671...3,229 		JBrowse link
G MTR 5-methyltetrahydrofolate-homocysteine methyltransferase multiple interactions EXP Aluminum inhibits the reaction [[Hydroxocobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form]; Aluminum inhibits the reaction [IGF1 protein results in increased activity of MTR protein]; Aluminum inhibits the reaction [mecobalamin results in increased activity of MTR protein alternative form] CTD PMID:14745455 PMID:26989453 NCBI chr 1:236,795,281...236,903,981
Ensembl chr 1:236,795,260...236,921,278 		JBrowse link
G MYC MYC proto-oncogene, bHLH transcription factor increases expression ISO Aluminum results in increased expression of MYC mRNA; Aluminum results in increased expression of MYC protein CTD PMID:37544489 NCBI chr 8:127,735,434...127,742,951
Ensembl chr 8:127,735,434...127,742,951 		JBrowse link
G NES nestin multiple interactions ISO [Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of NES protein; Sildenafil Citrate inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of NES protein] CTD PMID:32959702 NCBI chr 1:156,668,763...156,677,407
Ensembl chr 1:156,668,763...156,677,407 		JBrowse link
G NFE2L2 NFE2 like bZIP transcription factor 2 multiple interactions ISO [Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese co-treated with Selenium] results in decreased expression of NFE2L2 protein; [Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese co-treated with Zinc] results in decreased expression of NFE2L2 protein; [Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese] results in decreased expression of NFE2L2 protein CTD PMID:37415728 NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756 		JBrowse link
G NFKB1 nuclear factor kappa B subunit 1 multiple interactions ISO [Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese co-treated with Zinc] results in decreased expression of NFKB1 protein; [Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese] results in decreased expression of NFKB1 protein CTD PMID:37415728 NCBI chr 4:102,501,359...102,617,302
Ensembl chr 4:102,501,330...102,617,302 		JBrowse link
G NOS2 nitric oxide synthase 2 multiple interactions ISO [Aluminum co-treated with Iron] results in increased expression of NOS2 protein
[Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 mRNA]		 CTD PMID:16728372 PMID:23690655 NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529 		JBrowse link
G NRG1 neuregulin 1 multiple interactions EXP [aluminum chlorhydrate results in increased abundance of Aluminum] inhibits the reaction [NRG1 protein results in increased phosphorylation of ESR1 protein] CTD PMID:31945389 NCBI chr 8:31,639,245...32,774,046
Ensembl chr 8:31,639,222...32,855,666 		JBrowse link
G OAS1 2'-5'-oligoadenylate synthetase 1 decreases expression ISO Aluminum results in decreased expression of OAS1G mRNA CTD PMID:37544489 NCBI chr12:112,906,962...112,933,219
Ensembl chr12:112,905,856...112,933,219 		JBrowse link
G OASL2P 2'-5' oligoadenylate synthetase like 2, pseudogene decreases expression ISO Aluminum results in decreased expression of OASL2 mRNA CTD PMID:37544489 NCBI chr12:121,053,732...121,059,670
Ensembl chr12:121,053,732...121,059,670 		JBrowse link
G OGDH oxoglutarate dehydrogenase multiple interactions
increases activity		 EXP
ISO		 Aluminum results in decreased expression of and results in decreased activity of OGDH protein
Aluminum results in increased activity of OGDH protein		 CTD PMID:10806405 PMID:16906525 NCBI chr 7:44,606,627...44,709,066
Ensembl chr 7:44,606,572...44,709,066 		JBrowse link
G OPRD1 opioid receptor delta 1 multiple interactions ISO [Enkephalin, D-Penicillamine (2,5)- binds to and results in increased activity of OPRD1 protein] which results in decreased abundance of Aluminum CTD PMID:7477890 NCBI chr 1:28,812,170...28,871,267
Ensembl chr 1:28,812,170...28,871,267 		JBrowse link
G OR2T34 olfactory receptor family 2 subfamily T member 34 decreases expression ISO Aluminum results in decreased expression of IFIT3B mRNA CTD PMID:37544489 NCBI chr 1:248,573,801...248,574,757
Ensembl chr 1:248,573,801...248,574,757 		JBrowse link
G PARP10 poly(ADP-ribose) polymerase family member 10 decreases expression ISO Aluminum results in decreased expression of PARP10 mRNA CTD PMID:37544489 NCBI chr 8:143,977,158...144,012,764
Ensembl chr 8:143,977,153...144,012,772 		JBrowse link
G PARP9 poly(ADP-ribose) polymerase family member 9 decreases expression ISO Aluminum results in decreased expression of PARP9 mRNA; Aluminum results in decreased expression of PARP9 protein CTD PMID:37544489 NCBI chr 3:122,527,924...122,564,784
Ensembl chr 3:122,527,924...122,564,577 		JBrowse link
G PCK1 phosphoenolpyruvate carboxykinase 1 multiple interactions EXP [aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of PCK1 protein CTD PMID:31945389 NCBI chr20:57,561,110...57,568,121
Ensembl chr20:57,561,080...57,568,121 		JBrowse link
G PCNA proliferating cell nuclear antigen multiple interactions ISO [aluminum chloride results in increased abundance of Aluminum] which results in decreased expression of PCNA mRNA CTD PMID:29635646 NCBI chr20:5,114,953...5,126,622
Ensembl chr20:5,114,953...5,126,626 		JBrowse link
G PCYT2 phosphate cytidylyltransferase 2, ethanolamine increases expression ISO Aluminum results in increased expression of PCYT2 mRNA CTD PMID:37544489 NCBI chr17:81,900,958...81,911,399
Ensembl chr17:81,900,958...81,911,432 		JBrowse link
G PINK1 PTEN induced kinase 1 multiple interactions ISO [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of PINK1 mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of PINK1 protein; Acetylcholine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of PINK1 protein]; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of PINK1 mRNA] CTD PMID:34547296 NCBI chr 1:20,633,458...20,651,511
Ensembl chr 1:20,633,458...20,651,511 		JBrowse link
G PKLR pyruvate kinase L/R increases activity EXP Aluminum results in increased activity of PKLR protein CTD PMID:16979867 NCBI chr 1:155,289,293...155,308,654
Ensembl chr 1:155,289,293...155,301,438 		JBrowse link
G PLCD1 phospholipase C delta 1 increases expression ISO Aluminum results in increased expression of PLCD1 protein CTD PMID:10814511 NCBI chr 3:38,007,496...38,029,642
Ensembl chr 3:38,007,496...38,029,642 		JBrowse link
G PRKG2 protein kinase cGMP-dependent 2 increases expression ISO Aluminum results in increased expression of PRKG2 mRNA CTD PMID:37544489 NCBI chr 4:81,087,370...81,217,836
Ensembl chr 4:81,087,370...81,215,222 		JBrowse link
G PRKN parkin RBR E3 ubiquitin protein ligase multiple interactions ISO [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of PRKN mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of PRKN protein; Acetylcholine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of PRKN protein]; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of PRKN mRNA] CTD PMID:34547296 NCBI chr 6:161,347,417...162,727,766
Ensembl chr 6:161,347,417...162,727,775 		JBrowse link
G PSMB8 proteasome 20S subunit beta 8 decreases expression ISO Aluminum results in decreased expression of PSMB8 mRNA; Aluminum results in decreased expression of PSMB8 protein CTD PMID:37544489 NCBI chr 6:32,840,717...32,844,679
Ensembl chr 6:32,840,717...32,844,679 		JBrowse link
G PTGS1 prostaglandin-endoperoxide synthase 1 increases expression ISO Aluminum results in increased expression of PTGS1 mRNA; Aluminum results in increased expression of PTGS1 protein CTD PMID:37544489 NCBI chr 9:122,370,533...122,395,703
Ensembl chr 9:122,370,530...122,395,703 		JBrowse link
G PTGS2 prostaglandin-endoperoxide synthase 2 increases expression
multiple interactions		 ISO Aluminum results in increased expression of PTGS2 mRNA; Aluminum results in increased expression of PTGS2 protein
[Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 mRNA]; Meloxicam inhibits the reaction [Aluminum results in increased expression of PTGS2 mRNA]; Meloxicam inhibits the reaction [Aluminum results in increased expression of PTGS2 protein]		 CTD PMID:16928369 PMID:23690655 NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922 		JBrowse link
G PTH parathyroid hormone multiple interactions EXP [TF protein binds to and results in increased uptake of Aluminum] which results in decreased secretion of PTH protein CTD PMID:10978387 NCBI chr11:13,492,054...13,496,181
Ensembl chr11:13,492,054...13,496,181 		JBrowse link
G RCVRN recoverin multiple interactions EXP [APP protein modified form binds to Aluminum] which results in increased expression of RCVRN mRNA CTD PMID:21298039 NCBI chr17:9,896,320...9,905,271
Ensembl chr17:9,896,320...9,905,271 		JBrowse link
G RELA RELA proto-oncogene, NF-kB subunit multiple interactions ISO [Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 affects the localization of RELA protein] CTD PMID:23690655 NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090 		JBrowse link
G RPL37 ribosomal protein L37 decreases expression EXP Aluminum results in decreased expression of RPL37 mRNA; Aluminum results in decreased expression of RPL37 protein CTD PMID:27329587 NCBI chr 5:40,825,262...40,835,222
Ensembl chr 5:40,825,262...40,835,222 		JBrowse link
G RTP4 receptor transporter protein 4 decreases expression ISO Aluminum results in decreased expression of RTP4 mRNA CTD PMID:37544489 NCBI chr 3:187,368,385...187,372,076
Ensembl chr 3:187,368,385...187,372,076 		JBrowse link
G S100B S100 calcium binding protein B increases expression
multiple interactions		 ISO Aluminum results in increased expression of S100B protein
Vitamin E inhibits the reaction [Aluminum results in increased expression of S100B protein]		 CTD PMID:16545059 NCBI chr21:46,598,604...46,605,082
Ensembl chr21:46,598,604...46,605,208 		JBrowse link
G SCGB1A1 secretoglobin family 1A member 1 decreases expression ISO
EXP		 Aluminum results in decreased expression of SCGB1A1 protein CTD PMID:16052892 PMID:16099050 NCBI chr11:62,419,033...62,423,195
Ensembl chr11:62,405,103...62,423,195 		JBrowse link
G SHISA5 shisa family member 5 decreases expression ISO Aluminum results in decreased expression of SHISA5 mRNA CTD PMID:37544489 NCBI chr 3:48,467,876...48,504,810
Ensembl chr 3:48,467,798...48,504,826 		JBrowse link
G SLC2A1 solute carrier family 2 member 1 increases expression EXP Aluminum results in increased expression of SLC2A1 protein CTD PMID:16979867 NCBI chr 1:42,925,353...42,958,868
Ensembl chr 1:42,925,353...42,958,893 		JBrowse link
G SNAI1 snail family transcriptional repressor 1 multiple interactions EXP 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of SNAI1 protein]; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of SNAI1 mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of SNAI1 protein CTD PMID:32437896 NCBI chr20:49,982,980...49,988,886
Ensembl chr20:49,982,980...49,988,886 		JBrowse link
G SNCA synuclein alpha affects response to substance
multiple interactions		 EXP
ISO		 SNCA protein affects the susceptibility to Aluminum
[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of SNCA protein; Sildenafil Citrate inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of SNCA protein]		 CTD PMID:23106139 PMID:32959702 NCBI chr 4:89,724,099...89,838,304
Ensembl chr 4:89,700,345...89,838,315 		JBrowse link
G SOD2 superoxide dismutase 2 decreases activity ISO Aluminum results in decreased activity of SOD2 protein CTD PMID:19010380 NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529 		JBrowse link
G SPP1 secreted phosphoprotein 1 increases expression ISO Aluminum results in increased expression of SPP1 mRNA CTD PMID:37544489 NCBI chr 4:87,975,714...87,983,411
Ensembl chr 4:87,975,667...87,983,532 		JBrowse link
G SPRR1A small proline rich protein 1A increases expression ISO Aluminum results in increased expression of SPRR1A mRNA CTD PMID:37544489 NCBI chr 1:152,984,081...152,985,814
Ensembl chr 1:152,984,081...152,985,814 		JBrowse link
G SQSTM1 sequestosome 1 multiple interactions ISO [Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of SQSTM1 mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of SQSTM1 protein; Acetylcholine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of SQSTM1 protein]; Acetylcysteine inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of SQSTM1 mRNA] CTD PMID:34547296 NCBI chr 5:179,806,393...179,838,078
Ensembl chr 5:179,806,398...179,838,078 		JBrowse link
G STAT1 signal transducer and activator of transcription 1 decreases expression ISO Aluminum results in decreased expression of STAT1 mRNA; Aluminum results in decreased expression of STAT1 protein CTD PMID:37544489 NCBI chr 2:190,969,149...191,014,171
Ensembl chr 2:190,908,460...191,020,960 		JBrowse link
G TF transferrin multiple interactions
increases uptake
affects binding		 EXP
ISO		 [Aluminum binds to TF protein] which results in decreased uptake of Iron; [Aluminum binds to TF protein] which results in decreased uptake of Manganese; [Aluminum binds to TF protein] which results in increased uptake of Aluminum; [TF protein binds to Aluminum] affects the activity of [TF protein binds to Iron]; [TF protein binds to Aluminum] which results in increased uptake of Aluminum; [TF protein binds to Aluminum] which results in increased uptake of Iron; [TF protein binds to and results in increased uptake of Aluminum] which results in decreased secretion of PTH protein; TF protein binds to [Aluminum co-treated with Iron]; TF protein binds to and results in increased uptake of Aluminum
TF protein results in increased uptake of Aluminum
Aluminum binds to TF protein; TF protein binds to Aluminum
TRF protein binds to Aluminum		 CTD PMID:1375080 PMID:2039817 PMID:2308257 PMID:8782865 PMID:10978387 More... NCBI chr 3:133,661,998...133,796,641
Ensembl chr 3:133,746,040...133,796,641 		JBrowse link
G TFRC transferrin receptor decreases expression
affects uptake		 ISO Aluminum results in decreased expression of TFRC mRNA
TFRC protein affects the uptake of Aluminum		 CTD PMID:9630424 PMID:11068183 NCBI chr 3:196,049,284...196,082,090
Ensembl chr 3:196,012,511...196,082,153 		JBrowse link
G TGFB1 transforming growth factor beta 1 multiple interactions EXP [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of TGFB1 mRNA CTD PMID:32437896 NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922 		JBrowse link
G TNF tumor necrosis factor increases expression
multiple interactions		 ISO
EXP		 Aluminum results in increased expression of TNF protein
[Aluminum co-treated with Copper] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF mRNA]
[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of TNF protein; [Aluminum co-treated with Lead co-treated with Mercury co-treated with Manganese] results in increased expression of TNF protein; [Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of TNF mRNA; [Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of TNF protein; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of TNF mRNA]; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of TNF protein]; caffeic acid inhibits the reaction [Aluminum results in increased expression of TNF protein]; Sildenafil Citrate inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of TNF protein]; Vitamin E inhibits the reaction [Aluminum results in increased expression of TNF protein]
[Titanium co-treated with Vanadium co-treated with Aluminum] results in increased expression of TNF mRNA		 CTD PMID:16545059 PMID:17408380 PMID:23690655 PMID:27368151 PMID:29170048 More... NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336 		JBrowse link
G TUBB3 tubulin beta 3 class III multiple interactions ISO [Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of TUBB3 protein CTD PMID:31363819 NCBI chr16:89,921,925...89,936,097
Ensembl chr16:89,921,392...89,938,761 		JBrowse link
G TXN2 thioredoxin 2 multiple interactions EXP [aluminum chlorhydrate results in increased abundance of Aluminum] which results in decreased expression of TXN2 protein CTD PMID:31945389 NCBI chr22:36,467,046...36,481,640
Ensembl chr22:36,467,046...36,481,640 		JBrowse link
G UBA52 ubiquitin A-52 residue ribosomal protein fusion product 1 decreases expression EXP Aluminum results in decreased expression of UBA52 mRNA; Aluminum results in decreased expression of UBA52 protein CTD PMID:27329587 NCBI chr19:18,563,766...18,577,550
Ensembl chr19:18,571,730...18,577,550 		JBrowse link
G UBE2L6 ubiquitin conjugating enzyme E2 L6 decreases expression ISO Aluminum results in decreased expression of UBE2L6 mRNA CTD PMID:37544489 NCBI chr11:57,551,662...57,567,935
Ensembl chr11:57,551,656...57,568,284 		JBrowse link
G USP18 ubiquitin specific peptidase 18 decreases expression ISO Aluminum results in decreased expression of USP18 mRNA CTD PMID:37544489 NCBI chr22:18,150,170...18,177,397
Ensembl chr22:18,149,843...18,177,397 		JBrowse link
G VCAM1 vascular cell adhesion molecule 1 multiple interactions ISO [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of VCAM1 protein; Sildenafil Citrate inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of VCAM1 protein] CTD PMID:32959702 NCBI chr 1:100,719,742...100,739,045
Ensembl chr 1:100,719,742...100,739,045 		JBrowse link
G VEGFA vascular endothelial growth factor A multiple interactions EXP
ISO		 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of VEGFA protein]; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of and results in increased secretion of VEGFA protein; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased secretion of VEGFA protein
[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of VEGFA protein; Sildenafil Citrate inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in decreased expression of VEGFA protein]		 CTD PMID:32437896 PMID:32959702 NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487 		JBrowse link
G VIM vimentin multiple interactions
increases expression		 EXP
ISO		 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [[Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of VIM protein]; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of VIM mRNA; [Aluminum Chloride results in increased abundance of Aluminum] which results in increased expression of VIM protein
Aluminum results in increased expression of VIM mRNA		 CTD PMID:32437896 PMID:37544489 NCBI chr10:17,228,241...17,237,593
Ensembl chr10:17,228,241...17,237,593 		JBrowse link
G XAF1 XIAP associated factor 1 decreases expression ISO Aluminum results in decreased expression of XAF1 mRNA; Aluminum results in decreased expression of XAF1 protein CTD PMID:37544489 NCBI chr17:6,755,447...6,775,647
Ensembl chr17:6,755,447...6,775,647 		JBrowse link
G XBP1 X-box binding protein 1 decreases expression ISO Aluminum results in decreased expression of XBP1 mRNA CTD PMID:37544489 NCBI chr22:28,794,560...28,800,569
Ensembl chr22:28,794,555...28,800,597 		JBrowse link
G XDH xanthine dehydrogenase increases activity ISO Aluminum results in increased activity of XDH protein CTD PMID:11787993 NCBI chr 2:31,334,321...31,414,742
Ensembl chr 2:31,334,321...31,414,742 		JBrowse link
G ZBP1 Z-DNA binding protein 1 decreases expression ISO Aluminum results in decreased expression of ZBP1 mRNA CTD PMID:37544489 NCBI chr20:57,603,852...57,620,426
Ensembl chr20:57,603,846...57,620,576 		JBrowse link
boric acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ACE angiotensin I converting enzyme multiple interactions EXP boric acid inhibits the reaction [epigallocatechin gallate results in decreased activity of ACE protein] CTD PMID:28544013 NCBI chr17:63,477,061...63,498,373
Ensembl chr17:63,477,061...63,498,380 		JBrowse link
G ACSL4 acyl-CoA synthetase long chain family member 4 multiple interactions ISO boric acid inhibits the reaction [amyloid beta-protein (1-42) results in increased expression of ACSL4 mRNA]; boric acid inhibits the reaction [amyloid beta-protein (1-42) results in increased expression of ACSL4 protein] CTD PMID:38108610 NCBI chr  X:109,641,335...109,733,257
Ensembl chr  X:109,624,244...109,733,403 		JBrowse link
G ACTA2 actin alpha 2, smooth muscle decreases expression EXP boric acid results in decreased expression of ACTA2 protein CTD PMID:25637568 NCBI chr10:88,935,074...88,991,337
Ensembl chr10:88,934,822...88,991,339 		JBrowse link
G ADIPOQ adiponectin, C1Q and collagen domain containing multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of ADIPOQ mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein] CTD PMID:28285642 NCBI chr 3:186,842,710...186,858,463
Ensembl chr 3:186,842,704...186,858,463 		JBrowse link
G AGT angiotensinogen multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of AGT mRNA] CTD PMID:28285642 NCBI chr 1:230,702,523...230,745,583
Ensembl chr 1:230,690,776...230,745,576 		JBrowse link
G AKT1 AKT serine/threonine kinase 1 increases expression ISO boric acid results in increased expression of AKT1 mRNA CTD PMID:31368021 NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,759 		JBrowse link
G ARG1 arginase 1 decreases activity EXP boric acid results in decreased activity of ARG1 protein CTD PMID:21232540 NCBI chr 6:131,573,226...131,584,329
Ensembl chr 6:131,470,832...131,584,332 		JBrowse link
G ATF4 activating transcription factor 4 increases expression EXP boric acid results in increased expression of ATF4 mRNA; boric acid results in increased expression of ATF4 protein CTD PMID:25425213 PMID:27587023 NCBI chr22:39,520,559...39,522,686
Ensembl chr22:39,519,695...39,522,686 		JBrowse link
G ATF6 activating transcription factor 6 multiple interactions EXP boric acid results in increased cleavage of and affects the localization of ATF6 protein CTD PMID:27587023 NCBI chr 1:161,766,320...161,964,070
Ensembl chr 1:161,766,298...161,977,574 		JBrowse link
G BAX BCL2 associated X, apoptosis regulator decreases expression
increases expression
multiple interactions		 ISO
EXP		 boric acid results in decreased expression of BAX mRNA
boric acid results in increased expression of BAX mRNA
[boric acid results in increased abundance of Boron] which affects the expression of BAX mRNA; [boric acid results in increased abundance of Boron] which affects the expression of BAX protein		 CTD PMID:31368021 PMID:33137424 PMID:34175401 NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798 		JBrowse link
G BCL2 BCL2 apoptosis regulator increases expression
decreases expression
multiple interactions		 ISO
EXP		 boric acid results in increased expression of BCL2 mRNA
boric acid results in decreased expression of BCL2 mRNA
[boric acid results in increased abundance of Boron] which results in decreased expression of BCL2 mRNA; [boric acid results in increased abundance of Boron] which results in decreased expression of BCL2 protein		 CTD PMID:31368021 PMID:33137424 PMID:34175401 NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128 		JBrowse link
G BCL2L1 BCL2 like 1 decreases expression EXP boric acid results in decreased expression of BCL2L1 mRNA CTD PMID:34175401 NCBI chr20:31,664,452...31,723,963
Ensembl chr20:31,664,452...31,723,989 		JBrowse link
G BID BH3 interacting domain death agonist increases expression EXP boric acid results in increased expression of BID mRNA CTD PMID:34175401 NCBI chr22:17,734,138...17,774,665
Ensembl chr22:17,734,138...17,774,770 		JBrowse link
G CALR calreticulin increases expression EXP boric acid results in increased expression of CALR mRNA CTD PMID:27587023 NCBI chr19:12,938,609...12,944,489
Ensembl chr19:12,938,578...12,944,489 		JBrowse link
G CASP3 caspase 3 multiple interactions
increases expression
decreases expression		 EXP
ISO		 boric acid inhibits the reaction [Formaldehyde results in increased expression of CASP3 mRNA]
boric acid results in increased expression of CASP3 mRNA
boric acid results in decreased expression of CASP3 mRNA		 CTD PMID:31368021 PMID:31823256 PMID:34175401 NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062 		JBrowse link
G CASP9 caspase 9 increases expression EXP boric acid results in increased expression of CASP9 mRNA CTD PMID:34175401 NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534 		JBrowse link
G CAT catalase multiple interactions
decreases activity		 ISO
EXP		 [boric acid co-treated with Arsenic Trioxide] affects the activity of CAT protein; [boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in decreased activity of CAT protein]; boric acid inhibits the reaction [Acrylamide results in increased activity of CAT protein]
boric acid results in decreased activity of CAT protein
boric acid affects the reaction [Formaldehyde results in decreased activity of CAT protein]		 CTD PMID:26184899 PMID:29913234 PMID:30997025 PMID:31823256 NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060 		JBrowse link
G CCND1 cyclin D1 increases expression
multiple interactions		 ISO boric acid results in increased expression of CCND1 mRNA
boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of CCND1 protein]		 CTD PMID:28285642 NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474 		JBrowse link
G CEBPA CCAAT enhancer binding protein alpha multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]] CTD PMID:28285642 NCBI chr19:33,299,934...33,302,534
Ensembl chr19:33,299,934...33,302,534 		JBrowse link
G CEBPB CCAAT enhancer binding protein beta multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPB mRNA] CTD PMID:28285642 NCBI chr20:50,190,583...50,192,690
Ensembl chr20:50,190,734...50,192,690 		JBrowse link
G COL1A2 collagen type I alpha 2 chain affects expression ISO boric acid affects the expression of COL1A2 mRNA CTD PMID:24704097 NCBI chr 7:94,394,895...94,431,227
Ensembl chr 7:94,394,895...94,431,227 		JBrowse link
G CSF2 colony stimulating factor 2 increases expression EXP boric acid results in increased expression of CSF2 protein CTD PMID:27206737 NCBI chr 5:132,073,789...132,076,170
Ensembl chr 5:132,073,789...132,076,170 		JBrowse link
G CSF3 colony stimulating factor 3 increases expression EXP boric acid results in increased expression of CSF3 protein CTD PMID:27206737 NCBI chr17:40,015,440...40,017,813
Ensembl chr17:40,015,361...40,017,813 		JBrowse link
G CST3 cystatin C multiple interactions ISO [boric acid results in increased abundance of Boron] inhibits the reaction [Acetaminophen results in increased expression of CST3 protein] CTD PMID:35020164 NCBI chr20:23,626,706...23,637,955
Ensembl chr20:23,626,706...23,638,473 		JBrowse link
G CTNNB1 catenin beta 1 multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of CTNNB1 protein]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]] CTD PMID:28285642 NCBI chr 3:41,199,505...41,240,443
Ensembl chr 3:41,194,741...41,260,096 		JBrowse link
G DDIT3 DNA damage inducible transcript 3 decreases expression EXP boric acid results in decreased expression of DDIT3 mRNA; boric acid results in decreased expression of DDIT3 protein CTD PMID:27587023 NCBI chr12:57,516,588...57,520,517
Ensembl chr12:57,516,588...57,521,737 		JBrowse link
G DES desmin affects expression EXP boric acid affects the expression of DES mRNA CTD PMID:25637568 NCBI chr 2:219,418,377...219,426,734
Ensembl chr 2:219,418,377...219,426,735 		JBrowse link
G DVL2 dishevelled segment polarity protein 2 multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of DVL2 mRNA] CTD PMID:28285642 NCBI chr17:7,225,342...7,234,517
Ensembl chr17:7,225,342...7,234,517 		JBrowse link
G EDEM1 ER degradation enhancing alpha-mannosidase like protein 1 increases expression EXP boric acid results in increased expression of EDEM1 mRNA CTD PMID:27587023 NCBI chr 3:5,187,707...5,219,958
Ensembl chr 3:5,187,646...5,219,958 		JBrowse link
G EIF2AK3 eukaryotic translation initiation factor 2 alpha kinase 3 multiple interactions ISO EIF2AK3 protein affects the reaction [boric acid affects the localization of NFE2L2 protein]; EIF2AK3 protein affects the reaction [boric acid results in increased expression of GCLC mRNA]; EIF2AK3 protein affects the reaction [boric acid results in increased phosphorylation of EIF2S1 protein] CTD PMID:30196486 NCBI chr 2:88,556,741...88,628,145
Ensembl chr 2:88,556,741...88,691,518 		JBrowse link
G EIF2S1 eukaryotic translation initiation factor 2 subunit alpha increases phosphorylation
multiple interactions		 EXP
ISO		 boric acid results in increased phosphorylation of EIF2S1 protein
EIF2AK3 protein affects the reaction [boric acid results in increased phosphorylation of EIF2S1 protein]		 CTD PMID:25425213 PMID:27587023 PMID:30196486 NCBI chr14:67,360,328...67,386,516
Ensembl chr14:67,360,328...67,386,516 		JBrowse link
G FABP4 fatty acid binding protein 4 multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]] CTD PMID:28285642 NCBI chr 8:81,478,419...81,483,233
Ensembl chr 8:81,478,419...81,483,236 		JBrowse link
G FASN fatty acid synthase multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FASN mRNA] CTD PMID:28285642 NCBI chr17:82,078,338...82,098,236
Ensembl chr17:82,078,338...82,098,294 		JBrowse link
G FGF2 fibroblast growth factor 2 multiple interactions ISO boric acid promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FGF2 protein] CTD PMID:28285642 NCBI chr 4:122,826,682...122,898,236
Ensembl chr 4:122,826,682...122,898,236 		JBrowse link
G FGF7 fibroblast growth factor 7 increases expression EXP boric acid results in increased expression of FGF7 protein CTD PMID:27206737 NCBI chr15:49,423,242...49,488,775
Ensembl chr15:49,423,237...49,488,775 		JBrowse link
G FN1 fibronectin 1 increases expression
affects expression		 ISO
EXP		 boric acid results in increased expression of FN1 mRNA
boric acid affects the expression of FN1 mRNA		 CTD PMID:27206737 NCBI chr 2:215,360,865...215,436,068
Ensembl chr 2:215,360,440...215,436,073 		JBrowse link
G GAPDH glyceraldehyde-3-phosphate dehydrogenase decreases expression ISO boric acid results in decreased expression of GAPDH protein CTD PMID:28285642 NCBI chr12:6,534,517...6,538,371
Ensembl chr12:6,534,512...6,538,374 		JBrowse link
G GAS6 growth arrest specific 6 multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of GAS6 protein] CTD PMID:28285642 NCBI chr13:113,820,549...113,864,076
Ensembl chr13:113,820,549...113,864,076 		JBrowse link
G GCK glucokinase increases expression ISO boric acid results in increased expression of GCK mRNA CTD PMID:31368021 NCBI chr 7:44,143,213...44,189,439
Ensembl chr 7:44,143,213...44,198,170 		JBrowse link
G GCLC glutamate-cysteine ligase catalytic subunit multiple interactions
increases expression		 ISO
EXP		 EIF2AK3 protein affects the reaction [boric acid results in increased expression of GCLC mRNA] CTD PMID:30196486 NCBI chr 6:53,497,341...53,545,101
Ensembl chr 6:53,497,341...53,616,970 		JBrowse link
G GPT glutamic--pyruvic transaminase multiple interactions ISO [boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of GPT protein] CTD PMID:30997025 NCBI chr 8:144,503,068...144,507,172
Ensembl chr 8:144,502,973...144,507,174 		JBrowse link
G GPX4 glutathione peroxidase 4 multiple interactions ISO boric acid inhibits the reaction [amyloid beta-protein (1-42) results in decreased expression of GPX4 mRNA]; boric acid inhibits the reaction [amyloid beta-protein (1-42) results in decreased expression of GPX4 protein] CTD PMID:38108610 NCBI chr19:1,103,994...1,106,779
Ensembl chr19:1,103,982...1,106,791 		JBrowse link
G HAVCR1 hepatitis A virus cellular receptor 1 multiple interactions ISO [boric acid results in increased abundance of Boron] inhibits the reaction [Acetaminophen results in increased expression of HAVCR1 protein] CTD PMID:35020164 NCBI chr 5:157,029,413...157,069,407
Ensembl chr 5:157,026,742...157,069,396 		JBrowse link
G HERPUD1 homocysteine inducible ER protein with ubiquitin like domain 1 increases expression EXP boric acid results in increased expression of HERPUD1 mRNA CTD PMID:27587023 NCBI chr16:56,932,142...56,944,864
Ensembl chr16:56,932,142...56,944,864 		JBrowse link
G HMOX1 heme oxygenase 1 increases expression EXP
ISO		 boric acid results in increased expression of HMOX1 mRNA CTD PMID:30196486 NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214 		JBrowse link
G HOXA6 homeobox A6 affects expression ISO boric acid affects the expression of HOXA6 mRNA CTD PMID:12749385 NCBI chr 7:27,145,396...27,147,774
Ensembl chr 7:27,145,396...27,150,603 		JBrowse link
G HOXC6 homeobox C6 affects expression ISO boric acid affects the expression of HOXC6 mRNA CTD PMID:12749385 NCBI chr12:54,016,888...54,030,823
Ensembl chr12:53,990,624...54,030,823 		JBrowse link
G HSPA5 heat shock protein family A (Hsp70) member 5 increases expression EXP boric acid results in increased expression of HSPA5 mRNA; boric acid results in increased expression of HSPA5 protein CTD PMID:25425213 PMID:27587023 NCBI chr 9:125,234,853...125,241,343
Ensembl chr 9:125,234,853...125,241,382 		JBrowse link
G IFNG interferon gamma multiple interactions ISO [boric acid results in increased abundance of Boron] promotes the reaction [4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline results in decreased secretion of IFNG protein]; [boric acid results in increased abundance of Boron] which affects the secretion of IFNG protein; [Food Preservatives results in increased abundance of boric acid] which results in increased expression of IFNG mRNA; boric acid inhibits the reaction [Acrylamide results in increased expression of IFNG mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of IFNG mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of IFNG protein] CTD PMID:29913234 PMID:30368975 PMID:32179172 PMID:33137424 NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740 		JBrowse link
G IL10 interleukin 10 multiple interactions ISO [boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in decreased expression of IL10 mRNA]; [Food Preservatives results in increased abundance of boric acid] which results in increased expression of IL10 mRNA CTD PMID:30997025 PMID:32179172 NCBI chr 1:206,767,602...206,772,494
Ensembl chr 1:206,767,602...206,774,541 		JBrowse link
G IL18 interleukin 18 multiple interactions ISO [boric acid results in increased abundance of Boron] inhibits the reaction [Acetaminophen results in increased expression of IL18 protein] CTD PMID:35020164 NCBI chr11:112,143,260...112,164,094
Ensembl chr11:112,143,251...112,164,096 		JBrowse link
G IL1B interleukin 1 beta multiple interactions ISO [boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of IL1B mRNA]; [Food Preservatives results in increased abundance of boric acid] which results in increased expression of IL1B mRNA; boric acid inhibits the reaction [Acrylamide results in increased expression of IL1B mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of IL1B mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of IL1B protein] CTD PMID:29913234 PMID:30368975 PMID:30997025 PMID:32179172 NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816 		JBrowse link
G IL2 interleukin 2 multiple interactions ISO [boric acid results in increased abundance of Boron] promotes the reaction [4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline results in decreased secretion of IL2 protein]; [boric acid results in increased abundance of Boron] which results in decreased secretion of IL2 protein CTD PMID:33137424 NCBI chr 4:122,451,470...122,456,725
Ensembl chr 4:122,451,470...122,456,725 		JBrowse link
G IL4 interleukin 4 increases expression
multiple interactions		 ISO boric acid results in increased expression of IL4 mRNA
[boric acid results in increased abundance of Boron] which affects the secretion of IL4 protein		 CTD PMID:31368021 PMID:33137424 NCBI chr 5:132,673,989...132,682,678
Ensembl chr 5:132,673,986...132,682,678 		JBrowse link
G IL6 interleukin 6 multiple interactions ISO boric acid promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of IL6 mRNA]
[boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of IL6 mRNA]; [Food Preservatives results in increased abundance of boric acid] which results in increased expression of IL6 mRNA		 CTD PMID:28285642 PMID:30997025 PMID:32179172 NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002 		JBrowse link
G INS insulin multiple interactions
increases expression		 ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of CCND1 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of CTNNB1 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of DVL2 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of ADIPOQ mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of AGT mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPB mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FASN mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of GAS6 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of KLF5 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of LEP mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of LIPE mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SLC2A4 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SLC2A4 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SREBF1 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of TNFRSF1A protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased phosphorylation of MAPK1 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased phosphorylation of MAPK3 protein]; boric acid promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FGF2 protein]; boric acid promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of IL6 mRNA]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]]
boric acid results in increased expression of INS2 mRNA		 CTD PMID:28285642 PMID:31368021 NCBI chr11:2,159,779...2,161,209
Ensembl chr11:2,159,779...2,161,221 		JBrowse link
G INS-IGF2 INS-IGF2 readthrough increases expression ISO boric acid results in increased expression of INS1 mRNA CTD PMID:31368021 NCBI chr11:2,129,117...2,161,209
Ensembl chr11:2,132,538...2,161,209 		JBrowse link
G KLF5 KLF transcription factor 5 multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of KLF5 mRNA] CTD PMID:28285642 NCBI chr13:73,054,976...73,077,538
Ensembl chr13:73,054,976...73,077,541 		JBrowse link
G LAMA5 laminin subunit alpha 5 increases expression ISO
EXP		 boric acid results in increased expression of LAMA5 mRNA CTD PMID:27206737 NCBI chr20:62,309,065...62,367,312
Ensembl chr20:62,307,955...62,367,312 		JBrowse link
G LEP leptin multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of LEP mRNA]; boric acid results in decreased expression of and results in decreased secretion of LEP protein CTD PMID:28285642 NCBI chr 7:128,241,278...128,257,629
Ensembl chr 7:128,241,278...128,257,629 		JBrowse link
G LIPE lipase E, hormone sensitive type multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of LIPE mRNA] CTD PMID:28285642 NCBI chr19:42,401,514...42,427,388
Ensembl chr19:42,401,497...42,427,388 		JBrowse link
G MAPK1 mitogen-activated protein kinase 1 multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased phosphorylation of MAPK1 protein] CTD PMID:28285642 NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680 		JBrowse link
G MAPK3 mitogen-activated protein kinase 3 multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased phosphorylation of MAPK3 protein] CTD PMID:28285642 NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506 		JBrowse link
G MIR130A microRNA 130a decreases expression EXP boric acid results in decreased expression of MIR130A mRNA CTD PMID:34175401 NCBI chr11:57,641,198...57,641,286
Ensembl chr11:57,641,198...57,641,286 		JBrowse link
G MIR200A microRNA 200a decreases expression EXP boric acid results in decreased expression of MIR200A mRNA CTD PMID:34175401 NCBI chr 1:1,167,863...1,167,952
Ensembl chr 1:1,167,863...1,167,952 		JBrowse link
G MIR21 microRNA 21 decreases expression EXP boric acid results in decreased expression of MIR21 mRNA CTD PMID:34175401 NCBI chr17:59,841,266...59,841,337
Ensembl chr17:59,841,266...59,841,337 		JBrowse link
G MIR224 microRNA 224 decreases expression EXP boric acid results in decreased expression of MIR224 mRNA CTD PMID:34175401 NCBI chr  X:151,958,578...151,958,658
Ensembl chr  X:151,958,578...151,958,658 		JBrowse link
G MMP2 matrix metallopeptidase 2 decreases expression ISO boric acid results in decreased expression of MMP2 protein CTD PMID:28285642 NCBI chr16:55,478,830...55,506,691
Ensembl chr16:55,389,700...55,506,691 		JBrowse link
G MYH1 myosin heavy chain 1 affects expression EXP boric acid affects the expression of MYH1 mRNA CTD PMID:25637568 NCBI chr17:10,492,307...10,518,542
Ensembl chr17:10,492,307...10,518,542 		JBrowse link
G MYOD1 myogenic differentiation 1 affects expression
decreases expression		 EXP boric acid affects the expression of MYOD1 mRNA
boric acid results in decreased expression of MYOD1 protein		 CTD PMID:25637568 NCBI chr11:17,719,571...17,722,136
Ensembl chr11:17,719,571...17,722,136 		JBrowse link
G MYOG myogenin affects expression EXP boric acid affects the expression of MYOG mRNA CTD PMID:25637568 NCBI chr 1:203,083,129...203,086,012
Ensembl chr 1:203,083,129...203,086,012 		JBrowse link
G NFE2L2 NFE2 like bZIP transcription factor 2 affects localization
multiple interactions		 EXP
ISO		 boric acid affects the localization of NFE2L2 protein
EIF2AK3 protein affects the reaction [boric acid affects the localization of NFE2L2 protein]		 CTD PMID:30196486 NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756 		JBrowse link
G NFKB1 nuclear factor kappa B subunit 1 multiple interactions
affects expression		 EXP boric acid affects the reaction [Formaldehyde results in increased expression of NFKB1 mRNA]
boric acid affects the expression of NFKB1 mRNA		 CTD PMID:31823256 NCBI chr 4:102,501,359...102,617,302
Ensembl chr 4:102,501,330...102,617,302 		JBrowse link
G NOS2 nitric oxide synthase 2 multiple interactions ISO boric acid inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA] CTD PMID:27206737 NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529 		JBrowse link
G NQO1 NAD(P)H quinone dehydrogenase 1 increases expression EXP boric acid results in increased expression of NQO1 mRNA CTD PMID:30196486 NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668 		JBrowse link
G PCNA proliferating cell nuclear antigen increases expression
multiple interactions		 ISO boric acid results in increased expression of PCNA protein
[boric acid results in increased abundance of Boron] promotes the reaction [4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline results in decreased expression of PCNA protein]; [boric acid results in increased abundance of Boron] which affects the expression of PCNA protein; [boric acid results in increased abundance of Boron] which results in decreased expression of PCNA mRNA		 CTD PMID:17943231 PMID:33137424 NCBI chr20:5,114,953...5,126,622
Ensembl chr20:5,114,953...5,126,626 		JBrowse link
G PDX1 pancreatic and duodenal homeobox 1 increases expression ISO boric acid results in increased expression of PDX1 mRNA CTD PMID:31368021 NCBI chr13:27,920,000...27,926,313
Ensembl chr13:27,920,000...27,926,313 		JBrowse link
G PPARG peroxisome proliferator activated receptor gamma multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]] CTD PMID:28285642 NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356 		JBrowse link
G PPP1R15A protein phosphatase 1 regulatory subunit 15A increases expression EXP boric acid results in increased expression of PPP1R15A mRNA; boric acid results in increased expression of PPP1R15A protein CTD PMID:27587023 NCBI chr19:48,872,421...48,876,058
Ensembl chr19:48,872,212...48,876,059 		JBrowse link
G PTGS2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO boric acid inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] CTD PMID:27206737 NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922 		JBrowse link
G RELA RELA proto-oncogene, NF-kB subunit multiple interactions ISO boric acid inhibits the reaction [Acrylamide results in increased expression of RELA mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of RELA mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of RELA protein] CTD PMID:29913234 PMID:30368975 NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090 		JBrowse link
G RUNX2 RUNX family transcription factor 2 affects expression ISO boric acid affects the expression of RUNX2 mRNA CTD PMID:24704097 NCBI chr 6:45,328,330...45,551,082
Ensembl chr 6:45,328,157...45,664,349 		JBrowse link
G SLC2A2 solute carrier family 2 member 2 increases expression ISO boric acid results in increased expression of SLC2A2 mRNA CTD PMID:31368021 NCBI chr 3:170,996,347...171,026,720
Ensembl chr 3:170,996,347...171,026,743 		JBrowse link
G SLC2A4 solute carrier family 2 member 4 multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SLC2A4 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SLC2A4 protein] CTD PMID:28285642 NCBI chr17:7,281,718...7,288,257
Ensembl chr17:7,281,718...7,288,257 		JBrowse link
G SLC4A2 solute carrier family 4 member 2 increases expression EXP boric acid results in increased expression of SLC4A2 mRNA CTD PMID:22576912 NCBI chr 7:151,058,200...151,076,527
Ensembl chr 7:151,057,210...151,076,526 		JBrowse link
G SLC4A3 solute carrier family 4 member 3 increases expression EXP boric acid results in increased expression of SLC4A3 mRNA CTD PMID:22576912 NCBI chr 2:219,627,630...219,641,971
Ensembl chr 2:219,627,394...219,641,980 		JBrowse link
G SPARC secreted protein acidic and cysteine rich affects expression ISO boric acid affects the expression of SPARC mRNA CTD PMID:24704097 NCBI chr 5:151,661,096...151,686,915
Ensembl chr 5:151,661,096...151,686,975 		JBrowse link
G SREBF1 sterol regulatory element binding transcription factor 1 multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SREBF1 mRNA] CTD PMID:28285642 NCBI chr17:17,811,334...17,836,986
Ensembl chr17:17,810,399...17,837,002 		JBrowse link
G SYVN1 synoviolin 1 decreases expression EXP boric acid results in decreased expression of SYVN1 mRNA CTD PMID:27587023 NCBI chr11:65,127,279...65,134,519
Ensembl chr11:65,121,780...65,134,532 		JBrowse link
G TFRC transferrin receptor multiple interactions ISO boric acid inhibits the reaction [amyloid beta-protein (1-42) results in increased expression of TFRC mRNA]; boric acid inhibits the reaction [amyloid beta-protein (1-42) results in increased expression of TFRC protein] CTD PMID:38108610 NCBI chr 3:196,049,284...196,082,090
Ensembl chr 3:196,012,511...196,082,153 		JBrowse link
G TGFB1 transforming growth factor beta 1 increases expression EXP
ISO		 boric acid results in increased expression of TGFB1 protein
boric acid results in increased expression of TGFB1 mRNA		 CTD PMID:27206737 PMID:31368021 NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922 		JBrowse link
G TNF tumor necrosis factor multiple interactions
decreases expression
increases secretion
increases expression		 EXP
ISO		 boric acid inhibits the reaction [Formaldehyde results in increased expression of TNF mRNA]; boric acid inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; boric acid inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]
boric acid results in decreased expression of TNF mRNA
[boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of TNF mRNA]; [Food Preservatives results in increased abundance of boric acid] which results in increased expression of TNF mRNA; boric acid inhibits the reaction [Acrylamide results in increased expression of TNF mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of TNF mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of TNF protein]
boric acid results in increased secretion of TNF protein
boric acid results in increased expression of TNF mRNA		 CTD PMID:9618283 PMID:18755394 PMID:29913234 PMID:30368975 PMID:30997025 More... NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336 		JBrowse link
G TNFRSF1A TNF receptor superfamily member 1A multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of TNFRSF1A protein] CTD PMID:28285642 NCBI chr12:6,328,771...6,342,076
Ensembl chr12:6,328,757...6,342,114 		JBrowse link
G TP53 tumor protein p53 decreases expression ISO boric acid results in decreased expression of TRP53 mRNA CTD PMID:31368021 NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,546 		JBrowse link
G XBP1 X-box binding protein 1 increases expression EXP boric acid results in increased expression of XBP1 mRNA CTD PMID:27587023 NCBI chr22:28,794,560...28,800,569
Ensembl chr22:28,794,555...28,800,597 		JBrowse link
boric acids term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G GGT1 gamma-glutamyltransferase 1 decreases activity ISO Boric Acids analog results in decreased activity of GGT1 protein CTD PMID:6149445 NCBI chr22:24,583,750...24,628,996
Ensembl chr22:24,594,811...24,629,005 		JBrowse link
G MUC1 mucin 1, cell surface associated decreases expression EXP Boric Acids results in decreased expression of MUC1 mRNA CTD PMID:21060261 NCBI chr 1:155,185,824...155,192,915
Ensembl chr 1:155,185,824...155,192,916 		JBrowse link
G MUC16 mucin 16, cell surface associated decreases expression EXP Boric Acids results in decreased expression of MUC16 mRNA CTD PMID:21060261 NCBI chr19:8,848,844...9,065,751
Ensembl chr19:8,848,844...9,010,390 		JBrowse link
bortezomib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCA2 ATP binding cassette subfamily A member 2 decreases expression EXP Bortezomib results in decreased expression of ABCA2 mRNA CTD PMID:20977926 NCBI chr 9:137,007,234...137,028,922
Ensembl chr 9:137,007,234...137,028,915 		JBrowse link
G ABCB1 ATP binding cassette subfamily B member 1 multiple interactions
decreases expression
decreases activity		 EXP
ISO		 [Bortezomib co-treated with Doxorubicin] results in decreased expression of ABCB1 protein; ATP2A1 protein affects the reaction [Bortezomib results in decreased expression of ABCB1]; Bortezomib inhibits the reaction [CERS2 protein affects the expression of ABCB1 protein]; Bortezomib inhibits the reaction [CERS6 protein affects the expression of ABCB1 protein]; Bortezomib promotes the reaction [Chloroquine results in decreased expression of ABCB1 mRNA]; Bortezomib promotes the reaction [Chloroquine results in decreased expression of and results in increased nitrosation of ABCB1 protein]; Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1 protein; Chloroquine promotes the reaction [Bortezomib results in decreased expression of ABCB1 mRNA]; Chloroquine promotes the reaction [Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1 protein]
[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein; Bortezomib promotes the reaction [Chloroquine results in decreased expression of ABCB1A mRNA]; Bortezomib promotes the reaction [Chloroquine results in decreased expression of and results in increased nitrosation of ABCB1A protein]; Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1A protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]; Chloroquine promotes the reaction [Bortezomib results in decreased expression of ABCB1A mRNA]; Chloroquine promotes the reaction [Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1A protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]]
Bortezomib results in decreased expression of ABCB1; Bortezomib results in decreased expression of ABCB1 mRNA; Bortezomib results in decreased expression of ABCB1 protein
Bortezomib results in decreased activity of ABCB1 protein		 CTD PMID:25576094 PMID:30482226 PMID:33775688 PMID:34915026 NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323 		JBrowse link
G ABCC1 ATP binding cassette subfamily C member 1 (ABCC1 blood group) decreases expression
multiple interactions		 EXP Bortezomib results in decreased expression of ABCC1 mRNA
[Bortezomib co-treated with Doxorubicin] results in decreased expression of ABCC1 protein		 CTD PMID:20977926 PMID:33775688 NCBI chr16:15,949,143...16,143,053
Ensembl chr16:15,949,138...16,143,257 		JBrowse link
G ABCC2 ATP binding cassette subfamily C member 2 increases expression EXP Bortezomib results in increased expression of ABCC2 mRNA CTD PMID:21215737 NCBI chr10:99,782,640...99,852,594
Ensembl chr10:99,782,640...99,852,594 		JBrowse link
G ABCC4 ATP binding cassette subfamily C member 4 (PEL blood group) decreases expression EXP Bortezomib results in decreased expression of ABCC4 mRNA CTD PMID:20977926 NCBI chr13:95,019,835...95,301,451
Ensembl chr13:95,019,835...95,301,475 		JBrowse link
G ABHD16A abhydrolase domain containing 16A, phospholipase increases expression EXP Bortezomib results in increased expression of ABHD16A mRNA CTD PMID:20977926 NCBI chr 6:31,686,955...31,703,324
Ensembl chr 6:31,686,955...31,703,356 		JBrowse link
G ABHD2 abhydrolase domain containing 2, acylglycerol lipase increases expression EXP Bortezomib results in increased expression of ABHD2 mRNA CTD PMID:20977926 NCBI chr15:89,040,998...89,202,355
Ensembl chr15:89,087,459...89,202,355 		JBrowse link
G ABI1 abl interactor 1 increases expression EXP Bortezomib results in increased expression of ABI1 mRNA CTD PMID:20977926 NCBI chr10:26,746,596...26,860,958
Ensembl chr10:26,746,593...26,861,087 		JBrowse link
G ABL1 ABL proto-oncogene 1, non-receptor tyrosine kinase multiple interactions EXP [alvocidib co-treated with Bortezomib co-treated with ABL1 protein] results in decreased phosphorylation of LYN protein; [alvocidib co-treated with Bortezomib co-treated with ABL1] results in decreased phosphorylation of CRKL protein; [alvocidib co-treated with Bortezomib] results in decreased expression of ABL1 protein; [arsenic trioxide co-treated with Bortezomib] results in decreased expression of ABL1 protein; [Bortezomib co-treated with N,N-dimethylsphingosine] results in decreased expression of ABL1 protein; Bortezomib promotes the reaction [Dichlororibofuranosylbenzimidazole results in decreased expression of ABL1 protein] CTD PMID:15039284 PMID:17495969 PMID:21195056 NCBI chr 9:130,713,043...130,887,675
Ensembl chr 9:130,713,043...130,887,675 		JBrowse link
G ACE angiotensin I converting enzyme multiple interactions EXP [Butyrates co-treated with Bortezomib] results in increased activity of ACE protein mutant form CTD PMID:20454656 NCBI chr17:63,477,061...63,498,373
Ensembl chr17:63,477,061...63,498,380 		JBrowse link
G ACOT7 acyl-CoA thioesterase 7 decreases expression EXP Bortezomib results in decreased expression of ACOT7 mRNA CTD PMID:20977926 NCBI chr 1:6,264,272...6,393,767
Ensembl chr 1:6,264,269...6,393,767 		JBrowse link
G ADAM10 ADAM metallopeptidase domain 10 decreases expression EXP Bortezomib results in decreased expression of ADAM10 mRNA CTD PMID:20977926 NCBI chr15:58,588,809...58,749,707
Ensembl chr15:58,588,809...58,749,791 		JBrowse link
G ADM adrenomedullin multiple interactions
decreases expression		 EXP Bortezomib inhibits the reaction [arsenic trioxide results in decreased expression of ADM mRNA]
Bortezomib results in decreased expression of ADM mRNA		 CTD PMID:20471514 NCBI chr11:10,305,073...10,307,397
Ensembl chr11:10,305,073...10,307,397 		JBrowse link
G AFF1 ALF transcription elongation factor 1 increases expression EXP Bortezomib results in increased expression of AFF1 mRNA CTD PMID:20977926 NCBI chr 4:86,935,011...87,141,039
Ensembl chr 4:86,935,002...87,141,039 		JBrowse link
G AFF4 ALF transcription elongation factor 4 increases expression EXP Bortezomib results in increased expression of AFF4 mRNA CTD PMID:20977926 NCBI chr 5:132,875,395...132,963,634
Ensembl chr 5:132,875,395...132,963,634 		JBrowse link
G AFG2A AFG2 AAA ATPase homolog A increases expression EXP Bortezomib results in increased expression of AFG2A mRNA CTD PMID:20977926 NCBI chr 4:122,923,078...123,319,433
Ensembl chr 4:122,923,070...123,319,433 		JBrowse link
G AGER advanced glycosylation end-product specific receptor increases expression
multiple interactions		 ISO Bortezomib results in increased expression of AGER mRNA
Berberine inhibits the reaction [Bortezomib results in increased expression of AGER mRNA]		 CTD PMID:35121005 NCBI chr 6:32,180,969...32,184,253
Ensembl chr 6:32,180,968...32,184,322 		JBrowse link
G AGK acylglycerol kinase decreases expression EXP Bortezomib results in decreased expression of AGK mRNA CTD PMID:20977926 NCBI chr 7:141,551,410...141,655,244
Ensembl chr 7:141,551,278...141,655,244 		JBrowse link
G AGRN agrin decreases expression EXP Bortezomib results in decreased expression of AGRN mRNA CTD PMID:20977926 NCBI chr 1:1,020,120...1,056,116
Ensembl chr 1:1,020,120...1,056,119 		JBrowse link
G AGTPBP1 ATP/GTP binding carboxypeptidase 1 increases expression EXP Bortezomib results in increased expression of AGTPBP1 mRNA CTD PMID:20977926 NCBI chr 9:85,546,539...85,805,483
Ensembl chr 9:85,546,539...85,742,029 		JBrowse link
G AGTRAP angiotensin II receptor associated protein decreases expression EXP Bortezomib results in decreased expression of AGTRAP mRNA CTD PMID:20977926 NCBI chr 1:11,736,136...11,750,769
Ensembl chr 1:11,736,084...11,754,802 		JBrowse link
G AIFM1 apoptosis inducing factor mitochondria associated 1 affects localization
multiple interactions		 EXP Bortezomib affects the localization of AIFM1 protein
[Bortezomib co-treated with Butyrates] affects the localization of AIFM1 protein; [Bortezomib co-treated with vorinostat] affects the localization of AIFM1 protein		 CTD PMID:12893773 PMID:16024631 NCBI chr  X:130,129,362...130,165,841
Ensembl chr  X:130,124,666...130,165,879 		JBrowse link
G AIFM2 AIF family member 2 increases expression EXP Bortezomib results in increased expression of AIFM2 mRNA CTD PMID:20977926 NCBI chr10:70,112,271...70,132,825
Ensembl chr10:70,098,223...70,132,934 		JBrowse link
G AIM2 absent in melanoma 2 increases expression EXP Bortezomib results in increased expression of AIM2 mRNA CTD PMID:20977926 NCBI chr 1:159,055,051...159,147,132
Ensembl chr 1:159,056,129...159,187,843 		JBrowse link
G AIRIM AFG2 interacting ribosome maturation factor increases expression EXP Bortezomib results in increased expression of AIRIM mRNA CTD PMID:20977926 NCBI chr 1:37,681,570...37,692,242
Ensembl chr 1:37,681,570...37,692,249 		JBrowse link
G AKR1B1 aldo-keto reductase family 1 member B increases expression EXP Bortezomib results in increased expression of AKR1B1 mRNA; Bortezomib results in increased expression of AKR1B1 protein CTD PMID:21215737 NCBI chr 7:134,442,350...134,459,239
Ensembl chr 7:134,442,356...134,459,284 		JBrowse link
G AKR1B10 aldo-keto reductase family 1 member B10 increases expression EXP Bortezomib results in increased expression of AKR1B10 mRNA; Bortezomib results in increased expression of AKR1B10 protein CTD PMID:21215737 NCBI chr 7:134,527,567...134,541,412
Ensembl chr 7:134,527,567...134,541,412 		JBrowse link
G AKR1C1 aldo-keto reductase family 1 member C1 multiple interactions
increases expression		 EXP [arsenic trioxide co-treated with Bortezomib] results in increased expression of AKR1C1 mRNA
Bortezomib results in increased expression of AKR1C1 mRNA		 CTD PMID:21215737 PMID:25913414 NCBI chr10:4,963,415...4,983,283
Ensembl chr10:4,963,253...4,983,283 		JBrowse link
G AKR1C2 aldo-keto reductase family 1 member C2 affects expression EXP Bortezomib affects the expression of AKR1C2 mRNA CTD PMID:21215737 NCBI chr10:4,987,775...5,018,000
Ensembl chr10:4,987,775...5,018,031 		JBrowse link
G AKR1C3 aldo-keto reductase family 1 member C3 increases expression EXP Bortezomib results in increased expression of AKR1C3 mRNA CTD PMID:21215737 NCBI chr10:5,048,781...5,107,686
Ensembl chr10:5,035,354...5,107,686 		JBrowse link
G AKR7A2 aldo-keto reductase family 7 member A2 multiple interactions EXP [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of AKR7A2 mRNA CTD PMID:25522274 NCBI chr 1:19,302,708...19,312,146
Ensembl chr 1:19,301,991...19,312,144 		JBrowse link
G AKT1 AKT serine/threonine kinase 1 multiple interactions
decreases expression
decreases activity		 EXP [alvocidib co-treated with Bortezomib] results in decreased expression of AKT1 protein modified form; [Bortezomib co-treated with lapatinib] results in decreased phosphorylation of AKT1 protein; [Bortezomib co-treated with lonafarnib] results in decreased expression of AKT1 protein; [Bortezomib co-treated with lonafarnib] results in decreased expression of AKT1 protein modified form; [Bortezomib co-treated with panobinostat] results in decreased activity of AKT1 protein; [Bortezomib co-treated with sorafenib] results in decreased phosphorylation of AKT1 protein; [Bortezomib results in decreased activity of CBL protein] promotes the reaction [arsenic trioxide results in increased activity of AKT1 protein]; [geldanamycin co-treated with Bortezomib] results in decreased expression of AKT1 protein; [vorinostat co-treated with Bortezomib] results in decreased phosphorylation of and results in decreased expression of AKT1 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP3 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP9 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of PARP1 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein]; AKT1 protein results in decreased susceptibility to [Bortezomib co-treated with sorafenib]; Bortezomib inhibits the reaction [TNFSF10 protein results in increased activity of AKT1 protein]; Okadaic Acid inhibits the reaction [Bortezomib results in decreased expression of AKT1 protein modified form]
Bortezomib results in decreased activity of AKT1 protein		 CTD PMID:15039284 PMID:15781649 PMID:16118318 PMID:16985072 PMID:18445700 More... NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,759 		JBrowse link
G ALAD aminolevulinate dehydratase multiple interactions
decreases activity		 ISO Curcumin inhibits the reaction [Bortezomib results in decreased activity of ALAD protein] CTD PMID:25352650 NCBI chr 9:113,386,312...113,401,284
Ensembl chr 9:113,386,312...113,401,290 		JBrowse link
G ALDH18A1 aldehyde dehydrogenase 18 family member A1 decreases expression EXP Bortezomib results in decreased expression of ALDH18A1 mRNA CTD PMID:20977926 NCBI chr10:95,605,941...95,656,711
Ensembl chr10:95,605,941...95,656,711 		JBrowse link
G ALDH5A1 aldehyde dehydrogenase 5 family member A1 decreases expression EXP Bortezomib results in decreased expression of ALDH5A1 mRNA CTD PMID:20977926 NCBI chr 6:24,494,969...24,537,207
Ensembl chr 6:24,494,867...24,537,207 		JBrowse link
G ALDH6A1 aldehyde dehydrogenase 6 family member A1 decreases expression EXP Bortezomib results in decreased expression of ALDH6A1 mRNA CTD PMID:20977926 NCBI chr14:74,056,847...74,084,453
Ensembl chr14:74,056,847...74,084,492 		JBrowse link
G ALOX12 arachidonate 12-lipoxygenase, 12S type increases response to substance EXP ALOX12 gene SNP results in increased susceptibility to Bortezomib CTD PMID:20864405 NCBI chr17:6,996,049...7,010,754
Ensembl chr17:6,996,049...7,010,754 		JBrowse link
G ANAPC11 anaphase promoting complex subunit 11 decreases expression EXP Bortezomib results in decreased expression of ANAPC11 mRNA CTD PMID:17659339 NCBI chr17:81,890,790...81,900,533
Ensembl chr17:81,890,790...81,900,991 		JBrowse link
G ANAPC5 anaphase promoting complex subunit 5 decreases expression
increases expression		 EXP Bortezomib results in decreased expression of ANAPC5 mRNA
Bortezomib results in increased expression of ANAPC5 mRNA		 CTD PMID:17895889 PMID:20977926 NCBI chr12:121,308,245...121,354,209
Ensembl chr12:121,308,245...121,399,896 		JBrowse link
G ANKRD9 ankyrin repeat domain 9 increases expression EXP Bortezomib results in increased expression of ANKRD9 mRNA CTD PMID:20977926 NCBI chr14:102,501,767...102,509,776
Ensembl chr14:102,501,767...102,509,799 		JBrowse link
G ANO10 anoctamin 10 increases expression EXP Bortezomib results in increased expression of ANO10 mRNA CTD PMID:20977926 NCBI chr 3:43,365,848...43,691,594
Ensembl chr 3:43,354,859...43,691,594 		JBrowse link
G ANXA2P2 annexin A2 pseudogene 2 increases expression EXP Bortezomib results in increased expression of ANXA2P2 mRNA CTD PMID:20977926 NCBI chr 9:33,624,225...33,625,534
Ensembl chr 9:33,624,274...33,625,293 		JBrowse link
G AP1S1 adaptor related protein complex 1 subunit sigma 1 decreases expression EXP Bortezomib results in decreased expression of AP1S1 mRNA CTD PMID:20977926 NCBI chr 7:101,154,476...101,161,276
Ensembl chr 7:101,154,456...101,161,596 		JBrowse link
G AP2A1 adaptor related protein complex 2 subunit alpha 1 decreases expression EXP Bortezomib results in decreased expression of AP2A1 mRNA CTD PMID:20977926 NCBI chr19:49,767,001...49,807,114
Ensembl chr19:49,767,001...49,807,114 		JBrowse link
G APOBEC3G apolipoprotein B mRNA editing enzyme catalytic subunit 3G increases expression EXP Bortezomib results in increased expression of APOBEC3G mRNA CTD PMID:20977926 NCBI chr22:39,077,005...39,087,743
Ensembl chr22:39,077,067...39,087,743 		JBrowse link
G APOBR apolipoprotein B receptor decreases expression EXP Bortezomib results in decreased expression of APOBR mRNA CTD PMID:20977926 NCBI chr16:28,494,643...28,498,964
Ensembl chr16:28,494,643...28,498,964 		JBrowse link
G APOL1 apolipoprotein L1 increases expression EXP Bortezomib results in increased expression of APOL1 mRNA CTD PMID:20977926 NCBI chr22:36,253,133...36,267,525
Ensembl chr22:36,253,071...36,267,530 		JBrowse link
G APOL4 apolipoprotein L4 decreases expression EXP Bortezomib results in decreased expression of APOL4 mRNA CTD PMID:20977926 NCBI chr22:36,189,128...36,204,833
Ensembl chr22:36,189,124...36,204,840 		JBrowse link
G APOOL apolipoprotein O like increases expression EXP Bortezomib results in increased expression of APOOL mRNA CTD PMID:20977926 NCBI chr  X:85,003,877...85,093,315
Ensembl chr  X:85,003,877...85,093,315 		JBrowse link
G AQP3 aquaporin 3 (Gill blood group) increases expression EXP Bortezomib results in increased expression of AQP3 mRNA CTD PMID:20977926 NCBI chr 9:33,441,160...33,447,593
Ensembl chr 9:33,441,156...33,447,596 		JBrowse link
G AR androgen receptor multiple interactions EXP Bortezomib binds to and results in decreased activity of AR protein; Bortezomib inhibits the reaction [Metribolone results in increased activity of AR protein] CTD PMID:25752796 PMID:30818834 NCBI chr  X:67,544,021...67,730,619
Ensembl chr  X:67,544,021...67,730,619 		JBrowse link
G ARF6 ARF GTPase 6 increases expression EXP Bortezomib results in increased expression of ARF6 mRNA CTD PMID:20977926 NCBI chr14:49,893,082...49,897,054
Ensembl chr14:49,893,079...49,897,054 		JBrowse link
G ARFGAP1 ARF GTPase activating protein 1 decreases expression EXP Bortezomib results in decreased expression of ARFGAP1 mRNA CTD PMID:20977926 NCBI chr20:63,272,813...63,289,790
Ensembl chr20:63,272,785...63,289,790 		JBrowse link
G ARHGAP1 Rho GTPase activating protein 1 decreases expression EXP Bortezomib results in decreased expression of ARHGAP1 mRNA CTD PMID:20977926 NCBI chr11:46,677,080...46,700,619
Ensembl chr11:46,677,080...46,700,619 		JBrowse link
G ARHGDIA Rho GDP dissociation inhibitor alpha decreases expression EXP Bortezomib results in decreased expression of ARHGDIA mRNA CTD PMID:20977926 NCBI chr17:81,867,721...81,871,337
Ensembl chr17:81,867,719...81,871,378 		JBrowse link
G ARID3B AT-rich interaction domain 3B multiple interactions EXP [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ARID3B mRNA CTD PMID:25522274 NCBI chr15:74,541,220...74,598,131
Ensembl chr15:74,541,206...74,598,131 		JBrowse link
G ARL4C ARF like GTPase 4C decreases expression EXP Bortezomib results in decreased expression of ARL4C mRNA CTD PMID:20977926 NCBI chr 2:234,493,041...234,497,081
Ensembl chr 2:234,493,041...234,497,081 		JBrowse link
G ARL8A ARF like GTPase 8A increases expression EXP Bortezomib results in increased expression of ARL8A mRNA CTD PMID:20977926 NCBI chr 1:202,133,404...202,144,737
Ensembl chr 1:202,133,404...202,144,743 		JBrowse link
G ARLN allregulin decreases expression EXP Bortezomib results in decreased expression of ARLN mRNA CTD PMID:20977926 NCBI chr 4:119,296,419...119,304,445
Ensembl chr 4:119,296,419...119,304,445 		JBrowse link
G ARRB1 arrestin beta 1 decreases expression EXP Bortezomib results in decreased expression of ARRB1 mRNA CTD PMID:20977926 NCBI chr11:75,260,122...75,351,661
Ensembl chr11:75,260,122...75,351,705 		JBrowse link
G ASAP1 ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 decreases expression EXP Bortezomib results in decreased expression of ASAP1 mRNA CTD PMID:20977926 NCBI chr 8:130,052,104...130,443,674
Ensembl chr 8:130,052,104...130,443,674 		JBrowse link
G ATE1 arginyltransferase 1 increases expression EXP Bortezomib results in increased expression of ATE1 mRNA CTD PMID:20977926 NCBI chr10:121,740,424...121,928,463
Ensembl chr10:121,709,393...121,928,801 		JBrowse link
G ATF2 activating transcription factor 2 multiple interactions
increases phosphorylation
increases expression		 EXP pyrazolanthrone inhibits the reaction [Bortezomib results in increased phosphorylation of ATF2 protein]
Bortezomib results in increased expression of ATF2 mRNA		 CTD PMID:12393500 PMID:20977926 NCBI chr 2:175,072,259...175,168,203
Ensembl chr 2:175,072,250...175,168,382 		JBrowse link
G ATF3 activating transcription factor 3 increases response to substance
increases expression
multiple interactions		 EXP
ISO		 ATF3 results in increased susceptibility to Bortezomib
Bortezomib results in increased expression of ATF3 mRNA; Bortezomib results in increased expression of ATF3 protein
Bortezomib results in increased expression of ATF3; Bortezomib results in increased expression of ATF3 mRNA; Bortezomib results in increased expression of ATF3 protein
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ATF3 mRNA; ATF3 mutant form promotes the reaction [Bortezomib results in increased expression of PMAIP1 mRNA]		 CTD PMID:17898295 PMID:20022965 PMID:20830808 PMID:21762082 PMID:25522274 NCBI chr 1:212,565,407...212,620,777
Ensembl chr 1:212,565,334...212,620,777 		JBrowse link
G ATF4 activating transcription factor 4 multiple interactions
increases expression
decreases response to substance		 EXP
ISO		 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Bortezomib results in increased expression of ATF4 protein]; ATF4 mutant form inhibits the reaction [Bortezomib results in increased expression of PMAIP1 mRNA]; ATF4 mutant form inhibits the reaction [Bortezomib results in increased expression of PMAIP1 protein]; Bortezomib promotes the reaction [ATF4 protein binds to PMAIP1 promoter]; Dactinomycin inhibits the reaction [Bortezomib results in increased expression of ATF4 mRNA]; Dactinomycin inhibits the reaction [Bortezomib results in increased expression of ATF4 protein]; NUPR1 mutant form promotes the reaction [Bortezomib results in increased expression of ATF4 mRNA]
Bortezomib results in increased expression of ATF4 mRNA; Bortezomib results in increased expression of ATF4 protein
ATF4 results in decreased susceptibility to Bortezomib		 CTD PMID:15509775 PMID:16928686 PMID:20022965 NCBI chr22:39,520,559...39,522,686
Ensembl chr22:39,519,695...39,522,686 		JBrowse link
G ATF5 activating transcription factor 5 increases expression EXP Bortezomib results in increased expression of ATF5 mRNA CTD PMID:17898295 NCBI chr19:49,928,906...49,933,935
Ensembl chr19:49,928,702...49,933,935 		JBrowse link
G ATG5 autophagy related 5 multiple interactions ISO ATG5 gene mutant form inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; ATG5 gene mutant form inhibits the reaction [HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]] CTD PMID:22842577 NCBI chr 6:106,184,476...106,325,760
Ensembl chr 6:106,045,423...106,325,791 		JBrowse link
G ATM ATM serine/threonine kinase multiple interactions
increases cleavage		 EXP [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of ATM protein]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of ATM protein] CTD PMID:12393500 NCBI chr11:108,223,067...108,369,102
Ensembl chr11:108,222,804...108,369,102 		JBrowse link
G ATP1A3 ATPase Na+/K+ transporting subunit alpha 3 decreases expression EXP Bortezomib results in decreased expression of ATP1A3 mRNA CTD PMID:20977926 NCBI chr19:41,966,582...41,994,230
Ensembl chr19:41,966,582...41,997,497 		JBrowse link
G ATP2A1 ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 1 multiple interactions
affects response to substance		 EXP ATP2A1 protein affects the reaction [Bortezomib results in decreased expression of ABCB1]
ATP2A1 protein affects the susceptibility to Bortezomib		 CTD PMID:25576094 NCBI chr16:28,878,488...28,904,466
Ensembl chr16:28,878,405...28,904,466 		JBrowse link
G ATP6V0E1 ATPase H+ transporting V0 subunit e1 increases expression EXP Bortezomib results in increased expression of ATP6V0E1 mRNA CTD PMID:20977926 NCBI chr 5:172,983,771...173,035,445
Ensembl chr 5:172,983,771...173,035,445 		JBrowse link
G B2M beta-2-microglobulin decreases expression EXP Bortezomib results in decreased expression of B2M protein CTD PMID:17204182 NCBI chr15:44,711,517...44,718,145
Ensembl chr15:44,711,358...44,718,851 		JBrowse link
G B3GNT2 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 decreases expression EXP Bortezomib results in decreased expression of B3GNT2 mRNA CTD PMID:20977926 NCBI chr 2:62,196,115...62,224,731
Ensembl chr 2:62,196,115...62,224,731 		JBrowse link
G B4GALT6 beta-1,4-galactosyltransferase 6 increases expression EXP Bortezomib results in increased expression of B4GALT6 mRNA CTD PMID:20977926 NCBI chr18:31,622,246...31,724,641
Ensembl chr18:31,622,246...31,685,836 		JBrowse link
G BAG3 BAG cochaperone 3 increases expression EXP Bortezomib results in increased expression of BAG3 mRNA CTD PMID:15509775 PMID:17659339 PMID:20471514 NCBI chr10:119,651,380...119,677,819
Ensembl chr10:119,651,380...119,677,819 		JBrowse link
G BAK1 BCL2 antagonist/killer 1 multiple interactions
increases expression		 EXP
ISO		 [nutlin 3 co-treated with Bortezomib] results in increased activity of BAK1 protein; BAK1 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]
BAK1 protein results in increased susceptibility to [Bortezomib co-treated with TNFSF10 protein]
Bortezomib results in increased expression of BAK1 protein		 CTD PMID:12902978 PMID:17326159 PMID:20850924 NCBI chr 6:33,572,552...33,580,276
Ensembl chr 6:33,572,547...33,580,293 		JBrowse link
G BARD1 BRCA1 associated RING domain 1 increases response to substance EXP BARD1 mutant form results in increased susceptibility to Bortezomib CTD PMID:25522274 NCBI chr 2:214,725,646...214,809,683
Ensembl chr 2:214,725,646...214,809,683 		JBrowse link
G BAX BCL2 associated X, apoptosis regulator multiple interactions
increases expression		 EXP [Bortezomib co-treated with arsenic trioxide] affects the expression of BAX protein; [nutlin 3 co-treated with Bortezomib] results in increased activity of BAX protein; BAX results in increased susceptibility to [Bortezomib co-treated with panobinostat]; Bortezomib inhibits the reaction [BAX mutant form inhibits the reaction [TNFSF10 protein results in increased localization of DIABLO protein]]
Bortezomib results in increased expression of BAX protein		 CTD PMID:12902978 PMID:18445700 PMID:18718063 PMID:20383943 PMID:20850924 NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798 		JBrowse link
G BBC3 BCL2 binding component 3 increases expression EXP Bortezomib results in increased expression of BBC3 mRNA; Bortezomib results in increased expression of BBC3 protein CTD PMID:17898295 PMID:20051518 NCBI chr19:47,220,824...47,232,860
Ensembl chr19:47,220,822...47,232,766 		JBrowse link
G BBLN bublin coiled coil protein decreases expression EXP Bortezomib results in decreased expression of BBLN mRNA CTD PMID:20977926 NCBI chr 9:128,160,265...128,163,924
Ensembl chr 9:128,160,265...128,163,924 		JBrowse link
G BCL2 BCL2 apoptosis regulator multiple interactions
increases expression
increases cleavage
decreases expression		 EXP [Arsenic Trioxide co-treated with Bortezomib] results in decreased expression of BCL2 mRNA; [Bortezomib co-treated with Arsenic Trioxide] affects the expression of BCL2 protein; [Bortezomib co-treated with Arsenic Trioxide] results in decreased expression of BCL2 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of BCL2 protein; [Bortezomib co-treated with Daunorubicin] results in decreased expression of BCL2 mRNA; [Bortezomib co-treated with Vorinostat] results in increased cleavage of BCL2 protein; [geldanamycin co-treated with Bortezomib] results in decreased expression of BCL2 protein; [Vorinostat co-treated with Bortezomib] results in decreased expression of BCL2 protein; BCL2 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; lonafarnib promotes the reaction [Bortezomib results in increased cleavage of BCL2 protein modified form]
Bortezomib results in increased expression of BCL2 mRNA; Bortezomib results in increased expression of BCL2 protein
Bortezomib results in decreased expression of BCL2 mRNA; Bortezomib results in decreased expression of BCL2 protein		 CTD PMID:15173093 PMID:15781649 PMID:16022909 PMID:16118318 PMID:16446371 More... NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128 		JBrowse link
G BCL2A1 BCL2 related protein A1 multiple interactions
increases expression		 EXP [romidepsin co-treated with Bortezomib] results in decreased expression of BCL2A1 protein
Bortezomib results in increased expression of BCL2A1A protein		 CTD PMID:18223231 PMID:20051518 NCBI chr15:79,960,892...79,971,196
Ensembl chr15:79,960,892...79,971,196 		JBrowse link
G BCL2L1 BCL2 like 1 multiple interactions
decreases expression
increases expression
increases cleavage
decreases response to substance		 EXP [alvocidib co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [geldanamycin co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [romidepsin co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [Vorinostat co-treated with Bortezomib] results in decreased expression of BCL2L1 protein alternative form; [Vorinostat co-treated with Bortezomib] results in increased expression of BCL2L1 mRNA alternative form; [Vorinostat co-treated with Bortezomib] results in increased expression of BCL2L1 protein alternative form; BCL2L1 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; BCL2L1 protein results in decreased susceptibility to [Bortezomib co-treated with trichostatin A]; Bortezomib promotes the reaction [capillarisin results in decreased expression of BCL2L1 protein]; lonafarnib promotes the reaction [Bortezomib results in increased cleavage of BCL2L1 protein]; SCIO-469 promotes the reaction [Bortezomib results in decreased expression of BCL2L1 protein]; trichostatin A promotes the reaction [Bortezomib results in decreased expression of BCL2L1 mRNA]; trichostatin A promotes the reaction [Bortezomib results in decreased expression of BCL2L1 protein]
Bortezomib results in decreased expression of BCL2L1 mRNA; Bortezomib results in decreased expression of BCL2L1 protein
Bortezomib results in increased expression of BCL2L1 protein
BCL2L1 protein results in decreased susceptibility to Bortezomib		 CTD PMID:15039284 PMID:15543232 PMID:15781649 PMID:16118318 PMID:16446371 More... NCBI chr20:31,664,452...31,723,963
Ensembl chr20:31,664,452...31,723,989 		JBrowse link
G BCL2L11 BCL2 like 11 multiple interactions
increases expression
increases activity
increases response to substance		 EXP [Bortezomib co-treated with romidepsin] results in increased expression of BCL2L11 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with romidepsin] results in increased expression of BCL2L11 protein]; Bortezomib inhibits the reaction [Arsenic Trioxide results in increased degradation of BCL2L11 protein]
Bortezomib results in increased expression of BCL2L11 protein
Bortezomib results in increased activity of BCL2L11 protein
BCL2L11 results in increased susceptibility to Bortezomib		 CTD PMID:15173094 PMID:16024631 PMID:16446371 PMID:17326159 PMID:18566236 More... NCBI chr 2:111,120,914...111,168,445
Ensembl chr 2:111,119,378...111,168,444 		JBrowse link
G BCL2L2 BCL2 like 2 increases expression EXP Bortezomib results in increased expression of BCL2L2 mRNA CTD PMID:18928586 NCBI chr14:23,306,833...23,311,751
Ensembl chr14:23,298,790...23,311,751 		JBrowse link
G BCL3 BCL3 transcription coactivator multiple interactions
decreases expression		 EXP [arsenic trioxide co-treated with Bortezomib] results in decreased expression of BCL3 mRNA
Bortezomib results in decreased expression of BCL3 mRNA		 CTD PMID:20471514 PMID:20977926 NCBI chr19:44,747,705...44,760,044
Ensembl chr19:44,747,705...44,760,044 		JBrowse link
G BCL6 BCL6 transcription repressor increases expression EXP Bortezomib results in increased expression of BCL6 mRNA CTD PMID:20977926 NCBI chr 3:187,721,377...187,745,468
Ensembl chr 3:187,721,377...187,745,725 		JBrowse link
G BCL7A BAF chromatin remodeling complex subunit BCL7A decreases expression EXP Bortezomib results in decreased expression of BCL7A mRNA CTD PMID:20977926 NCBI chr12:122,021,884...122,062,044
Ensembl chr12:122,019,422...122,062,044 		JBrowse link
G BCR BCR activator of RhoGEF and GTPase decreases expression EXP Bortezomib results in decreased expression of BCR mRNA CTD PMID:20977926 NCBI chr22:23,180,509...23,318,037
Ensembl chr22:23,179,704...23,318,037 		JBrowse link
G BECN1 beclin 1 multiple interactions
decreases response to substance		 EXP BECN1 mutant form promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]
BECN1 protein results in decreased susceptibility to Bortezomib		 CTD PMID:22842577 NCBI chr17:42,810,132...42,824,282
Ensembl chr17:42,810,134...42,833,350 		JBrowse link
G BID BH3 interacting domain death agonist multiple interactions
increases cleavage		 EXP [Bortezomib co-treated with Butyrates] results in decreased expression of BID protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of BID protein; [Bortezomib co-treated with vorinostat] results in decreased expression of BID protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of BID protein; [TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of BID protein; [vorinostat co-treated with Bortezomib] results in increased cleavage of BID protein; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of BID protein]
Bortezomib results in increased cleavage of BID protein		 CTD PMID:12893773 PMID:12902978 PMID:15930312 PMID:17326159 PMID:17351739 More... NCBI chr22:17,734,138...17,774,665
Ensembl chr22:17,734,138...17,774,770 		JBrowse link
G BIK BCL2 interacting killer increases response to substance
increases expression
increases activity		 EXP BIK results in increased susceptibility to Bortezomib
Bortezomib results in increased expression of BIK protein
Bortezomib results in increased activity of BIK protein		 CTD PMID:16446371 PMID:18566236 NCBI chr22:43,110,750...43,129,712
Ensembl chr22:43,110,750...43,129,712 		JBrowse link
G BIN1 bridging integrator 1 increases expression EXP Bortezomib results in increased expression of BIN1 mRNA CTD PMID:17659339 NCBI chr 2:127,048,023...127,107,154
Ensembl chr 2:127,048,027...127,107,288 		JBrowse link
G BIRC2 baculoviral IAP repeat containing 2 decreases expression
multiple interactions		 EXP Bortezomib results in decreased expression of BIRC2 protein
[geldanamycin co-treated with Bortezomib] results in decreased expression of BIRC2 protein; [romidepsin co-treated with Bortezomib] results in decreased expression of BIRC2 protein		 CTD PMID:15543232 PMID:15781649 PMID:17626072 PMID:18223231 NCBI chr11:102,347,214...102,378,670
Ensembl chr11:102,347,211...102,378,670 		JBrowse link
G BIRC3 baculoviral IAP repeat containing 3 decreases expression
increases expression
multiple interactions		 EXP Bortezomib results in decreased expression of BIRC3 protein
Bortezomib results in increased expression of BIRC3 mRNA; Bortezomib results in increased expression of BIRC3 protein
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of BIRC3 mRNA		 CTD PMID:17626072 PMID:24085292 PMID:25522274 NCBI chr11:102,317,484...102,339,403
Ensembl chr11:102,317,484...102,339,403 		JBrowse link
G BIRC5 baculoviral IAP repeat containing 5 decreases expression
multiple interactions
increases expression		 EXP Bortezomib results in decreased expression of BIRC5 mRNA; Bortezomib results in decreased expression of BIRC5 protein
[Irinotecan co-treated with Bortezomib] results in decreased expression of BIRC5 protein; [romidepsin co-treated with Bortezomib] results in increased cleavage of BIRC5 protein; Bortezomib promotes the reaction [capillarisin results in decreased expression of BIRC5 protein]
Bortezomib results in increased expression of BIRC5 protein		 CTD PMID:16373703 PMID:17510429 PMID:17898295 PMID:18223231 PMID:18850583 More... NCBI chr17:78,214,253...78,225,635
Ensembl chr17:78,214,186...78,225,636 		JBrowse link
G BIRC7 baculoviral IAP repeat containing 7 multiple interactions
decreases expression		 EXP arsenic trioxide promotes the reaction [Bortezomib results in decreased expression of BIRC7 mRNA] CTD PMID:21867610 NCBI chr20:63,235,905...63,240,495
Ensembl chr20:63,235,883...63,240,495 		JBrowse link
G BLK BLK proto-oncogene, Src family tyrosine kinase decreases expression EXP Bortezomib results in decreased expression of BLK mRNA CTD PMID:20977926 NCBI chr 8:11,494,387...11,564,599
Ensembl chr 8:11,486,894...11,564,599 		JBrowse link
G BLVRB biliverdin reductase B increases expression EXP Bortezomib results in increased expression of BLVRB mRNA CTD PMID:20977926 NCBI chr19:40,447,768...40,465,745
Ensembl chr19:40,447,765...40,465,764 		JBrowse link
G BNIP3 BCL2 interacting protein 3 increases expression EXP Bortezomib results in increased expression of BNIP3 protein CTD PMID:20110775 NCBI chr10:131,967,684...131,981,923
Ensembl chr10:131,967,684...131,981,967 		JBrowse link
G BRCA1 BRCA1 DNA repair associated decreases expression
multiple interactions
increases response to substance
decreases ubiquitination		 EXP
ISO		 Bortezomib results in decreased expression of BRCA1 mRNA
BRCA1 protein inhibits the reaction [BRCA1 gene mutant form results in increased susceptibility to Bortezomib]
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of AKR7A2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNF mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNG2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CRYGEP mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DAPK2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DLGAP5 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of EGLN3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of FZD2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of H3C6 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of LGR4 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of RPS7P5 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of THRA mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of TNFAIP8L1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of TNKS mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased activity of E2F1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ARID3B mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ATF3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of BIRC3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CCNB1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CRYAB mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CTH mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of DUSP5 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ERN1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of FGF21 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GADD45A mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GDF15 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of HECW1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of HIKESHI mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of IL7R mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of KRTAP21-1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of MIR568 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of PAWR mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of PCYT1A mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of RND3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TNFAIP3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TNFRSF9 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TRIB3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TRIML2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ZNF613 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased phosphorylation of RB1 protein; TP53BP1 protein affects the reaction [[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein]; TP53BP1 protein affects the reaction [[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased phosphorylation of RB1 protein]
Bortezomib results in decreased ubiquitination of BRCA1 protein		 CTD PMID:21917757 PMID:25522274 NCBI chr17:43,044,295...43,170,327
Ensembl chr17:43,044,295...43,170,245 		JBrowse link
G BRCA2 BRCA2 DNA repair associated decreases expression
multiple interactions		 EXP Bortezomib results in decreased expression of BRCA2 mRNA
[arsenic trioxide co-treated with Bortezomib] results in increased expression of BRCA2 mRNA		 CTD PMID:21917757 PMID:25913414 NCBI chr13:32,315,077...32,400,268
Ensembl chr13:32,315,086...32,400,268 		JBrowse link
G BRCC3 BRCA1/BRCA2-containing complex subunit 3 decreases expression EXP Bortezomib results in decreased expression of BRCC3 mRNA CTD PMID:20977926 NCBI chr  X:155,071,508...155,123,077
Ensembl chr  X:155,071,420...155,123,077 		JBrowse link
G BRF2 BRF2 general transcription factor IIIB subunit increases expression EXP Bortezomib results in increased expression of BRF2 mRNA CTD PMID:20977926 NCBI chr 8:37,843,268...37,849,861
Ensembl chr 8:37,843,268...37,849,861 		JBrowse link
G BSDC1 BSD domain containing 1 increases expression EXP Bortezomib results in increased expression of BSDC1 mRNA CTD PMID:20977926 NCBI chr 1:32,364,633...32,394,441
Ensembl chr 1:32,364,633...32,394,731 		JBrowse link
G C11orf68 chromosome 11 open reading frame 68 decreases expression EXP Bortezomib results in decreased expression of C11ORF68 mRNA CTD PMID:20977926 NCBI chr11:65,916,810...65,919,062
Ensembl chr11:65,916,810...65,919,062 		JBrowse link
G C14orf132 chromosome 14 open reading frame 132 decreases expression EXP Bortezomib results in decreased expression of C14ORF132 mRNA CTD PMID:20977926 NCBI chr14:96,039,362...96,093,971
Ensembl chr14:96,039,362...96,093,971 		JBrowse link
G C1orf43 chromosome 1 open reading frame 43 decreases expression EXP Bortezomib results in decreased expression of C1ORF43 mRNA CTD PMID:20977926 NCBI chr 1:154,206,720...154,220,590
Ensembl chr 1:154,206,696...154,220,637 		JBrowse link
G C6orf62 chromosome 6 open reading frame 62 increases expression EXP Bortezomib results in increased expression of C6ORF62 mRNA CTD PMID:20977926 NCBI chr 6:24,704,861...24,720,836
Ensembl chr 6:24,704,861...24,720,825 		JBrowse link
G C9orf85 chromosome 9 open reading frame 85 increases expression EXP Bortezomib results in increased expression of C9ORF85 mRNA CTD PMID:20977926 NCBI chr 9:71,911,639...71,986,058
Ensembl chr 9:71,911,510...71,986,054 		JBrowse link
G CA9 carbonic anhydrase 9 decreases expression EXP Bortezomib results in decreased expression of CA9 protein CTD PMID:16061869 NCBI chr 9:35,673,928...35,681,159
Ensembl chr 9:35,673,928...35,681,159 		JBrowse link
G CAAP1 caspase activity and apoptosis inhibitor 1 increases expression EXP Bortezomib results in increased expression of CAAP1 mRNA CTD PMID:20977926 NCBI chr 9:26,840,685...26,892,802
Ensembl chr 9:26,840,685...26,892,803 		JBrowse link
G CACNA1H calcium voltage-gated channel subunit alpha1 H decreases degradation ISO Bortezomib results in decreased degradation of CACNA1H protein CTD PMID:30552955 NCBI chr16:1,153,106...1,221,768
Ensembl chr16:1,153,103...1,224,169 		JBrowse link
G CALR calreticulin increases expression
multiple interactions		 EXP
ISO		 Bortezomib results in increased expression of CALR mRNA
[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]]
[CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CALR mRNA]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; [Chloroquine co-treated with Bortezomib] promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; [Chloroquine co-treated with Bortezomib] results in increased expression of and affects the localization of CALR protein; [Chloroquine co-treated with Bortezomib] results in increased expression of CALR mRNA; Bortezomib promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; Bortezomib results in increased expression of and affects the localization of CALR protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR mRNA]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] affects the localization of CALR protein]; DDIT3 protein affects the reaction [Bortezomib affects the localization of CALR protein]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] affects the localization of CALR protein]; Doxorubicin promotes the reaction [Bortezomib affects the localization of CALR protein]		 CTD PMID:30482226 NCBI chr19:12,938,609...12,944,489
Ensembl chr19:12,938,578...12,944,489 		JBrowse link
G CAPN15 calpain 15 decreases expression EXP Bortezomib results in decreased expression of CAPN15 mRNA CTD PMID:20977926 NCBI chr16:527,712...554,636
Ensembl chr16:527,712...554,636 		JBrowse link
G CARD9 caspase recruitment domain family member 9 multiple interactions EXP [arsenic trioxide co-treated with Bortezomib] results in increased expression of CARD9 mRNA CTD PMID:20471514 NCBI chr 9:136,363,956...136,373,669
Ensembl chr 9:136,363,956...136,373,681 		JBrowse link
G CASP12 caspase 12 (gene/pseudogene) increases cleavage ISO Bortezomib results in increased cleavage of CASP12 protein CTD PMID:15509775 PMID:16357177 NCBI chr11:104,883,286...104,898,460
Ensembl chr11:104,885,718...104,898,670 		JBrowse link
G CASP2 caspase 2 multiple interactions
increases response to substance
increases cleavage		 EXP benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP2 protein]; Bortezomib promotes the reaction [Brefeldin A results in increased cleavage of and results in increased activity of CASP2 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP2 protein; Brefeldin A promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP2 protein]; CASP2 protein affects the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]
CASP2 results in increased susceptibility to Bortezomib
Bortezomib results in increased cleavage of CASP2 protein		 CTD PMID:15509775 PMID:16446371 PMID:18723477 NCBI chr 7:143,288,351...143,307,696
Ensembl chr 7:143,288,215...143,307,696 		JBrowse link
G CASP3 caspase 3 increases activity
increases cleavage
multiple interactions
increases expression		 EXP
ISO		 Bortezomib results in increased activity of CASP3 protein
Bortezomib results in increased cleavage of CASP3 protein
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein]; [Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein; [Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [SCIO-469 co-treated with Bortezomib] results in increased activity of CASP3 protein; ATG5 gene mutant form inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; ATG5 gene mutant form inhibits the reaction [HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]]; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Betulinic Acid inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]]; HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt affects the reaction [Bortezomib results in increased cleavage of CASP3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein]; [Arsenic Trioxide co-treated with Bortezomib] results in increased activity of CASP3 protein; [Arsenic Trioxide co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in increased activity of CASP3 protein; [Bortezomib co-treated with abexinostat] results in increased activity of CASP3 protein; [Bortezomib co-treated with Arsenic Trioxide] affects the expression of CASP3 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased activity of CASP3 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased expression of CASP3 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with Doxorubicin] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with N,N-dimethylsphingosine] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib co-treated with oblimersen co-treated with Cyclophosphamide] results in increased activity of CASP3 protein; [Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib co-treated with Vorinostat] results in increased activity of CASP3 protein; [Bortezomib co-treated with Vorinostat] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP3 protein; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of ATM protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of MDM2 protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of PRKDC protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased phosphorylation of TP53 protein]; [Cisplatin co-treated with Bortezomib] results in increased activity of CASP3 protein; [Dexamethasone co-treated with Bortezomib] results in increased activity of CASP3 protein; [gambogic acid co-treated with Bortezomib] results in increased activity of CASP3 protein; [lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [nutlin 3 co-treated with Bortezomib] results in increased activity of CASP3 protein; [TNFSF10 protein co-treated with Bortezomib] results in increased activity of CASP3 protein; [trichostatin A co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [Vorinostat co-treated with Bortezomib] results in increased activity of CASP3 protein; [Vorinostat co-treated with Bortezomib] results in increased cleavage of CASP3 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP3 protein]; BECN1 mutant form promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[gambogic acid co-treated with Bortezomib] results in increased activity of CASP3 protein]; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Betulinic Acid inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [belinostat results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [Butyrates results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [capillarisin results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [gallium nitrate results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [NSC606985 results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [romidepsin results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [Thapsigargin results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [Tunicamycin results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [Vorinostat results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP3 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; DDIT3 protein affects the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; MAPK14 mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; PMAIP1 protein promotes the reaction [[Bortezomib co-treated with Arsenic Trioxide] results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; ricolinostat promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; STK4 mutant form inhibits the reaction [Bortezomib results in increased activity of CASP3 protein]; TNFRSF10B mutant form inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein]; TNFRSF10B mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased activity of CASP3 protein]; ZFAND2A protein inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]
Bortezomib results in increased expression of CASP3 protein		 CTD PMID:12393500 PMID:12893773 PMID:15070698 PMID:15173093 PMID:15509775 More... NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062 		JBrowse link
G CASP4 caspase 4 multiple interactions
increases response to substance
increases cleavage
increases activity		 EXP [Bortezomib co-treated with vorinostat] results in increased activity of CASP4 protein; CASP4 protein results in increased susceptibility to [Cisplatin co-treated with Bortezomib]; PMAIP1 protein promotes the reaction [[Bortezomib co-treated with vorinostat] results in increased activity of CASP4 protein]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased cleavage of CASP4 protein]
CASP4 protein results in increased susceptibility to Bortezomib
Bortezomib results in increased activity of CASP4 protein		 CTD PMID:16357177 PMID:18641367 NCBI chr11:104,942,866...104,968,574
Ensembl chr11:104,942,866...104,969,366 		JBrowse link
G CASP6 caspase 6 multiple interactions
increases cleavage		 EXP Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of CASP6 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP6 protein] CTD PMID:16617327 PMID:17510429 NCBI chr 4:109,664,388...109,709,767
Ensembl chr 4:109,688,622...109,703,583 		JBrowse link
G CASP7 caspase 7 multiple interactions
increases cleavage
increases activity		 EXP [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP7 protein; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP7 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP7 protein; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP7 protein]; ZFAND2A protein affects the reaction [Bortezomib results in increased cleavage of CASP7 protein]
Bortezomib results in increased activity of CASP7 protein		 CTD PMID:16024631 PMID:16617327 PMID:16904634 PMID:18342500 PMID:18534018 More... NCBI chr10:113,679,194...113,730,909
Ensembl chr10:113,679,162...113,730,907 		JBrowse link
G CASP8 caspase 8 multiple interactions
increases cleavage		 EXP [Arsenic Trioxide co-treated with Bortezomib] results in decreased expression of CASP8 mRNA; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in increased activity of CASP8 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased expression of CASP8 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of and results in increased activity of CASP8 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP8 protein; [Bortezomib co-treated with Vorinostat] results in increased activity of CASP8 protein; [Bortezomib co-treated with Vorinostat] results in increased cleavage of and results in increased activity of CASP8 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP8 protein; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of ATM protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of MDM2 protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of PRKDC protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased phosphorylation of TP53 protein]; [gambogic acid co-treated with Bortezomib] results in increased activity of CASP8 protein; [IFNA2 protein co-treated with Bortezomib] results in increased activity of CASP8 protein; [lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP8 protein; [TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of CASP8 protein; [trichostatin A co-treated with Bortezomib] results in increased cleavage of CASP8 protein; [Vorinostat co-treated with Bortezomib] results in increased cleavage of CASP8 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [abexinostat results in increased cleavage of CASP8 protein]; Bortezomib promotes the reaction [Arsenic Trioxide results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [Butyrates results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of CASP8 protein]; Bortezomib promotes the reaction [Vorinostat results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP8 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP8 protein; CDKN1A protein affects the reaction [[TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of CASP8 protein]; ricolinostat promotes the reaction [Bortezomib results in increased cleavage of CASP8 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP8 protein]; TNFRSF10B mutant form inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein]; TNFRSF10B mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP8 protein]; ZFAND2A protein affects the reaction [Bortezomib results in increased cleavage of CASP8 protein] CTD PMID:12393500 PMID:12893773 PMID:12902978 PMID:15070698 PMID:15173093 More... NCBI chr 2:201,233,463...201,287,711
Ensembl chr 2:201,233,443...201,361,836 		JBrowse link
G CASP9 caspase 9 multiple interactions
increases expression
increases response to substance
increases cleavage		 EXP 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt affects the reaction [Bortezomib results in increased cleavage of CASP9 protein]; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in increased activity of CASP9 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased activity of CASP9 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased expression of CASP9 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of and results in increased activity of CASP9 protein; [Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP9 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP9 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP9 protein; [Bortezomib co-treated with Vorinostat] results in increased activity of CASP9 protein; [Bortezomib co-treated with Vorinostat] results in increased cleavage of and results in increased activity of CASP9 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP9 protein; [gambogic acid co-treated with Bortezomib] results in increased activity of CASP9 protein; [lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP9 protein; [nutlin 3 co-treated with Bortezomib] results in increased activity of CASP9 protein; [ricolinostat co-treated with Bortezomib] results in increased cleavage of CASP9 protein; [trichostatin A co-treated with Bortezomib] results in increased cleavage of CASP9 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP9 protein]; benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]; benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[gambogic acid co-treated with Bortezomib] results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [abexinostat results in increased cleavage of CASP9 protein]; Bortezomib promotes the reaction [Arsenic Trioxide results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [belinostat results in increased cleavage of CASP9 protein]; Bortezomib promotes the reaction [Butyrates results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [romidepsin results in increased cleavage of CASP9 protein]; Bortezomib promotes the reaction [Vorinostat results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP9 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein; CASP2 protein affects the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP9 protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased cleavage of CASP9 protein]; ZFAND2A protein affects the reaction [Bortezomib results in increased cleavage of CASP9 protein]
Bortezomib results in increased expression of CASP9 protein
CASP9 gene SNP results in increased susceptibility to Bortezomib; CASP9 results in increased susceptibility to Bortezomib		 CTD PMID:12893773 PMID:15070698 PMID:15173093 PMID:15509775 PMID:16024631 More... NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534 		JBrowse link
G CAT catalase multiple interactions
decreases expression		 ISO Berberine inhibits the reaction [Bortezomib results in decreased expression of CAT protein] CTD PMID:35121005 NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060 		JBrowse link
G CBL Cbl proto-oncogene multiple interactions EXP [Bortezomib results in decreased activity of CBL protein] promotes the reaction [arsenic trioxide results in increased activity of AKT1 protein] CTD PMID:19457607 NCBI chr11:119,206,339...119,308,149
Ensembl chr11:119,206,298...119,313,926 		JBrowse link
G CBR3 carbonyl reductase 3 increases expression EXP [Bortezomib results in increased expression of NFE2L2 protein] which results in increased expression of CBR3 mRNA; Bortezomib results in increased expression of CBR3 mRNA CTD PMID:20806931 PMID:20977926 NCBI chr21:36,135,079...36,146,562
Ensembl chr21:36,135,079...36,146,562 		JBrowse link
G CBX3 chromobox 3 increases expression EXP Bortezomib results in increased expression of CBX3 mRNA CTD PMID:20977926 NCBI chr 7:26,201,443...26,213,607
Ensembl chr 7:26,201,162...26,213,607 		JBrowse link
G CCAR1 cell division cycle and apoptosis regulator 1 increases expression EXP Bortezomib results in increased expression of CCAR1 protein CTD PMID:21594647 PMID:21903591 NCBI chr10:68,721,239...68,792,377
Ensembl chr10:68,721,012...68,792,377 		JBrowse link
G CCDC186 coiled-coil domain containing 186 increases expression EXP Bortezomib results in increased expression of CCDC186 mRNA CTD PMID:20977926 NCBI chr10:114,120,862...114,174,220
Ensembl chr10:114,120,862...114,174,232 		JBrowse link
G CCDC32 coiled-coil domain containing 32 increases expression EXP Bortezomib results in increased expression of CCDC32 mRNA CTD PMID:20977926 NCBI chr15:40,520,993...40,565,042
Ensembl chr15:40,528,683...40,565,054 		JBrowse link
G CCDC6 coiled-coil domain containing 6 decreases expression EXP Bortezomib results in decreased expression of CCDC6 mRNA CTD PMID:20977926 NCBI chr10:59,788,747...59,906,556
Ensembl chr10:59,788,747...59,906,556 		JBrowse link
G CCDC82 coiled-coil domain containing 82 increases expression EXP Bortezomib results in increased expression of CCDC82 mRNA CTD PMID:20977926 NCBI chr11:96,352,773...96,389,912
Ensembl chr11:96,349,241...96,389,956 		JBrowse link
G CCL2 C-C motif chemokine ligand 2 decreases expression EXP Bortezomib results in decreased expression of CCL2 mRNA CTD PMID:20471514 NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,274...34,257,208 		JBrowse link
G CCL3 C-C motif chemokine ligand 3 increases expression
decreases expression		 ISO
EXP		 Bortezomib results in increased expression of CCL3 mRNA; Bortezomib results in increased expression of CCL3 protein
Bortezomib results in decreased expression of CCL3 mRNA		 CTD PMID:18089816 PMID:20830808 NCBI chr17:36,088,256...36,090,143
Ensembl chr17:36,088,256...36,090,169 		JBrowse link
G CCL8 C-C motif chemokine ligand 8 affects expression EXP Bortezomib affects the expression of CCL8 protein CTD PMID:19922463 NCBI chr17:34,319,435...34,321,402
Ensembl chr17:34,319,435...34,321,402 		JBrowse link
G CCNB1 cyclin B1 multiple interactions
increases expression		 EXP [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CCNB1 protein; Bortezomib results in increased ubiquitination of and results in increased expression of CCNB1 protein
Bortezomib results in increased expression of CCNB1 protein		 CTD PMID:19074855 PMID:20367638 PMID:25522274 NCBI chr 5:69,167,150...69,178,245
Ensembl chr 5:69,167,135...69,178,245 		JBrowse link
G CCND1 cyclin D1 multiple interactions EXP [[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of CCND1 protein; [[Bortezomib co-treated with Vorinostat] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of CCND1 protein; [Bortezomib co-treated with Butyrates] results in decreased expression of CCND1 protein; [Bortezomib co-treated with Vorinostat] results in decreased expression of CCND1 protein; [geldanamycin co-treated with Bortezomib] results in decreased expression of CCND1 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of CCND1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of CCND1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Vorinostat] results in decreased expression of CCND1 protein]; Bortezomib promotes the reaction [capillarisin results in decreased expression of CCND1 protein] CTD PMID:12893773 PMID:15173093 PMID:15781649 PMID:24333736 NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474 		JBrowse link
G CCND2 cyclin D2 decreases expression EXP Bortezomib results in decreased expression of CCND2 mRNA CTD PMID:20977926 NCBI chr12:4,273,762...4,305,353
Ensembl chr12:4,269,771...4,305,353 		JBrowse link
G CCNF cyclin F multiple interactions EXP [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNF mRNA CTD PMID:25522274 NCBI chr16:2,429,447...2,458,854
Ensembl chr16:2,429,394...2,458,854 		JBrowse link
G CCNG2 cyclin G2 multiple interactions EXP [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNG2 mRNA CTD PMID:25522274 NCBI chr 4:77,157,207...77,170,060
Ensembl chr 4:77,157,207...77,433,388 		JBrowse link
G CCPG1 cell cycle progression 1 increases expression EXP Bortezomib results in increased expression of CCPG1 mRNA CTD PMID:20471514 PMID:20977926 NCBI chr15:55,355,239...55,408,359
Ensembl chr15:55,340,032...55,408,510 		JBrowse link
G CD27 CD27 molecule increases expression EXP Bortezomib results in increased expression of CD27 mRNA CTD PMID:17895889 NCBI chr12:6,443,892...6,451,713
Ensembl chr12:6,444,955...6,451,718 		JBrowse link
G CD38 CD38 molecule decreases expression EXP Bortezomib results in decreased expression of CD38 mRNA CTD PMID:20977926 NCBI chr 4:15,778,328...15,853,232
Ensembl chr 4:15,778,275...15,853,232 		JBrowse link
G CD5 CD5 molecule decreases expression EXP Bortezomib results in decreased expression of CD5 mRNA CTD PMID:20977926 NCBI chr11:61,093,963...61,127,852
Ensembl chr11:61,102,489...61,127,852 		JBrowse link
G CD69 CD69 molecule increases expression EXP Bortezomib results in increased expression of CD69 mRNA CTD PMID:20977926 NCBI chr12:9,752,486...9,760,901
Ensembl chr12:9,752,486...9,760,901 		JBrowse link
G CD79A CD79a molecule decreases expression EXP Bortezomib results in decreased expression of CD79A mRNA CTD PMID:20977926 NCBI chr19:41,877,279...41,881,372
Ensembl chr19:41,877,279...41,881,372 		JBrowse link
G CD82 CD82 molecule decreases expression EXP Bortezomib results in decreased expression of CD82 mRNA CTD PMID:20977926 NCBI chr11:44,564,409...44,620,358
Ensembl chr11:44,564,427...44,620,363 		JBrowse link
G CD9 CD9 molecule increases expression EXP Bortezomib results in increased expression of CD9 mRNA CTD PMID:20977926 NCBI chr12:6,199,946...6,238,266
Ensembl chr12:6,199,715...6,238,271 		JBrowse link
G CDC23 cell division cycle 23 increases expression EXP Bortezomib results in increased expression of CDC23 mRNA CTD PMID:20977926 NCBI chr 5:138,187,650...138,213,323
Ensembl chr 5:138,187,650...138,213,343 		JBrowse link
G CDC34 cell division cycle 34, ubiqiutin conjugating enzyme increases expression EXP Bortezomib results in increased expression of CDC34 mRNA CTD PMID:20977926 NCBI chr19:531,760...542,087
Ensembl chr19:531,760...542,092 		JBrowse link
G CDC37 cell division cycle 37, HSP90 cochaperone increases expression EXP Bortezomib results in increased expression of CDC37 mRNA CTD PMID:17895889 NCBI chr19:10,391,133...10,403,542
Ensembl chr19:10,391,090...10,420,121